



**THE STATUTES OF THE REPUBLIC OF SINGAPORE**

**MISUSE OF DRUGS ACT**

**(CHAPTER 185)**

**(Original Enactment: Act 5 of 1973)**

**REVISED EDITION 2008**

(31st March 2008)

*Prepared and Published by*

THE LAW REVISION COMMISSION  
UNDER THE AUTHORITY OF  
THE REVISED EDITION OF THE LAWS ACT (CHAPTER 275)

Informal Consolidation – version in force from 1/5/2021

# Misuse of Drugs Act

## ARRANGEMENT OF SECTIONS

### PART I

#### PRELIMINARY

#### Section

1. Short title
2. Interpretation
3. Appointment of Director and other officers of Central Narcotics Bureau
4. Advisory committees

### PART II

#### OFFENCES INVOLVING CONTROLLED DRUGS AND SUBSTANCES

5. Trafficking in controlled drugs
6. Manufacture of controlled drugs
7. Import and export of controlled drugs
8. Possession and consumption of controlled drugs
- 8A. Consumption of drug outside Singapore by citizen or permanent resident
9. Possession of pipes, utensils, etc.
10. Cultivation of cannabis, opium and coca plants
- 10A. Manufacture, supply, possession, import or export of equipment, materials or substances useful for manufacture of controlled drugs
- 10B. Regulations on controlled equipment, material or substances
11. Responsibilities of owners, tenants, etc.
- 11A. Arranging or planning gatherings where controlled drugs are to be consumed or trafficked
- 11B. Exposing child to drugs, etc., and permitting young person to consume drugs
- 11C. Introducing drug trafficker to another person
- 11D. Instructing person to cultivate cannabis, etc., or to manufacture or consume controlled drugs, etc.
- 11E. Causing or procuring young person or vulnerable person to commit certain offences

## Section

12. Abetments and attempts punishable as offences
- 12A. [*Repealed*]
13. Abetting or procuring commission of offences within or outside Singapore
14. Offences by body corporate

## PART III

## EVIDENCE, ENFORCEMENT AND PUNISHMENT

15. Certificate of corresponding law
16. Certificate of analyst, etc.
17. Presumption concerning trafficking
18. Presumption of possession and knowledge of controlled drugs
19. Presumption concerning premises
20. Presumption relating to ship or aircraft
21. Presumption relating to vehicle
22. Presumption relating to urine test
23. Protection of informers
24. Powers of search and seizure
25. Powers of arrest
26. Power to search ship, hovercraft, etc., and person arriving in or departing from Singapore
- 26A. Procedure when person entitled to seized item is known, unknown or cannot be found
27. Forfeiture of controlled drugs, controlled substances and articles seized
28. Forfeiture of ship, hovercraft, etc.
29. Disposal of things forfeited
30. Obstruction of inspection or search
31. Urine tests
- 31A. Hair tests
- 31B. Oral fluid tests
32. Power of investigation of officers of Bureau
- 32A. Officer of Bureau to be armed
33. Punishment for offences
- 33A. Punishment for repeat consumption of specified drugs
- 33B. Discretion of court not to impose sentence of death in certain circumstances

**PART IV****TREATMENT AND REHABILITATION**

## Section

- 34. Supervision, treatment and rehabilitation of drug addicts
- 34A. Parents or guardians to attend counselling with supervisees
- 35. Approved institutions and community rehabilitation centres
- 36. Administration of approved institutions
- 36A. Administration of community rehabilitation centres
- 37. Review Committees for approved institutions and community rehabilitation centres
- 38. Review, discharge and transfer of inmates
- 39. Power of Magistrate to inquire into complaint of misconduct or breach of duty
- 40. Inmates deemed to be in legal custody

**PART V****TAKING OF PHOTOGRAPHS, FINGER IMPRESSIONS, PARTICULARS  
AND BODY SAMPLES**

- 40A. Interpretation of this Part
- 40B. Taking of photographs, finger impressions, particulars and body samples from person subject to supervision or in approved institutions
- 40C. Further provisions for taking of body samples
- 40D. Retention of photographs, finger impressions, particulars and body samples taken

**PART VI****COMMITTEE OF INQUIRY**

- 41. Committee of inquiry
- 42. Composition of committee of inquiry
- 43. Powers of committee of inquiry
- 44. Disobedience to summons
- 45. Refusal to give evidence
- 46. Giving of false evidence
- 47. Evidence and procedure
- 48. Admissibility of evidence
- 49. Proceedings not open to public
- 50. Persons who may be affected by findings
- 51. Record of proceedings

## Section

52. Offence to influence or attempt to influence committee of inquiry

## PART VII

## GENERAL

53. Jurisdiction of court  
54. Indemnity  
55. Protection of persons acting under authority of Act  
56. Use of weapons  
57. Employment of auxiliary police officers as escorts and guards  
58. Regulations  
58A. Specifying drugs as temporarily listed drugs in Fifth Schedule  
59. Power of Minister to amend First, Third and Fourth Schedules  
First Schedule — Controlled Drugs  
Second Schedule — Offences Punishable on Conviction  
Third Schedule — Controlled equipment, materials or substances useful for manufacturing controlled drugs  
Fourth Schedule — Specified Drugs  
Fifth Schedule — Temporarily listed drugs
- 

An Act for the control of dangerous or otherwise harmful drugs and substances and for purposes connected therewith.

[7th July 1973]

## PART I

## PRELIMINARY

**Short title**

1. This Act may be cited as the Misuse of Drugs Act.

**Interpretation**

2. In this Act, unless the context otherwise requires —

“aircraft” has the same meaning as in section 2(1) of the Air Navigation Act (Cap. 6);

*[Act 1 of 2019 wef 01/04/2019]*

“approved institution” means any institution or place declared by the Minister to be an approved institution under section 35;

“article liable to seizure” means any money, thing, controlled equipment or controlled material by means of or in respect of which an offence under this Act has been committed or which contains evidence of an offence under this Act;

“autonomous system”, in relation to a motor vehicle or vessel, means a system that enables the operation of the motor vehicle or vessel without the active physical control of, or monitoring by, a human operator;

*[Act 1 of 2019 wef 01/04/2019]*

“autonomous vehicle” means a motor vehicle equipped wholly or substantially with an autonomous system (also commonly known as a driverless vehicle), and includes a trailer drawn by such a motor vehicle;

*[Act 1 of 2019 wef 01/04/2019]*

“cannabis” means any part of a plant of the genus *Cannabis*, or any part of such plant, by whatever name it is called;

“cannabis mixture” means any mixture of vegetable matter containing tetrahydrocannabinol and cannabinal in any quantity;

“cannabis resin” means any substance containing resinous material and in which is found tetrahydrocannabinol and cannabinal in any quantity;

“Class A drug”, “Class B drug” and “Class C drug” mean any of the substances and products for the time being specified in Parts I, II and III of the First Schedule, respectively;

“Commissioner of Prisons” means the Commissioner of Prisons appointed under section 20 of the Prisons Act (Cap. 247);

*[Act 1 of 2014 wef 01/07/2014]*

“committee of inquiry” means a committee of inquiry convened under section 41;

“community rehabilitation centre” means any place declared by the Minister as such under section 35;

*[Act 30 of 2012 wef 28/04/2014]*

“controlled drug” means any substance or product which is for the time being specified in Part I, II or III of the First Schedule or anything that contains any such substance or product;

“controlled equipment, controlled material or controlled substance” means any equipment, material or substance, respectively, specified in the Third Schedule;

“corresponding law” means a law stated in a certificate purporting to be issued by or on behalf of the government of a country outside Singapore to be a law providing for the control and regulation in that country of —

- (a) the production, supply, use, export and import of drugs and other substances in accordance with the provisions of the Single Convention on Narcotic Drugs signed at New York on 30th March 1961; or
- (b) the production, supply, use, export and import of dangerous or otherwise harmful drugs in pursuance of any treaty, convention or other agreement or arrangement to which the government of that country and the Government of Singapore are for the time being parties;

“Director” means the Director of the Central Narcotics Bureau appointed under section 3(1);

*[Deleted by Act 1 of 2014 wef 01/07/2014]*

“drug addict” means a person who, through the use of any controlled drug, has developed —

(a) a desire or need to continue to take that controlled drug; or

(b) a psychological or physical dependence upon the effect of that controlled drug;

“Health Sciences Authority” means the Health Sciences Authority established under the Health Sciences Authority Act (Cap. 122C);

“immigration officer” has the same meaning as in the Immigration Act (Cap. 133);

“inmate” means a person who is detained in an approved institution or a community rehabilitation centre;

*[Act 30 of 2012 wef 28/04/2014]*

“manufacture”, in relation to —

(a) a controlled drug, includes any process of producing the drug and the refining or transformation of one drug into another; or

(b) a controlled substance, includes any process of producing the substance and the refining or transformation of one substance into another;

“officer of customs” has the same meaning as in the Customs Act (Cap. 70);

“officer of the Bureau” means the Director or any person appointed under section 3 as a Deputy Director, a Divisional Director or an officer of the Central Narcotics Bureau;

*[Act 30 of 2012 wef 01/01/2013]*

“opium” means any substance containing in any quantity morphine and one or more of the following, namely, codeine, narcotine, papaverine and thebaine but does not include poppy-straw which is not mixed in any such substance;

“permanent resident of Singapore” includes the holder of a Singapore blue identity card and a person who holds an entry



permit or a re-entry permit issued by the Controller of Immigration;

“place” includes —

- (a) any building or structure, whether permanent or temporary;
- (b) any land, whether or not built on;
- (c) any place, whether or not enclosed, and whether or not situated underground or underwater;
- (d) any vessel, aircraft, train, or vehicle (whether mechanically propelled or otherwise) or any other means of transport; and
- (e) any part of any place referred to in paragraphs (a) to (d);

*[Act 30 of 2012 wef 01/01/2013]*

“police officer” has the same meaning as in the Police Force Act (Cap. 235);

“prison officer” has the same meaning as in the Prisons Act (Cap. 247);

“regulations” means any regulations made under this Act;

“Review Committee”, in relation to an approved institution, means the Review Committee appointed for the institution under section 37;

“senior officer of customs” has the same meaning as in the Customs Act;

“special police officer” means a member of the Special Constabulary constituted under Part VIII of the Police Force Act;

“specified drug”, except for the purposes of the Second Schedule, means a drug specified in the Fourth Schedule;

“traffic” means —

(a) to sell, give, administer, transport, send, deliver or distribute; or

(b) to offer to do anything mentioned in paragraph (a), otherwise than under the authority of this Act, and “trafficking” has a corresponding meaning;

“unmanned aircraft” and “unmanned aircraft system” have the same meanings as in section 2(1) of the Air Navigation Act;

*[Act 1 of 2019 wef 01/04/2019]*

“unmanned vessel” means a vessel equipped wholly or substantially with an autonomous system (such as an unmanned surface vehicle and a saildrone) and includes a barge drawn by an unmanned vessel;

*[Act 1 of 2019 wef 01/04/2019]*

“vehicle” means any means of transport used on land, whether self-propelled or not, such as a train, motor car, bicycle or personal mobility device;

*[Act 1 of 2019 wef 01/04/2019]*

“vessel” includes a floating facility;

*[Act 1 of 2019 wef 01/04/2019]*

*[Deleted by Act 1 of 2019 wef 01/04/2019]*

“vulnerable person” means any person who suffers from an impairment of, or a disturbance in the functioning of, the mind or brain resulting from any disability or disorder of the mind or brain which impairs the ability to make a proper judgment in relation to the commission of any offence under this Act;

*[Act 30 of 2012 wef 01/01/2013]*

“young person” means any person who is below 21 years of age.

*[Act 30 of 2012 wef 01/01/2013]*

### **Appointment of Director and other officers of Central Narcotics Bureau**

3.—(1) The Minister may appoint a Director of the Central Narcotics Bureau and such numbers of Deputy Directors, Divisional Directors and other officers as the Minister may think fit.

[2/2006]

[Act 30 of 2012 wef 01/01/2013]

(2) All officers of the Bureau appointed by the Minister before 12th December 1975 shall be deemed to have been appointed under subsection (1).

[49/75]

(3) Subject to the provisions of this Act, the powers and functions conferred upon the Director under this Act, and the duties required to be discharged by him may, subject to such limitations as the Director may impose, be exercised and discharged by any Deputy Director or Divisional Director of the Central Narcotics Bureau duly authorised by the Director to act on his behalf.

[Act 30 of 2012 wef 01/01/2013]

(4) The Director may issue such orders not inconsistent with the provisions of this Act and the regulations made thereunder, to be called General Orders, as he may think necessary and expedient for the control, direction and information of the officers of the Bureau.

[Act 30 of 2012 wef 01/01/2013]

(5) It shall not be necessary to publish any General Orders in the *Gazette*.

[Act 30 of 2012 wef 01/01/2013]

### **Advisory committees**

4.—(1) For the purpose of assisting in the administration of this Act, the Minister may from time to time appoint such advisory committees as he thinks fit.

[12/77]

(2) Every such committee shall have such functions as the Minister may from time to time determine.

[12/77]

(3) Subject to the regulations, every such committee may regulate its own procedure.

[12/77]

**PART II****OFFENCES INVOLVING CONTROLLED DRUGS AND  
SUBSTANCES****Trafficking in controlled drugs**

**5.**—(1) Except as authorised by this Act, it shall be an offence for a person, on his own behalf or on behalf of any other person, whether or not that other person is in Singapore —

- (a) to traffic in a controlled drug;
- (b) to offer to traffic in a controlled drug; or
- (c) to do or offer to do any act preparatory to or for the purpose of trafficking in a controlled drug.

(2) For the purposes of this Act, a person commits the offence of trafficking in a controlled drug if he has in his possession that drug for the purpose of trafficking.

[40/93]

**Manufacture of controlled drugs**

**6.** Except as authorised by this Act, it shall be an offence for a person to manufacture a controlled drug.

**Import and export of controlled drugs**

**7.** Except as authorised by this Act, it shall be an offence for a person to import into or export from Singapore a controlled drug.

**Possession and consumption of controlled drugs**

**8.** Except as authorised by this Act, it shall be an offence for a person to —

- (a) have in his possession a controlled drug; or
- (b) smoke, administer to himself or otherwise consume —
  - (i) a controlled drug, other than a specified drug; or
  - (ii) a specified drug.

[20/98]

**Consumption of drug outside Singapore by citizen or permanent resident**

**8A.**—(1) Section 8(b) shall have effect in relation to a person who is a citizen or a permanent resident of Singapore outside as well as within Singapore where he is found as a result of urine tests conducted under section 31(4)(b) to have smoked, administered to himself or otherwise consumed a controlled drug or a specified drug.

[20/98; 2/2006]

(2) Where an offence under section 8(b) is committed by a person referred to in subsection (1) in any place outside Singapore, he may be dealt with as if that offence had been committed within Singapore.

[20/98]

**Possession of pipes, utensils, etc.**

**9.** Except as authorised by this Act, it shall be an offence for a person to have in his possession any pipe, syringe, utensil, apparatus or other article intended for the smoking, administration or consumption of a controlled drug.

**Cultivation of cannabis, opium and coca plants**

**10.** It shall be an offence for a person to cultivate any plant of the genus Cannabis, or any plant of the species papaver somniferum or any plant of the genus erythroxylon from which cocaine can be extracted.

**Manufacture, supply, possession, import or export of equipment, materials or substances useful for manufacture of controlled drugs**

**10A.**—(1) Any person who —

- (a) manufactures any controlled equipment, controlled material or controlled substance;
- (b) supplies any controlled equipment, controlled material or controlled substance to another person;
- (c) has in his possession any controlled equipment, controlled material or controlled substance; or

- (d) imports or exports any controlled equipment, controlled material or controlled substance,

knowing or having reason to believe that the controlled equipment, controlled material or controlled substance is to be used in or for the manufacture of a controlled drug in contravention of section 6 shall be guilty of an offence.

[20/98]

(2) It shall not be a defence to a person who contravenes subsection (1)(d) in respect of any controlled equipment, controlled material or controlled substance to show that the equipment, material or substance is the subject of a licence, permit or any other form of authorisation issued or granted under any regulations made under section 10B.

[20/98]

### **Regulations on controlled equipment, material or substances**

**10B.**—(1) The Minister may by regulations make provisions for —

- (a) the licensing, by such person or authority as may be prescribed, of persons who intend to import or export any controlled equipment, controlled material or controlled substance;
- (b) the regulation and control of the import or export of any controlled equipment, controlled material or controlled substance;
- (c) imposing requirements for the registration of premises used in connection with the import, export, manufacture, processing, storage, distribution or supply of any controlled equipment, controlled material or controlled substance;
- (d) imposing requirements as to the documentation of transactions involving any controlled equipment, controlled material or controlled substance;
- (e) requiring the keeping of records and the furnishing of information with respect to any controlled equipment, controlled material or controlled substance;

- (f) the inspection and production of records kept pursuant to the regulations; and
- (g) the labelling of consignments of any controlled equipment, controlled material or controlled substance.

[20/98]

(2) Regulations made under subsection (1) may, in particular, require —

- (a) the notification of the proposed exportation of any controlled equipment, controlled material or controlled substance to such countries as may be specified in the regulations; and
- (b) the production, in such circumstances as may be specified, of evidence that the required notification has been given,

and any such equipment, material or substance shall be deemed to be exported contrary to a restriction for the time being in force with respect to the equipment, material or substance under such regulations if it is exported without the requisite notice being given.

[20/98]

(3) Regulations made under this section may make different provisions in relation to different controlled equipment, controlled material or controlled substance and in relation to different cases or circumstances.

[20/98]

(4) Regulations made under this section may provide that any person who contravenes any provision thereof shall be guilty of an offence and shall be liable on conviction to be punished with a fine not exceeding \$10,000 or with imprisonment for a term not exceeding 3 years or with both as may be specified in the regulations.

[20/98]

(5) No information obtained pursuant to any regulations made under this section shall be disclosed except for the purposes of criminal proceedings or of proceedings under or in relation to the Corruption, Drug Trafficking and Other Serious Crimes (Confiscation of Benefits) Act (Cap. 65A).

[20/98]

**Responsibilities of owners, tenants, etc.**

**11.** It shall be an offence for a person being the owner, tenant, occupier or person in charge of any place or premises, to permit or suffer such place or premises or any part thereof to be opened, kept or used for —

- (a) the purpose of smoking, administration or consumption of any controlled drug; or
- (b) the unlawful trafficking in or the unlawful manufacturing of any controlled drug.

**Arranging or planning gatherings where controlled drugs are to be consumed or trafficked**

**11A.**—(1) Where there is a gathering of 2 or more persons in any place, any person who arranges or plans the gathering with the knowledge that any controlled drug is, or is to be, consumed or trafficked at that gathering shall be guilty of an offence and shall on conviction —

- (a) be punished with imprisonment for a term of not less than 3 years and not more than 20 years; and
- (b) be liable to caning of not more than 10 strokes.

(2) A person may be guilty of an offence under subsection (1) notwithstanding that he does not supply any controlled drug to be consumed or trafficked at that gathering.

*[Act 30 of 2012 wef 01/05/2013]*

**Exposing child to drugs, etc., and permitting young person to consume drugs**

**11B.**—(1) Any person of or above 21 years of age who, being in possession of any controlled drug or drug paraphernalia —

- (a) knowingly or recklessly leaves the controlled drug or drug paraphernalia —
  - (i) exposed in any place; or
  - (ii) in any refrigerator, cupboard, cabinet, box, chest or any other article, that is not locked; and



(b) knows that any child has, or is likely to have, access to —

- (i) the place where the controlled drug or drug paraphernalia is left exposed; or
- (ii) the refrigerator, cupboard, cabinet, box, chest or other article in which the controlled drug or drug paraphernalia is located,

shall be guilty of an offence.

(2) Any person of or above 21 years of age who, being in possession of any controlled drug —

- (a) permits a young person to smoke, administer (whether or not to himself) or consume the controlled drug; or
- (b) does not take all reasonable steps to prevent a young person from smoking, administering (whether or not to himself) or consuming the controlled drug,

shall be guilty of an offence.

(3) Any person guilty of an offence under subsection (1) or (2) shall —

- (a) on conviction, be punished with imprisonment for a term not exceeding 10 years; and
- (b) on a second or subsequent conviction, be punished with imprisonment for a term of not less than 2 years and not more than 10 years.

(4) Subsection (1) does not apply in relation to a person who is in possession of any controlled drug or drug paraphernalia if the possession of the controlled drug or drug paraphernalia is authorised under this Act.

(5) In this section —

“child” means any person below 16 years of age;

“drug paraphernalia” means any pipe, syringe, utensil, apparatus or other article for the purpose of smoking, administering or consuming a controlled drug.

*[Act 1 of 2019 wef 01/08/2019]*

**Introducing drug trafficker to another person**

**11C.**—(1) Any person (*A*) who, knowing or having reason to believe that another person (*B*) intends —

- (a) to procure, whether or not for himself, any controlled drug;  
or
- (b) to smoke, administer (whether or not to himself) or consume any controlled drug,

introduces *B* (whether or not through the use of any electronic media) to a person whom *A* knows or has reason to believe is trafficking in any controlled drug and is likely to supply *B* with any controlled drug shall be guilty of an offence.

(2) Any person guilty of an offence under subsection (1) shall —

- (a) on conviction, be punished with imprisonment for a term not exceeding 10 years; and
- (b) on a second or subsequent conviction, be punished with imprisonment for a term of not less than 2 years and not more than 10 years.

(3) In a prosecution for an offence under subsection (1), it is not necessary for the prosecution to prove that —

- (a) *B* procures, smokes, administers or consumes any controlled drug after the introduction is made; or
- (b) both *A* and *B* are within Singapore at the time the introduction is made, as long as either *A* or *B* is within Singapore at that time.

(4) In this section, “introduce” includes giving any address, telephone number, email address or any other details of one person to another person.

*[Act 1 of 2019 wef 01/08/2019]*

**Instructing person to cultivate cannabis, etc., or to manufacture or consume controlled drugs, etc.**

**11D.**—(1) Any person (*A*) who, whether or not through the use of any electronic media, teaches or instructs another person (*B*) to carry

out, or who provides information to *B* on the carrying out of, any of the following activities:

- (a) the cultivating of any plant of the genus *Cannabis*, or any plant of the species *papaver somniferum* or any plant of the genus *erythroxyton* from which cocaine can be extracted;
- (b) the manufacture of any controlled drug;
- (c) the smoking, administering or consuming of any controlled drug;
- (d) the trafficking or doing of any act preparatory to or for the purpose of trafficking in any controlled drug;
- (e) the importing into or exporting from Singapore of any controlled drug,

knowing or having reason to believe that *B* intends to carry out the activity, shall be guilty of an offence.

(2) Any person who disseminates or publishes, or causes the dissemination or publication of, information (whether or not through the use of any electronic media) on the carrying out of any activity mentioned in subsection (1) shall be guilty of an offence.

- (3) Any person guilty of an offence under subsection (1) shall —
- (a) on conviction, be punished with imprisonment for a term not exceeding 10 years; and
  - (b) on a second or subsequent conviction, be punished with imprisonment for a term of not less than 2 years and not more than 10 years.
- (4) Any person guilty of an offence under subsection (2) shall —
- (a) on conviction, be liable to be punished with a fine not exceeding \$10,000 or with imprisonment for a term not exceeding 5 years or with both; and
  - (b) on a second or subsequent conviction, be punished with imprisonment for a term of not less than one year and not more than 5 years.

(5) In a prosecution for an offence under subsection (1), it is not necessary for the prosecution to prove, in relation to any activity mentioned in that subsection for which *B* is taught, instructed or provided with information, that —

- (a) *B* carries out the activity after *B* is so taught, instructed or provided with information; or
- (b) both *A* and *B* are within Singapore at the time when *B* is so taught, instructed or provided with information, as long as either *A* or *B* is within Singapore at that time.

(6) Subsection (1) does not apply in relation to *A* teaching or instructing *B* to carry out, or providing information to *B* on the carrying out of, any activity mentioned in that subsection if the teaching, instructing or provision of information is authorised under this Act.

(7) It is a defence to a charge under subsection (1) if *A* who teaches or instructs *B* to carry out, or provides information to *B* on the carrying out of, any activity mentioned in that subsection proves, on a balance of probabilities, that the teaching, instructing or provision of information has a legitimate purpose related to the administration of justice, the investigation and prosecution of offences, or to science, medicine, education or art.

(8) Subsection (2) does not apply in relation to any dissemination or publication of information on the carrying out of any activity mentioned in subsection (1) if the dissemination or publication of information is authorised under this Act.

(9) It is a defence to a charge under subsection (2) if the person who disseminates or publishes information on the carrying out of any activity mentioned in subsection (1) proves, on a balance of probabilities, that the dissemination or publication of information has a legitimate purpose related to the administration of justice, the investigation and prosecution of offences, or to science, medicine, education or art.

*[Act 1 of 2019 wef 01/08/2019]*

**Causing or procuring young person or vulnerable person to commit certain offences**

**11E.** Any person of or above 21 years of age who causes or procures any young person or vulnerable person to commit any offence under section 5(1) or 7 shall be guilty of an offence.

*[Act 1 of 2019 wef 01/08/2019]*

**Abetments and attempts punishable as offences**

**12.** Any person who abets the commission of or who attempts to commit or does any act preparatory to, or in furtherance of, the commission of any offence under this Act shall be guilty of that offence and shall be liable on conviction to the punishment provided for that offence.

**12A.** *[Repealed by Act 1 of 2019 wef 01/08/2019]*

**Abetting or procuring commission of offences within or outside Singapore**

**13.** Any person who —

- (a) aids, abets, counsels or procures the commission in any place outside Singapore of an offence punishable under a corresponding law in force in that place;
- (b) aids, abets, counsels or procures the commission of any offence under this Act within Singapore, even though all or any of the acts constituting the aiding, abetment, counselling or procurement were done outside Singapore; or
- (c) does an act preparatory to, or in furtherance of, an act outside Singapore which if committed in Singapore would constitute an offence under this Act,

shall be guilty of an offence and shall be liable on conviction —

- (d) in relation to an offence mentioned in paragraph (a) or (c), to imprisonment for a term of not less than 2 years but not more than 10 years, or to a fine of not less than \$4,000 and not more than \$40,000, or to both; and

- (e) in relation to an offence mentioned in paragraph (b), to the same punishment provided for the offence that the person aided, abetted, counselled or procured.

*[Act 1 of 2019 wef 01/04/2019]*

### **Offences by body corporate**

**14.** Where any offence under this Act committed by a body corporate is proved to have been committed with the consent or connivance of, or to be attributable to any neglect on the part of, any director, manager, secretary or other similar officer of the body corporate, or any person purporting to act in any such capacity, he as well as the body corporate shall be guilty of that offence and shall be liable to be proceeded against accordingly.

## **PART III**

### **EVIDENCE, ENFORCEMENT AND PUNISHMENT**

#### **Certificate of corresponding law**

**15.—**(1) A document purporting to be issued by or on behalf of the government of a country outside Singapore and purporting to state the terms of a corresponding law in force in that country shall be admitted in evidence, in any proceedings for an offence under this Act, on its production by the prosecution without further proof.

(2) Such document shall be conclusive evidence that —

- (a) it is issued by or on behalf of the government of that country;
- (b) the terms of that law are as stated in the document; and
- (c) any fact stated in the document as constituting an offence under that law does constitute such offence.

#### **Certificate of analyst, etc.**

**16.** A certificate purporting —

(a) to be signed by —

- (i) an analyst employed by the Health Sciences Authority; or

(ii) such other person as the Minister may, by notification in the *Gazette*, appoint; and

(b) to relate to a controlled drug or controlled substance,

shall be admitted in evidence, in any proceedings for an offence under this Act, on its production by the prosecution without proof of signature and, until the contrary is proved, shall be proof of all matters contained therein.

[2/2006]

### **Presumption concerning trafficking**

17. Any person who is proved to have had in his possession more than —

- (a) 100 grammes of opium;
- (b) 3 grammes of morphine;
- (c) 2 grammes of diamorphine;
- (d) 15 grammes of cannabis;
- (e) 30 grammes of cannabis mixture;
- (f) 10 grammes of cannabis resin;
- (g) 3 grammes of cocaine;
- (h) 25 grammes of methamphetamine;
- (ha) 113 grammes of ketamine; or
- (i) 10 grammes of any or any combination of the following:
  - (i) N,  $\alpha$ -dimethyl-3,4-(methylenedioxy)phenethylamine;
  - (ii)  $\alpha$ -methyl-3,4-(methylenedioxy)phenethylamine; or
  - (iii) N-ethyl- $\alpha$ -methyl-3,4-(methylenedioxy)phenethylamine,

whether or not contained in any substance, extract, preparation or mixture, shall be presumed to have had that drug in possession for the purpose of trafficking unless it is proved that his possession of that drug was not for that purpose.

[38/89; 40/93; 20/98; 2/2006]

**Presumption of possession and knowledge of controlled drugs**

**18.**—(1) Any person who is proved to have had in his possession or custody or under his control —

- (a) anything containing a controlled drug;
- (b) the keys of anything containing a controlled drug;
- (c) the keys of any place or premises or any part thereof in which a controlled drug is found; or
- (d) a document of title relating to a controlled drug or any other document intended for the delivery of a controlled drug,

shall, until the contrary is proved, be presumed to have had that drug in his possession.

(2) Any person who is proved or presumed to have had a controlled drug in his possession shall, until the contrary is proved, be presumed to have known the nature of that drug.

(3) The presumptions provided for in this section shall not be rebutted by proof that the accused never had physical possession of the controlled drug.

(4) Where one of 2 or more persons with the knowledge and consent of the rest has any controlled drug in his possession, it shall be deemed to be in the possession of each and all of them.

**Presumption concerning premises**

**19.**—(1) Where a pipe, syringe, utensil, apparatus or other article intended for the smoking, administration or consumption of a controlled drug is found in any place or premises, it shall be presumed, until the contrary is proved, that the place or premises is used for the purpose of smoking, administering or consuming a controlled drug.

(2) Any person found in or escaping from any place or premises which is proved or presumed to be used for the purpose of smoking or administering a controlled drug shall, until the contrary is proved, be presumed to have been smoking or administering a controlled drug in that place or premises.



**Presumption relating to ship or aircraft**

**20.** If any controlled drug is found in any ship or aircraft, it shall be presumed, until the contrary is proved, that the drug has been imported in that ship or aircraft with the knowledge of the master or the captain thereof.

**Presumption relating to vehicle**

**21.** If any controlled drug is found in any vehicle, it shall be presumed, until the contrary is proved, to be in the possession of the owner of the vehicle and of the person in charge of the vehicle for the time being.

**Presumption relating to urine test**

**22.** If any controlled drug is found in the urine of a person as a result of both urine tests conducted under section 31(4)(b), he shall be presumed, until the contrary is proved, to have consumed that controlled drug in contravention of section 8(b).

[49/75; 38/89; 2/2006]

**Protection of informers**

**23.—(1)** Except as provided in subsection (3) —

- (a) no information for an offence under this Act shall be admitted in evidence in any civil or criminal proceedings; and
- (b) no witness in any civil or criminal proceedings shall be obliged —
  - (i) to disclose the name and address of any informer who has given information with respect to an offence under this Act; or
  - (ii) to answer any question if the answer thereto would lead, or would tend to lead, to the discovery of the name or address of the informer.

(2) If any book, document or paper which is in evidence or liable to inspection in any civil or criminal proceedings contains any entry in which any informer is named or described or which may lead to his

discovery, the court shall cause those entries to be concealed from view or to be obliterated so far as may be necessary to protect the informer from discovery.

(3) If —

- (a) in any proceedings before a court for an offence under this Act, the court, after full inquiry into the case, is satisfied that an informer wilfully made a material statement which he knew or believed to be false or did not believe to be true; or
- (b) in any other proceedings, the court is of the opinion that justice cannot be fully done between the parties thereto without the disclosure of the name of an informer,

the court may permit inquiry and require full disclosure concerning the informer.

### **Powers of search and seizure**

**24.—(1)** Any officer of the Bureau, police officer or senior officer of customs may at any time —

- (a) without a warrant enter and search any place or premises in which he reasonably suspects that there is to be found —
  - (i) any controlled drug, controlled substance, drug specified in the Fifth Schedule, substance containing any drug specified in the Fifth Schedule or article liable to seizure;  
*[Act 30 of 2012 wef 01/05/2013]*  
*[Act 1 of 2019 wef 01/04/2019]*
  - (ia) any vehicle, autonomous vehicle, unmanned aircraft, unmanned vessel, component of the autonomous system of an autonomous vehicle or unmanned vessel, or component of an unmanned aircraft system, which is or has been used in the commission of or in connection with an offence under this Act; or  
*[Act 1 of 2019 wef 01/04/2019]*

- (ii) a person who has committed or is reasonably suspected to have committed any offence under this Act or any seizable offence under the regulations;
- (b) search any person found in that place or premises; and
- (c) seize and detain all of the following which is found in that place or premises:
  - (i) any controlled drug, controlled substance, or drug specified in the Fifth Schedule or substance containing any drug specified in that Schedule;
  - (ii) any article liable to seizure;
  - (iii) any vehicle, autonomous vehicle, unmanned aircraft, unmanned vessel, component of the autonomous system of an autonomous vehicle or unmanned vessel, or component of an unmanned aircraft system, which is or has been used in the commission of or in connection with an offence under this Act.

*[Act 1 of 2019 wef 01/04/2019]*

(2) For the purpose of exercising his power under this section, an officer may, with such assistance as he considers necessary, break open any door, window, lock, fastener, floor, wall, ceiling, compartment, box, container or any other thing.

(3) Notwithstanding subsection (1), if the use of any drug specified in the Fifth Schedule or any substance containing such drug at any place or premises searched under that subsection is authorised by the Director, that drug or substance shall not be liable to seizure under that subsection.

*[Act 30 of 2012 wef 01/05/2013]*

### **Powers of arrest**

**25.—**(1) Any officer of the Bureau, police officer, special police officer or officer of customs may arrest and search without a warrant any person who has committed or whom he reasonably suspects to

have committed an offence under this Act or a seizable offence under the regulations.

[12/77; 20/98]

[Act 1 of 2019 wef 01/04/2019]

(2) Any person arrested under subsection (1) shall, together with any controlled drug, controlled substance or article liable to seizure, be taken to the Central Narcotics Bureau, a police station or a customs station and may be searched.

[49/75; 20/98]

(3) No woman shall be searched under this Act except by another woman.

(4) An officer making an arrest under this section may seize and detain any controlled drug, controlled substance or article liable to seizure.

[20/98]

### **Power to search ship, hovercraft, etc., and person arriving in or departing from Singapore**

**26.—**(1) Any officer of the Bureau, police officer, special police officer or officer of customs may —

(a) stop, board and search any ship, hovercraft, aircraft, vehicle or train if he has reason to suspect that there is therein any controlled drug in contravention of this Act, controlled substance, drug specified in the Fifth Schedule, substance containing any drug specified in the Fifth Schedule or any article liable to seizure;

[Act 30 of 2012 wef 01/05/2013]

(b) search any person in that ship, hovercraft, aircraft, vehicle or train;

[Act 1 of 2019 wef 01/04/2019]

(ba) intercept and search any autonomous vehicle, unmanned aircraft or unmanned vessel if he has reason to suspect that there is in any such vehicle, aircraft or vessel —

(i) any controlled drug or controlled substance;

(ii) any drug specified in the Fifth Schedule;

(iii) any substance containing any drug specified in the Fifth Schedule; or

(iv) any article liable to seizure; and

*[Act 1 of 2019 wef 01/04/2019]*

(c) search any person arriving in Singapore or about to depart from Singapore.

*[20/98]*

*[Act 1 of 2019 wef 01/04/2019]*

(2) An officer may seize and detain —

(a) any controlled drug, controlled substance, drug specified in the Fifth Schedule, substance containing any drug specified in the Fifth Schedule or article liable to seizure as a result of any search under this section; and

*[Act 30 of 2012 wef 01/05/2013]*

(b) any ship, hovercraft, aircraft, autonomous vehicle, unmanned aircraft, unmanned vessel, component of the autonomous system of an autonomous vehicle or unmanned vessel, or component of an unmanned aircraft system, vehicle or train which has been used in the commission of or in connection with an offence under this Act.

*[20/98]*

*[Act 1 of 2019 wef 01/04/2019]*

(2A) An officer may —

(a) in relation to any autonomous vehicle, unmanned aircraft or unmanned vessel that is to be intercepted and searched under subsection (1)(ba), direct any person whom the officer reasonably believes to be involved in operating the autonomous vehicle, unmanned aircraft or unmanned vessel —

(i) to end the flight of the unmanned aircraft, or land it, safely in the fastest practicable way;

(ii) to stop the autonomous vehicle or unmanned vessel safely in the fastest practicable way; or

- (iii) to fly the unmanned aircraft or to operate the autonomous vehicle or unmanned vessel in the manner specified by the officer;
- (b) in relation to any autonomous vehicle, unmanned aircraft or unmanned vessel that is to be intercepted and searched under subsection (1)(ba), without warrant and with such assistance and by such force as is necessary —
  - (i) assume control of the unmanned aircraft to fly the aircraft, or to end the flight of the aircraft, or land it, safely in the fastest practicable way;
  - (ii) assume control of the autonomous vehicle or unmanned vessel to steer the vehicle or vessel, or to stop the vehicle or vessel (as the case may be) safely in the fastest practicable way;
  - (iii) end the flight of the unmanned aircraft, or land it, in the fastest and safest practicable way; or
  - (iv) stop the autonomous vehicle or unmanned vessel in the fastest and safest practicable way; or
- (c) direct any person to operate any ship, hovercraft, aircraft, autonomous vehicle, unmanned aircraft, unmanned vessel, vehicle or train seized and detained under subsection (2)(b), in such manner as the officer determines.

*[Act 1 of 2019 wef 01/04/2019]*

(3) Notwithstanding subsection (2), if the use of any drug specified in the Fifth Schedule or any substance containing such drug onboard any ship, hovercraft, aircraft, autonomous vehicle, unmanned aircraft, unmanned vessel, vehicle or train or by any person searched under that subsection is authorised by the Director, that drug or substance shall not be liable to seizure under that subsection.

*[Act 30 of 2012 wef 01/05/2013]*

*[Act 1 of 2019 wef 01/04/2019]*

### **Procedure when person entitled to seized item is known, unknown or cannot be found**

**26A.**—(1) Subject to subsections (2) to (11), if a relevant officer determines that any seized item is not required for the purposes of any

investigation or proceedings for any offence under this Act, the relevant officer may return the seized item to the owner of the seized item, or any person authorised by the owner.

(2) If the owner of any seized item is known, a relevant officer must notify the owner to claim the seized item, and such notification may be given —

- (a) by posting a notice in writing to the owner of the seized item at the owner's usual or last known place of residence or business in Singapore; or
- (b) in such other manner as the relevant officer thinks expedient.

(3) If the owner or the person authorised by the owner does not claim the seized item within one month after the notification is given under subsection (2), any relevant officer may cause to be sold, or otherwise dispose of, the seized item but only after giving one month's notice in the *Gazette* of the relevant officer's intention to do so.

(4) Despite subsection (3), if the value of the seized item is, in the opinion of the Director, less than \$500, any relevant officer may cause the seized item to be sold or disposed of at any time.

(5) If the owner or the person authorised by the owner claims the seized item after it is sold under subsection (3) or (4), the owner is only entitled to the net proceeds.

(6) If the owner of a seized item is unknown or cannot be found, a relevant officer must issue a public notice, specifying the seized item and requiring any person who has a claim to it to appear before the relevant officer and establish the person's claim within 6 months after the date of the public notice.

(7) Every public notice under subsection (6) must be published in the *Gazette* or any daily newspaper but only if, in the opinion of the Director, the value of the seized item is at least \$1,000.

(8) If no person establishes a claim to the seized item within one month after the publication of a public notice issued under subsection (6), and if the person in whose possession the seized

item was found cannot show he had legally acquired it, then the seized item may be sold on the order of a relevant officer.

(9) Despite subsection (8), if the value of the seized item is, in the opinion of the Director, less than \$1,000, or if keeping the seized item involves unreasonable expense or inconvenience, a relevant officer may cause the seized item to be sold or disposed of at any time.

(10) If no person has established a claim to the seized item within 6 months after the publication of the public notice mentioned in subsection (6), the ownership of the seized item or (if sold) its net proceeds is to pass and be vested in the Government absolutely.

(11) If a person establishes the person's claim to the seized item within 6 months after the publication of the public notice mentioned in subsection (6), and the seized item has already been sold by a relevant officer, that person is only entitled to the net proceeds.

(12) This section applies in relation to any ship, hovercraft, aircraft, vehicle or train even though it was seized before the date of commencement of section 9 of the Misuse of Drugs (Amendment) Act 2019.

(13) In this section —

“relevant officer” means any Deputy Director of the Central Narcotics Bureau appointed under section 3(1) or any person authorised by the Deputy Director;

“seized item” means any ship, hovercraft, aircraft, autonomous vehicle, unmanned aircraft, unmanned vessel, component of the autonomous system of an autonomous vehicle or unmanned vessel, or component of an unmanned aircraft system, vehicle or train that is seized under section 24 or 26.

*[Act 1 of 2019 wef 01/08/2019]*

### **Forfeiture of controlled drugs, controlled substances and articles seized**

**27.—**(1) Where anything is seized under this Act, the officer who carried out the seizure shall immediately give notice in writing of the seizure to the owner of that thing, if known, either by delivering the notice to him personally or by post at his place of residence, if known.



(2) The notice under subsection (1) shall not be required to be given where the seizure is made in the presence of the offender or the owner or his agent, or in the case of a ship or an aircraft, in the presence of the master or captain thereof.

(3) An order for the forfeiture of any controlled drug, controlled substance or article shall be made if it is proved to the satisfaction of a court that an offence under this Act has been committed and that such drug, substance or article was the subject matter of or was used in the commission of the offence notwithstanding that no person may have been convicted of that offence.

*[20/98]*

(4) If there is no prosecution with regard to any controlled drug, controlled substance or article seized under this Act, that drug, substance or article shall be deemed to be forfeited to the Government at the expiration of one month from the date of the seizure thereof unless a claim thereto has been made before that date in such manner as may be prescribed.

*[20/98]*

*[Act 1 of 2019 wef 01/04/2019]*

(5) Any drug specified in the Fifth Schedule or any substance containing such drug shall be deemed to be forfeited to the Government at the expiration of one month after the date of the seizure thereof unless a claim thereto has been made before that date in such manner as may be prescribed.

*[Act 30 of 2012 wef 01/05/2013]*

*[Act 1 of 2019 wef 01/04/2019]*

### **Forfeiture of ship, hovercraft, etc.**

**28.—**(1) Where a person has been convicted of an offence under this Act, the court may order to be forfeited to the Government any ship, hovercraft, aircraft, unmanned aircraft, unmanned vessel, component of the autonomous system of an unmanned vessel, or component of an unmanned aircraft system which has been proved to have been used in any manner in connection with the offence.

*[20/98]*

*[Act 1 of 2019 wef 01/04/2019]*

(2) Where a person has been convicted of an offence under this Act, the court shall, upon the application of the Public Prosecutor, order to be forfeited to the Government any vehicle, autonomous vehicle, or component of the autonomous system of the autonomous vehicle which has been proved to have been used in any manner in connection with the offence.

[20/98]

[Act 1 of 2019 wef 01/04/2019]

(3) This section shall not apply to any ship, hovercraft or unmanned vessel of more than 200 tons net or to any aircraft or unmanned aircraft belonging to any person carrying on a regular passenger service to and from Singapore by means of that aircraft.

[Act 1 of 2019 wef 01/04/2019]

(4) Any ship, hovercraft, aircraft, vehicle, autonomous vehicle, unmanned aircraft, unmanned vessel, component of the autonomous system of an autonomous vehicle or unmanned vessel, or component of an unmanned aircraft system, must not be forfeited under this section if its owner establishes that the ship, hovercraft, aircraft, vehicle, autonomous vehicle, unmanned aircraft or unmanned vessel was unlawfully in the possession of another person without the consent of the owner.

[Act 1 of 2019 wef 01/04/2019]

### **Disposal of things forfeited**

**29.**—(1) All things which are forfeited to the Government under this Act shall be disposed of in such manner as the Minister thinks fit.

(2) The Minister may, in his discretion and after any proceedings under this Act are concluded, entertain and give effect to any claim to or in respect of anything which has been forfeited to the Government.

### **Obstruction of inspection or search**

**30.**—(1) It shall be an offence for a person to —

- (a) obstruct any officer of the Bureau, police officer, officer of customs or other public officer in the exercise of any power under this Act;

- (b) fail to comply with any lawful requirement of any officer of the Bureau, police officer, officer of customs or other public officer in the execution of his duty under this Act;
- (c) fail, without reasonable excuse, to furnish such information in his possession as may be required by any officer of the Bureau, police officer, officer of customs or other public officer; or
- (d) furnish to any officer of the Bureau, police officer, officer of customs or other public officer any information which he knows or has reason to believe to be false.

[12/77]

(2) In subsection (1), “public officer” includes any special police officer exercising any power under section 25 or 26.

[12/77]

[Act 1 of 2019 wef 01/04/2019]

### **Urine tests**

**31.—**(1) Any officer of the Bureau, immigration officer or police officer not below the rank of sergeant may, if he reasonably suspects any person to have committed an offence under section 8(b), require that person to provide a specimen of his urine for urine tests to be conducted under this section.

[12/77; 38/89]

(1A) The Director may, for the purpose of ensuring that a relevant person is no longer a drug addict, after the relevant time, order the relevant person —

- (a) to present himself to any officer of the Bureau, immigration officer or police officer not below the rank of sergeant; and
- (b) to provide a specimen of the relevant person’s urine for urine tests to be conducted under this section as required by such officer.

[Act 1 of 2019 wef 01/04/2019]

(1B) Any serviceman in the Singapore Armed Forces who is appointed by the Minister as an enforcement officer may, if the enforcement officer reasonably suspects a person subject to military

law under section 3 of the Singapore Armed Forces Act (Cap. 295) to have committed an offence under section 8(b), require that person to provide a specimen of that person's urine for urine tests to be conducted under this section.

[Act 1 of 2019 wef 01/04/2019]

(2) A person who fails, without reasonable excuse, to provide a specimen of his urine within such time as may be required by any of the officers referred to in subsection (1), (1A) or (1B) shall be guilty of an offence.

[12/77]

[Act 1 of 2019 wef 01/04/2019]

(2A) A person who fails, without reasonable excuse, to comply with an order under subsection (1A) shall be guilty of an offence.

[Act 1 of 2019 wef 01/04/2019]

(3) Any person (other than a citizen of Singapore or a permanent resident) arriving in Singapore by land, sea or air who —

(a) fails to comply with the requirement of an immigration officer under this section; or

(b) is found as a result of urine tests conducted under subsection (4)(a) or (b) to have consumed a controlled drug,

may be prohibited from entering or remaining in Singapore.

[38/89; 2/2006]

(4) A specimen of urine provided under this section shall be divided into 3 parts and dealt with, in such manner and in accordance with such procedure as may be prescribed, as follows:

(a) a preliminary urine test shall be conducted on one part of the urine specimen; and

(b) each of the remaining 2 parts of the urine specimen shall be marked and sealed and a urine test shall be conducted on each part by a different person, being either an analyst employed by the Health Sciences Authority or any person as the Minister may, by notification in the *Gazette*, appoint for such purpose.

[2/2006]

(5) Notwithstanding subsection (4), where upon conducting any preliminary urine test under subsection (4)(a), a part of a urine specimen has tested negative for controlled drugs, any of the officers referred to in subsection (1), (1A) or (1B) may either discard the remaining 2 parts of the same urine specimen or proceed in accordance with subsection (4)(b).

[Act 30 of 2012 wef 01/05/2013]

[Act 1 of 2019 wef 01/04/2019]

(6) A certificate stating the result of a urine test shall be signed by an analyst employed by the Health Sciences Authority or any other person that the Minister, by notification in the *Gazette*, appoints for such purpose.

[Act 30 of 2012 wef 01/05/2013]

(7) The certificate stating the result of a urine test may be signed by an analyst or person appointed under subsection (6) notwithstanding that he did not personally conduct the test to analyse the urine specimen as long as the test was conducted by another person acting under his direction.

[Act 30 of 2012 wef 01/05/2013]

(8) In this section, a specimen of urine may be collected from a person on different occasions within the time referred to in subsection (2).

[Act 30 of 2012 wef 01/05/2013]

(9) In this section and section 31A —

“relevant person” means —

- (a) any person discharged from an approved institution;
- (b) any person convicted of an offence under subsection (2) or section 8(b) or 31A(2);
- (c) any person subject to a supervision order made under section 34(2)(a) whose supervision order has lapsed; or
- (d) any person who —
  - (i) after having undergone treatment and rehabilitation at approved or other institutions; or

- (ii) after having been convicted of an offence under subsection (2) or section 8(b) or 31A(2) or an offence under section 34 of the Singapore Armed Forces Act,

has been subject to a supervision order made pursuant to the regulations, and the supervision order has lapsed;

“relevant time” means —

- (a) in relation to a person mentioned in paragraph (a) of the definition of “relevant person”, the time the person is discharged from the approved institution;
- (b) in relation to a person mentioned in paragraph (b) of the definition of “relevant person”, the time the person is convicted of the offence under subsection (2) or section 8(b) or 31A(2);
- (c) in relation to a person mentioned in paragraph (c) of the definition of “relevant person”, the time the supervision order lapses; or
- (d) in relation to a person mentioned in paragraph (d) of the definition of “relevant person”, the time the supervision order lapses.

[Act 1 of 2019 wef 01/04/2019]

### Hair tests

**31A.—(1)** Any officer of the Bureau, immigration officer or police officer not below the rank of sergeant may, if he reasonably suspects any person to have committed an offence under section 8(b), require that person to provide specimens of his hair for a hair test to be conducted under this section.

(1A) The Director may, for the purpose of ensuring that a relevant person is no longer a drug addict, after the relevant time, order the relevant person —

- (a) to present himself to any officer of the Bureau, immigration officer or police officer not below the rank of sergeant; and

- (b) to provide specimens of the relevant person's hair for a hair test to be conducted under this section as required by such officer.

[Act 1 of 2019 wef 01/04/2019]

(2) A person who fails, without reasonable excuse, to provide specimens of his hair of such type and quantity as may be required by any of the officers referred to in subsection (1) or (1A) shall be guilty of an offence.

[Act 1 of 2019 wef 01/04/2019]

(2A) A person who fails, without reasonable excuse, to comply with an order under subsection (1A) shall be guilty of an offence.

[Act 1 of 2019 wef 01/04/2019]

(3) All specimens of hair provided under this section shall be marked and sealed for hair testing in accordance with the prescribed procedure.

(4) A certificate stating the result of a hair test shall be signed by an analyst employed by the Health Sciences Authority or any other person that the Minister, by notification in the *Gazette*, appoints for such purpose.

(5) The certificate stating the result of a hair test may be signed by an analyst or person appointed under subsection (4) notwithstanding that he did not personally conduct the test to analyse the specimens of hair as long as the test was conducted by another person acting under his direction.

[Act 30 of 2012 wef 01/05/2013]

### **Oral fluid tests**

**31B.**—(1) Any officer of the Bureau, immigration officer or police officer not below the rank of sergeant may, if the officer reasonably suspects any person to have committed an offence under section 8(b), require that person to provide one or more specimens of the person's oral fluid for the purpose of conducting any oral fluid test.

(2) A person who fails, without reasonable excuse, to provide any specimen of the person's oral fluid as required under subsection (1) shall be guilty of an offence.

(3) In this section —

“oral fluid test” means a test carried out by an oral fluid testing device for the purpose of ascertaining whether any controlled drug is present in the person’s oral fluid;

“oral fluid testing device” means any device that is designed to indicate the presence of any controlled drug in the person’s oral fluid.

*[Act 1 of 2019 wef 01/04/2019]*

### **Power of investigation of officers of Bureau**

**32.—**(1) In any case relating to the commission of an offence under this Act, an officer of the Bureau shall have all the powers of a police officer under the Criminal Procedure Code (Cap. 68) in relation to an investigation into a seizable offence.

*[49/75; 20/98]*

(1A) Where any search is conducted by an officer of the Bureau under section 24 or 26 in relation to a drug specified in the Fifth Schedule or any substance containing such drug, the officer may examine orally any person found within the place searched and section 22 of the Criminal Procedure Code shall apply, with the necessary modifications, to any statement made by any person so examined.

*[Act 30 of 2012 wef 01/05/2013]*

(2) In any case relating to the commission of an offence under the regulations —

(a) where the offence is seizable, an officer of the Bureau shall have all the powers of a police officer under the Criminal Procedure Code in relation to an investigation into a seizable offence; and

(b) where the offence is non-seizable, an officer of the Bureau shall have all the powers of a police officer under the Criminal Procedure Code in relation to an investigation into a non-seizable offence.

*[20/98]*

(3) For the purposes of subsections (1) and (2)(a), when an officer of the Bureau is exercising the powers of a police officer under the



Criminal Procedure Code 2010, the officer of the Bureau shall be deemed to be an officer not below the rank of inspector of police.

*[15/2010 wef 02/01/2011]*

### **Officer of Bureau to be armed**

**32A.** Every officer of the Bureau shall be provided with such staves, arms, ammunition and other accoutrements as may be necessary for the effective discharge of his duties.

*[2/2006]*

### **Punishment for offences**

**33.—**(1) Except as provided in subsection (4A), (4B) or (4C) or under section 33A, the Second Schedule shall have effect, in accordance with subsections (2) and (3), with respect to the way in which offences under this Act are punishable on conviction.

*[12/77; 20/98]*

*[Act 30 of 2012 wef 01/05/2013]*

*[Act 1 of 2019 wef 01/04/2019]*

(2) In relation to an offence under any provision of this Act specified in the first column of the Second Schedule (the general nature of the offence being described in the second column thereof) —

- (a) the third, fourth and fifth columns show, respectively, the punishments to be imposed on a person convicted of the offence according to whether the controlled drug in relation to which the offence was committed was a Class A drug, a Class B drug or a Class C drug, except as otherwise provided in paragraph (b);
- (b) the sixth column shows the punishments to be imposed on a person convicted of the offence where the offence was committed —
  - (i) in the case of unauthorised manufacture, in relation to such specified controlled drug as is mentioned in the second column; and
  - (ii) in the case of unauthorised traffic or import or export, in relation to a specified quantity of such

controlled drug or to a controlled drug (except opium) containing such quantity of morphine or diamorphine as is mentioned in the second column; and

- (c) the seventh column shows the punishments to be imposed on a person convicted of the offence whether or not the offence was committed in relation to a controlled drug and, if it was so committed, irrespective of the nature of the drug.

(3) In the third, fourth, fifth, sixth and seventh columns of the Second Schedule, a reference to a period gives the maximum or minimum term of imprisonment as is specified, a reference to a sum of money gives the maximum or minimum fine as is specified, and a reference to a number of strokes gives the number of strokes of caning with which the offender shall, subject to sections 325(1) and 330(1) of the Criminal Procedure Code 2010, be punished.

*[15/2010 wef 02/01/2011]*

*[49/75]*

(3A) Any person convicted of an offence under section 8(b), 31(2) or 31A(2) that is committed on or after the date of commencement of section 16 of the Misuse of Drugs (Amendment) Act 2019 shall on conviction be punished with imprisonment for a term of not less than one year but not more than 10 years and shall also be liable to a fine not exceeding \$20,000, unless the person is punished under subsection (4), (4AA) or (4AB) or section 33A (as the case may be) for that same offence.

*[Act 1 of 2019 wef 01/04/2019]*

(4) If any person who has a previous conviction under section 8(b) or 31(2) is again convicted of an offence under section 8(b) or 31(2), he shall on conviction be punished with imprisonment for a term of not less than 3 years unless he is punished under section 33A for that same offence.

*[20/98]*

*[Act 1 of 2019 wef 01/04/2019]*

(4AA) If a person —

(a) has —

- (i) a previous conviction under section 31A(2);
- (ii) a previous admission under section 34(2) to an approved institution; or
- (iii) a previous conviction under section 34 of the Singapore Armed Forces Act; and

(b) is convicted of an offence under section 8(b) or 31(2), being an offence which is committed on or after the date of commencement of section 16 of the Misuse of Drugs (Amendment) Act 2019,

he shall on conviction be punished with imprisonment for a term of not less than 3 years unless he is punished under section 33A for that same offence.

*[Act 1 of 2019 wef 01/04/2019]*

(4AB) If a person —

(a) has —

- (i) a previous conviction under section 8(b), 31(2) or 31A(2);
- (ii) a previous admission under section 34(2) to an approved institution; or
- (iii) a previous conviction under section 34 of the Singapore Armed Forces Act; and

(b) is convicted of an offence under section 31A(2), being an offence which is committed on or after the date of commencement of section 16 of the Misuse of Drugs (Amendment) Act 2019,

he shall on conviction be punished with imprisonment for a term of not less than 3 years unless he is punished under section 33A for that same offence.

*[Act 1 of 2019 wef 01/04/2019]*

(4AC) A certificate purporting to be signed by an officer authorised by the Commissioner of Prisons and purporting to relate to a person's

previous admission to an approved institution under this Act is admissible in evidence in any proceedings under this section, on its production by the prosecution without proof of signature.

*[Act 1 of 2019 wef 01/04/2019]*

(4AD) A certificate —

(a) purporting to be signed by the registrar for the subordinate military courts, or the registrar for the Military Court of Appeal, appointed under section 82(5)(c) of the Singapore Armed Forces Act; and

(b) purporting to relate to a person's previous conviction under section 34 of the Singapore Armed Forces Act,

is admissible in evidence, in any proceedings under this section, on its production by the prosecution without proof of signature.

*[Act 1 of 2019 wef 01/04/2019]*

(4AE) The certificate mentioned in subsection (4AC) or (4AD) is, until the contrary is proved, evidence of the matters contained in it.

*[Act 1 of 2019 wef 01/04/2019]*

(4A) Where —

(a) any person is convicted of an offence under section 5(1) or 7; and

(b) that person is again convicted of an offence under section 5(1) or 7,

that person so convicted shall be punished with —

(i) in relation to a Class A drug —

(A) imprisonment for a term of not less than 10 years and not more than 30 years; and

(B) not less than 10 strokes and not more than 15 strokes of the cane;

(ii) in relation to a Class B drug —

(A) imprisonment for a term of not less than 6 years and not more than 30 years; and

(B) not less than 6 strokes and not more than 15 strokes of the cane; and

(iii) in relation to a Class C drug —

- (A) imprisonment for a term of not less than 4 years and not more than 20 years; and
- (B) not less than 4 strokes and not more than 15 strokes of the cane.

*[Act 30 of 2012 wef 01/05/2013]*

(4B) If a person of or above the age of 21 years is convicted of an offence under section 5(1) or 7 and the intended recipient of the controlled drug which is, or is to be, trafficked is a young person or a vulnerable person, that person so convicted shall be punished with —

(a) in relation to a Class A drug —

- (i) imprisonment for a term of not less than 10 years and not more than 30 years; and
- (ii) not less than 10 strokes and not more than 15 strokes of the cane;

(b) in relation to a Class B drug —

- (i) imprisonment for a term of not less than 6 years and not more than 30 years; and
- (ii) not less than 6 strokes and not more than 15 strokes of the cane; and

(c) in relation to a Class C drug —

- (i) imprisonment for a term of not less than 4 years and not more than 20 years; and
- (ii) not less than 4 strokes and not more than 15 strokes of the cane.

*[Act 30 of 2012 wef 01/05/2013]*

(4C) If a person of or above the age of 21 years is convicted of an offence under section 11A (Arranging or planning gatherings where controlled drugs are to be consumed or trafficked) and the gathering consists of any young person or vulnerable person, that person so convicted shall be punished with —

- (a) imprisonment for a term of not less than 5 years and not more than 20 years; and

- (b) not less than 3 strokes and not more than 10 strokes of the cane.

*[Act 30 of 2012 wef 01/05/2013]*

(4D) The punishment provided under subsection (4A) or (4B) in relation to an offence shall apply only if the punishment as shown in the sixth column of the Second Schedule is not applicable in relation to that offence.

*[Act 30 of 2012 wef 01/05/2013]*

(5) For the purposes of this section —

- (a) a conviction under section 8(b) by a court including a subordinate military court or the Military Court of Appeal constituted under the Singapore Armed Forces Act at any time on or after 1 October 1992 is deemed to be a previous conviction under section 8(b);
- (b) a conviction under section 31(2) by a court including a subordinate military court or the Military Court of Appeal constituted under the Singapore Armed Forces Act at any time on or after 1 October 1992 is deemed to be a previous conviction under section 31(2);
- (c) a conviction under section 31A(2) by a court including a subordinate military court or the Military Court of Appeal constituted under the Singapore Armed Forces Act at any time on or after 1 May 2013 is deemed to be a previous conviction under section 31A(2);
- (d) a conviction under section 34 of the Singapore Armed Forces Act on or after the date of commencement of section 16 of the Misuse of Drugs (Amendment) Act 2019 is deemed to be a previous conviction under section 34 of the Singapore Armed Forces Act;
- (e) “admission” means an admission under section 34(2) to an approved institution at any time on or after 1 October 1992; and
- (f) “convicted of an offence”, in relation to an offence under section 8(b), 31(2) or 31A(2), includes a conviction by a

subordinate military court or the Military Court of Appeal constituted under the Singapore Armed Forces Act.

*[Act 1 of 2019 wef 01/04/2019]*

### **Punishment for repeat consumption of specified drugs**

**33A.**—(1) Where a person who has not less than —

- (a) 2 previous admissions;
- (b) 2 previous convictions for consumption of a specified drug under section 8(b);
- (c) 2 previous convictions for an offence of failure to provide a urine specimen under section 31(2);
- (d) one previous admission and one previous conviction for consumption of a specified drug under section 8(b);
- (e) one previous admission and one previous conviction for an offence of failure to provide a urine specimen under section 31(2); or
- (f) one previous conviction for consumption of a specified drug under section 8(b) and one previous conviction for an offence of failure to provide a urine specimen under section 31(2),

is convicted of an offence under section 8(b) for consumption of a specified drug or an offence of failure to provide a urine specimen under section 31(2), he shall on conviction be punished with —

- (i) imprisonment for a term of not less than 5 years and not more than 7 years; and
- (ii) not less than 3 strokes and not more than 6 strokes of the cane.

*[20/98]*

(1A) Where a person who has not less than —

- (a) 2 previous admissions;
- (b) 2 previous convictions for consumption of a specified drug under section 8(b);

- (c) 2 previous convictions for an offence of failure to provide a urine specimen under section 31(2);
- (d) one previous admission and one previous conviction for consumption of a specified drug under section 8(b);
- (e) one previous admission and one previous conviction for an offence of failure to provide a urine specimen under section 31(2); or
- (f) one previous conviction for consumption of a specified drug under section 8(b) and one previous conviction for an offence of failure to provide a urine specimen under section 31(2),

is convicted of an offence under section 31A(2) for failure to provide a hair specimen, being an offence that is committed on or after the date of commencement of section 17 of the Misuse of Drugs (Amendment) Act 2019, he shall on conviction be punished with the same punishment mentioned in subsection (1).

*[Act 1 of 2019 wef 01/04/2019]*

(1B) Where a person who has not less than —

- (a) 2 previous convictions for an offence relating to the consumption of a controlled drug that is a specified drug under section 34 of the Singapore Armed Forces Act;
- (b) one previous admission and one previous conviction for an offence relating to the consumption of a controlled drug that is a specified drug under section 34 of the Singapore Armed Forces Act;
- (c) one previous conviction for an offence relating to the consumption of a controlled drug that is a specified drug under section 34 of the Singapore Armed Forces Act and one previous conviction for an offence of failure to provide a urine specimen under section 31(2);
- (d) 2 previous convictions for an offence of failure to provide a hair specimen under section 31A(2);



- (e) one previous admission and one previous conviction for an offence of failure to provide a hair specimen under section 31A(2);
- (f) one previous conviction for consumption of a specified drug under section 8(b) and one previous conviction for an offence of failure to provide a hair specimen under section 31A(2);
- (g) one previous conviction for consumption of a specified drug under section 8(b) and one previous conviction for an offence relating to the consumption of a controlled drug that is a specified drug under section 34 of the Singapore Armed Forces Act;
- (h) one previous conviction for an offence relating to the consumption of a controlled drug that is a specified drug under section 34 of the Singapore Armed Forces Act, and one previous conviction for an offence of failure to provide a hair specimen under section 31A(2); or
- (i) one previous conviction for an offence of failure to provide a urine specimen under section 31(2) and one previous conviction for an offence of failure to provide a hair specimen under section 31A(2),

is convicted of an offence of consumption of a specified drug under section 8(b), an offence of failure to provide a urine specimen under section 31(2), or an offence of failure to provide a hair specimen under section 31A(2), being an offence that is committed on or after the date of commencement of section 17 of the Misuse of Drugs (Amendment) Act 2019, he shall on conviction be punished with the same punishment mentioned in subsection (1).

*[Act 1 of 2019 wef 01/04/2019]*

(2) Where a person who has been convicted under subsection (1), (1A) or (1B) is again convicted of an offence for consumption of a specified drug under section 8(b), an offence of failure to provide a urine specimen under section 31(2), or an offence of failure to provide a hair specimen under section 31A(2), he shall on conviction be punished with —

- (a) imprisonment for a term of not less than 7 years and not more than 13 years; and
- (b) not less than 6 strokes and not more than 12 strokes of the cane.

*[Act 1 of 2019 wef 01/04/2019]*

(3) A certificate purporting to be signed by an officer authorised in writing by the Commissioner of Prisons and purporting to relate to a person's previous admission to an approved institution under this Act shall be admissible in evidence in any proceedings under this section, on its production by the prosecution without proof of signature; and, until the contrary is proved, that certificate shall be evidence of all matters contained therein.

*[20/98]*

*[Act 1 of 2014 wef 01/07/2014]*

(4) A certificate purporting to be signed by the Registrar for the subordinate military courts or for the Military Court of Appeal appointed under section 82(5) of the Singapore Armed Forces Act (Cap. 295) shall be admissible in evidence, in any proceedings under this section, on its production by the prosecution without proof of signature; and, until the contrary is proved, that certificate shall be evidence of a person's previous conviction by a subordinate military court or the Military Court of Appeal.

*[20/98]*

(5) For the purposes of this section —

- (a) a conviction under section 8(b) by a court including a subordinate military court or the Military Court of Appeal constituted under the Singapore Armed Forces Act at —
  - (i) any time on or after 1st October 1992 but before the relevant date for the consumption of a controlled drug which, on the date of any subsequent conviction, is specified in the Fourth Schedule; or
  - (ii) any time on or after the relevant date for the consumption of a specified drug,

shall be deemed to be a previous conviction for consumption of a specified drug under section 8(b);

- (b) a conviction under section 31(2) by a court including a subordinate military court or the Military Court of Appeal constituted under the Singapore Armed Forces Act at any time on or after 1st October 1992 shall be deemed to be a previous conviction for an offence of failure to provide a urine specimen under section 31(2);
- (ba) a conviction under section 31A(2) by a court including a subordinate military court or the Military Court of Appeal constituted under the Singapore Armed Forces Act at any time on or after 1 May 2013 is deemed to be a previous conviction for an offence of failure to provide a hair specimen under section 31A(2);  
*[Act 1 of 2019 wef 01/04/2019]*
- (bb) a conviction under section 34 of the Singapore Armed Forces Act on or after the date of commencement of section 17 of the Misuse of Drugs (Amendment) Act 2019 for an offence of consumption of a controlled drug that is a specified drug is deemed to be a previous conviction for an offence relating to the consumption of a controlled drug that is a specified drug under section 34 of the Singapore Armed Forces Act;  
*[Act 1 of 2019 wef 01/04/2019]*
- (c) “admission” means an admission under section 34(2) to an approved institution at —
- (i) any time on or after 1st October 1992 but before the relevant date for the consumption of a controlled drug which, on the date of any subsequent conviction, is specified in the Fourth Schedule; or
  - (ii) any time on or after the relevant date for the consumption of a specified drug;
- (ca) “convicted of an offence”, in relation to an offence under section 8(b), 31(2) or 31A(2), includes a conviction by a subordinate military court or the Military Court of Appeal constituted under the Singapore Armed Forces Act; and  
*[Act 1 of 2019 wef 01/04/2019]*

(d) “relevant date” —

- (i) in relation to a conviction or admission for consumption of diamorphine, morphine or opium, means 20th July 1998; and
- (ii) in relation to a conviction or admission for consumption of any drug added to the Fourth Schedule after 20th July 1998, means the date on which the amendment to that Schedule for the inclusion of such drug commences.

[2/2006]

### **Discretion of court not to impose sentence of death in certain circumstances**

**33B.**—(1) Where a person commits or attempts to commit an offence under section 5(1) or 7, being an offence punishable with death under the sixth column of the Second Schedule, and he is convicted thereof, the court —

- (a) may, if the person satisfies the requirements of subsection (2), instead of imposing the death penalty, sentence the person to imprisonment for life and, if the person is sentenced to life imprisonment, he shall also be sentenced to caning of not less than 15 strokes; or
  - (b) shall, if the person satisfies the requirements of subsection (3), instead of imposing the death penalty, sentence the person to imprisonment for life.
- (2) The requirements referred to in subsection (1)(a) are as follows:
- (a) the person convicted proves, on a balance of probabilities, that his involvement in the offence under section 5(1) or 7 was restricted —
    - (i) to transporting, sending or delivering a controlled drug;
    - (ii) to offering to transport, send or deliver a controlled drug;

- (iii) to doing or offering to do any act preparatory to or for the purpose of his transporting, sending or delivering a controlled drug; or
    - (iv) to any combination of activities in sub-paragraphs (i), (ii) and (iii); and
  - (b) the Public Prosecutor certifies to any court that, in his determination, the person has substantively assisted the Central Narcotics Bureau in disrupting drug trafficking activities within or outside Singapore.
- (3) The requirements referred to in subsection (1)(b) are that the person convicted proves, on a balance of probabilities, that —
- (a) his involvement in the offence under section 5(1) or 7 was restricted —
    - (i) to transporting, sending or delivering a controlled drug;
    - (ii) to offering to transport, send or deliver a controlled drug;
    - (iii) to doing or offering to do any act preparatory to or for the purpose of his transporting, sending or delivering a controlled drug; or
    - (iv) to any combination of activities in sub-paragraphs (i), (ii) and (iii); and
  - (b) he was suffering from such abnormality of mind (whether arising from a condition of arrested or retarded development of mind or any inherent causes or induced by disease or injury) as substantially impaired his mental responsibility for his acts and omissions in relation to the offence under section 5(1) or 7.
- (4) The determination of whether or not any person has substantively assisted the Central Narcotics Bureau in disrupting drug trafficking activities shall be at the sole discretion of the Public Prosecutor and no action or proceeding shall lie against the Public

Prosecutor in relation to any such determination unless it is proved to the court that the determination was done in bad faith or with malice.

*[Act 30 of 2012 wef 01/01/2013]*

## PART IV

### TREATMENT AND REHABILITATION

#### **Supervision, treatment and rehabilitation of drug addicts**

**34.**—(1) The Director may order any person whom the Director reasonably suspects to be a drug addict to be committed, for a period not exceeding 7 days, to any place specified by the Director for the purpose of any medical examination or observation.

*[38/89]*

*[Act 1 of 2019 wef 01/08/2019]*

(2) If, as a result of such medical examination or observation under subsection (1) or both the urine tests conducted under section 31(4)(b) or the hair test conducted under section 31A, it appears to the Director that it is necessary for any person examined or observed, or who supplied the urine specimen for the urine tests, or who supplied the hair specimens for the hair test —

(a) to be subject to supervision, the Director may make a supervision order requiring that person to be subject to the supervision of an officer of the Bureau for a period not exceeding 5 years; or

*[Act 1 of 2019 wef 01/08/2019]*

(b) to undergo treatment or rehabilitation or both at an approved institution, the Director may make an order in writing requiring that person to be admitted for that purpose to an approved institution.

*[38/89]*

*[Act 1 of 2019 wef 01/08/2019]*

(2A) *[Deleted by Act 1 of 2019 wef 01/08/2019]*

(3) Every person who is admitted to an approved institution under this section shall be detained in the institution for a period of 12

months unless he is discharged earlier by the Director or the Review Committee of the institution.

[12/77]

[Act 1 of 2019 wef 01/08/2019]

(3A) Where a person who is admitted to an approved institution under this section is transferred from that approved institution to one or more other approved institutions or to one or more community rehabilitation centres, the combined period of his detention in all the approved institutions and community rehabilitation centres shall not be less than 12 months unless he is discharged earlier by the Director or the Review Committee of the approved institution or community rehabilitation centre.

[Act 30 of 2012 wef 28/04/2014]

[Act 1 of 2019 wef 01/08/2019]

(4) If the Review Committee of an approved institution or a community rehabilitation centre is of the opinion that an inmate of that institution or centre whose period of detention therein is about to expire requires further treatment or rehabilitation or both, the Committee may, by order in writing, direct that the inmate be detained in the institution or centre for a further period or periods not exceeding 12 months at any one time.

[Act 30 of 2012 wef 28/04/2014]

[Act 1 of 2019 wef 01/08/2019]

(4A) [*Deleted by Act 1 of 2019 wef 01/08/2019*]

(5) No person in respect of whom an order has been made under subsection (2)(b) shall be detained in an approved institution or institutions or a community rehabilitation centre or centres for a period of more than 4 years after his admission to any approved institution pursuant to that order.

[Act 1 of 2019 wef 01/08/2019]

[Act 30 of 2012 wef 28/04/2014]

[12/77; 28/79; 2/2006]

### **Parents or guardians to attend counselling with supervisees**

**34A.**—(1) If the Director, on or after the date of commencement of section 19 of the Misuse of Drugs (Amendment) Act 2019, makes a supervision order under section 34(2)(a) against a supervisee who is

below 21 years of age, the Director may require the parent or guardian of the supervisee to attend any counselling session (whether or not together with the supervisee) at such place and time as the Director, or any person authorised by the Director, determines.

(2) Any parent or guardian of a supervisee who fails, without reasonable excuse, to comply with the requirement under subsection (1) shall be guilty of an offence and shall be liable on conviction to a fine not exceeding \$5,000.

(3) A court may, in lieu of imposing a fine, order a parent or guardian of a supervisee to attend any counselling session at such place and time as the Director, or any person authorised by the Director, determines.

*[Act 1 of 2019 wef 01/08/2019]*

### **Approved institutions and community rehabilitation centres**

**35.** The Minister may, from time to time, by notification in the *Gazette*, declare any institution or place to be an approved institution or a community rehabilitation centre for the purpose of the treatment and rehabilitation of drug addicts and other persons under this Act, and may at any time in like manner revoke or amend any such notification.

*[Act 30 of 2012 wef 28/04/2014]*

### **Administration of approved institutions**

**36.—(1)** Subject to the directions of the Minister, the general charge and administration of —

(a) approved institutions, except those designated under paragraph (b), shall be under the Commissioner of Prisons; and

*[Act 1 of 2014 wef 01/07/2014]*

(b) such approved institutions as the Minister may designate, shall be under such person as the Minister may appoint.

*[20/98]*

(2) The Commissioner of Prisons or the person appointed under subsection (1)(b), as the case may be, may appoint a person to be the superintendent of an approved institution and such person shall be



responsible for the supervision and administration of that approved institution.

[20/98]

[Act 1 of 2014 wef 01/07/2014]

(3) Subject to such modifications as may be made by the Commissioner of Prisons, the standing orders issued under the Prisons Act (Cap. 247) shall apply to an approved institution under the charge of the Commissioner of Prisons as they apply to a prison.

[20/98]

[Act 1 of 2014 wef 01/07/2014]

(4) The person appointed under subsection (1)(b) may in writing issue orders, to be called standing orders, for the approved institutions designated under his charge.

[20/98]

### **Administration of community rehabilitation centres**

**36A.**—(1) Subject to the directions of the Minister, the general charge and administration of a community rehabilitation centre shall be under the Director of Prisons.

[Act 30 of 2012 wef 28/04/2014]

(2) The Director of Prisons may appoint a person to be the manager of the community rehabilitation centre and such person shall be responsible for the supervision and administration of that community rehabilitation centre.

[Act 30 of 2012 wef 28/04/2014]

### **Review Committees for approved institutions and community rehabilitation centres**

**37.**—(1) The Minister shall appoint for any approved institution or institutions, or any community rehabilitation centre or centres, a Review Committee which shall have such functions as are conferred upon it by this Act.

[Act 30 of 2012 wef 28/04/2014]

[12/77]

(2) Every Review Committee shall consist of a Chairman, who shall be a person registered under the Medical Registration Act

(Cap. 174), and such other members, not being less than 3, as the Minister may determine.

[12/77; 38/89]

(3) The Chairman and members of a Review Committee shall be appointed by the Minister for a term not exceeding 3 years, but may —

- (a) from time to time be reappointed;
- (b) at any time be removed from office by the Minister; or
- (c) at any time resign from their office in writing addressed to the Minister.

[12/77]

(4) At any meeting of the Review Committee, 3 members of the Committee shall constitute a quorum.

[12/77]

(5) The Chairman shall preside at every meeting of the Review Committee at which he is present and in his absence the members present shall elect one of their number to preside at the meeting.

[12/77]

(6) Every question before the Review Committee shall be determined by a majority of the votes of the members present and voting thereon, and in the event of an equality of votes the Chairman or the member presiding at the meeting shall have a casting vote in addition to his original vote.

[12/77]

(7) Subject to the provisions of this Act, the Review Committee may determine its own procedure.

[12/77]

(8) Any order of the Review Committee may be signed by the Chairman or a member of the Committee.

[12/77]

### **Review, discharge and transfer of inmates**

**38.**—(1) The Review Committee of an approved institution or a community rehabilitation centre shall keep the case of every inmate under review and shall, as often as practicable, consider whether he should be discharged.

(2) The Director or the Review Committee of an approved institution or a community rehabilitation centre may at any time by order in writing —

- (a) discharge any inmate; or
- (b) transfer any inmate from one approved institution or community rehabilitation centre to another approved institution or community rehabilitation centre.

(3) The Superintendent of an approved institution or the manager of a community rehabilitation centre may enter into an arrangement with the Superintendent of another approved institution or the manager of another community rehabilitation centre for the transfer of any inmate to that other institution or community rehabilitation centre and may, subject to any direction given by the Director or the Review Committee, carry out any transfer in accordance with that arrangement.

(4) On proof to his satisfaction that the presence at any place of an inmate is required in the interests of justice, or for the purpose of any inquiry, or in the public interest or in the interest of the inmate, the Superintendent of an approved institution or the manager of a community rehabilitation centre may order that the inmate be taken to that place.

*[Act 30 of 2012 wef 28/04/2014]*

### **Power of Magistrate to inquire into complaint of misconduct or breach of duty**

**39.—**(1) Where a complaint is made on oath to a Magistrate that any person is improperly detained in an approved institution or a community rehabilitation centre by reason of any misconduct or breach of duty on the part of any officer in the discharge of his functions pursuant to this Act, the Magistrate may —

- (a) inquire into the complaint himself; or
- (b) direct a police officer to make an inquiry for the purpose of ascertaining the truth or falsehood of the complaint and report to the Magistrate the result of the inquiry.

*[Act 30 of 2012 wef 28/04/2014]*

*[12/77]*

(2) Every inquiry under subsection (1) shall be conducted in private, except that the procedure for conducting any inquiry shall be such as the Magistrate considers appropriate in the circumstances of the case.

[12/77]

(3) A Magistrate or a police officer conducting any inquiry under subsection (1) shall have all the powers conferred on him by the Criminal Procedure Code (Cap. 68) in relation to the attendance and examination of witnesses, the taking of evidence and the production of documents.

[12/77]

(4) If, after considering the result of any such inquiry, the Magistrate is satisfied that any person who is detained in an approved institution or a community rehabilitation centre ought not to be so detained, the Magistrate may make an order for the discharge of that person from the approved institution or community rehabilitation centre and that person shall be discharged accordingly.

[Act 30 of 2012 wef 28/04/2014]

(5) Any order or decision of the Magistrate made under this section shall be final.

[12/77]

(6) No evidence taken for the purpose of any such inquiry shall be admissible in any civil or criminal proceedings, except where the person who gave that evidence is charged with giving or fabricating false evidence.

[12/77]

### **Inmates deemed to be in legal custody**

**40.**—(1) Every inmate shall be deemed to be in the legal custody of the approved institution or community rehabilitation centre in which he is for the time being detained.

(2) An inmate shall be deemed to be in legal custody —

- (a) while he is confined in, or is being taken to or from, an approved institution or a community rehabilitation centre;
- (b) while he is for any other reason outside an approved institution or a community rehabilitation centre and in the

custody or under the control of an officer of the approved institution or community rehabilitation centre; or

- (c) while he is being taken to any place to which he is required or authorised under this Act to be taken, or is kept in custody in pursuance of any such requirement or authorisation.

*[Act 30 of 2012 wef 28/04/2014]*

## PART V

### TAKING OF PHOTOGRAPHS, FINGER IMPRESSIONS, PARTICULARS AND BODY SAMPLES

#### **Interpretation of this Part**

**40A.—**(1) In this Part, unless the context otherwise requires —

“appropriate consent” means —

- (a) for a person aged 16 years and above, the written consent of that person;
- (b) for a person aged 14 years and above but below the age of 16 years, the written consent of both that person and of his parent or guardian; and
- (c) for a person below the age of 14 years, the written consent of his parent or guardian,

given to —

- (i) a police officer or an officer of the Bureau in charge of the case; or
- (ii) a prison officer,

after that officer has informed the person concerned, his parent or guardian or both, as the case may be, of the purpose for which a body sample is required from such person and the manner by which such body sample is to be taken from him;

“authorised analyst” means a person appointed by the Commissioner of Police to be an analyst for the purposes of this Part;

“body sample” means —

- (a) a sample of blood;
- (b) a sample of head hair, including the roots thereof;
- (c) a swab taken from a person’s mouth; or
- (d) such other sample as may be prescribed under subsection (2);

“DNA” means deoxyribonucleic acid;

“DNA information” means genetic information derived from the forensic DNA analysis of a body sample;

“finger impression” includes thumb impression and palmar impression;

“intimate sample” means any body sample that is obtained by means of any invasive procedure, but does not include any sample described in subsection (3);

“particulars”, in relation to a person, means any particulars, information or description of that person that may be relevant or useful in the identification of that person;

“photograph”, in relation to a person, includes the photograph of any distinguishing feature or mark on the body of that person;

“registered medical practitioner” has the same meaning as in the Medical Registration Act (Cap. 174) and includes a dentist registered under the Dental Registration Act (Cap. 76).

[2/2006; 22/2007]

(2) Subject to subsection (3), the Minister may prescribe additional types of body samples that may be taken under section 40B.

[2/2006]

(3) The additional types of body samples that may be prescribed under subsection (2) shall not include samples to be obtained from —

- (a) the genital or anal area of a person’s body;
- (b) a person’s body orifice other than the mouth; or
- (c) the breast of a woman.

[2/2006]

**Taking of photographs, finger impressions, particulars and body samples from person subject to supervision or in approved institutions**

**40B.**—(1) Any police officer, prison officer, officer of the Bureau or person authorised by the Commissioner of Police may exercise all or any of the following powers in respect of any person referred to in subsection (2):

- (a) take or cause to be taken photographs and finger impressions of such person;
- (b) make or cause to be made a record of the particulars of such person;
- (c) cause body samples of such person to be taken by a person authorised under section 40C(1);
- (d) send any photograph, finger impression, record of particulars or body sample so taken or made to the Commissioner of Police for identification and report.

[2/2006]

(2) The powers referred to in subsection (1) may be exercised in respect of a person who on or after 1st March 2006 —

- (a) is subject to supervision pursuant to a supervision order made at any time (whether before, on or after that date) under section 34(2)(a);
- (b) is in an approved institution pursuant to an order made at any time (whether before, on or after that date) under section 34(2)(b); or
- (c) is subject to a supervision order made at any time (whether before, on or after that date) under any regulations providing for the supervision and aftercare of persons.

[2/2006]

(3) Every person mentioned in subsection (2) shall —

- (a) submit to the taking of his photographs and finger impressions under subsection (1);
- (b) provide such particulars as may be required under subsection (1); and

- (c) subject to subsection (5), submit to the taking of his body samples by a person authorised under section 40C(1).

[2/2006]

(4) Where any person mentioned in subsection (2) fails, without reasonable excuse, to comply with subsection (3) —

- (a) that person shall be guilty of an offence and shall be liable on conviction to a fine not exceeding \$1,000 or to imprisonment for a term not exceeding one month or to both; and

- (b) any police officer, prison officer, officer of the Bureau or person authorised by the Commissioner of Police may use such force as is reasonably necessary to take or cause to be taken the photographs, finger impressions and body samples of that person.

[2/2006]

(5) No —

- (a) sample of blood; or

- (b) intimate sample prescribed under section 40A(2),

shall be taken from any person unless the appropriate consent is given for the taking of the sample.

[2/2006]

### **Further provisions for taking of body samples**

**40C.**—(1) For the purposes of section 40B(1)(c), a body sample may only be taken by —

- (a) a registered medical practitioner;

- (b) a police officer, a prison officer or an officer of the Bureau who has received training for the purpose; or

- (c) any other suitably qualified or trained person who is duly appointed in writing by the Commissioner of Police as an authorised person for the purpose.

[2/2006]

(2) Before taking any body sample, the person authorised under subsection (1) to take the sample must satisfy himself that the taking



of the sample does not endanger the person from whom the sample is to be taken.

[2/2006]

(3) The fact that a body sample has been taken shall be recorded by the person who took the sample in such form or manner as may be required by the Commissioner of Police.

[2/2006]

(4) Every body sample taken shall be sent to an authorised analyst for forensic DNA analysis.

[2/2006]

### **Retention of photographs, finger impressions, particulars and body samples taken**

**40D.**—(1) The Commissioner of Police shall cause to be maintained —

- (a) a register (whether in a computerised form or otherwise) in which shall be stored all photographs, finger impressions and particulars of a person taken under section 40B; and
- (b) a DNA database (whether in a computerised form or otherwise) in which shall be stored all DNA information derived from a body sample taken from a person under section 40B.

[2/2006]

(2) Any information stored in the register and the DNA database under subsection (1) may be used for all or any of the following purposes:

- (a) for comparison with any other information or any other DNA information, as the case may be, obtained in the course of an investigation of an offence conducted by a police officer or an officer of the Bureau;
- (b) for comparison with information in the register established under section 4 of the Registration of Criminals Act (Cap. 268) or with DNA information in the DNA database established under section 13F of that Act, as the case may be;

- (c) for comparison with information or DNA information, as the case may be, in the register or DNA database, respectively, established under —
- (i) section 27C of the Criminal Law (Temporary Provisions) Act (Cap. 67); or
  - (ii) section 26D of the Intoxicating Substances Act (Cap. 146A);
- (d) for any proceedings for any offence;
- (e) for administering the register and DNA database for the purposes of this Act;
- (f) for such other purposes as may be prescribed.

[2/2006]

(3) For the purposes of subsection (2)(d) —

- (a) any photograph, finger impression or particulars stored in the register under subsection (1)(a);
- (b) any DNA information stored in the DNA database under subsection (1)(b); and
- (c) any certificate or report purporting to have been compiled or made from information stored in the register or DNA database maintained under subsection (1),

shall, if produced from proper custody and authenticated by the signature of the Commissioner of Police or a police officer authorised by the Commissioner of Police, be admissible in evidence in any proceedings without proof of signature and, until the contrary is proved, shall be proof of all matters contained therein.

[2/2006]

## PART VI

### COMMITTEE OF INQUIRY

#### **Committee of inquiry**

**41.—**(1) Where it is expedient that the Minister, or such other person as the Minister may appoint to exercise the powers conferred upon the Minister by sections 42, 49 and 51, should be informed on

any matter connected with the discipline, administration or functions of any approved institution or affecting any inmate, the Minister or the person appointed by the Minister may convene a committee of inquiry.

[8/2000]

(2) A committee of inquiry shall inquire into and report on the facts relating to any matter referred to it and, if directed by the Minister to do so, express its opinion on any question arising out of any such matter.

[8/2000]

(3) In this section and in sections 42, 49 and 51, “Minister” includes the person appointed by the Minister under subsection (1) to act on his behalf for the purposes of this section and sections 42, 49 and 51.

[8/2000]

### **Composition of committee of inquiry**

**42.—**(1) A committee of inquiry shall consist of one or more persons who shall be appointed by the Minister.

[8/2000]

(2) Where a committee of inquiry consists of more than one person, the Minister shall appoint one of the members to be the chairman.

[8/2000]

(3) Where a committee of inquiry consists of one member only, he shall be vested with the powers of a chairman.

[8/2000]

(4) Every member of a committee of inquiry appointed under this section shall be deemed to be a public servant within the meaning of the Penal Code (Cap. 224).

[8/2000]

### **Powers of committee of inquiry**

**43.** A committee of inquiry may —

- (a) summon any person to give evidence on oath or on affirmation or to produce any document or material necessary for the purpose of the inquiry; and

(b) visit any place in order to inquire into any matter which may arise in the course of the inquiry.

[8/2000]

### **Disobedience to summons**

**44.**—(1) A person who is summoned to give evidence before a committee of inquiry shall not, without lawful excuse, fail to appear in obedience to the summons.

[8/2000]

(2) A person who is required by a committee of inquiry to produce any document or material for the purpose of the inquiry shall not, without lawful excuse, fail to produce the document or material.

[8/2000]

(3) Any person who contravenes subsection (1) or (2) shall be guilty of an offence and shall be liable on conviction to a fine not exceeding \$2,000 or to imprisonment for a term not exceeding 6 months or to both.

[8/2000]

### **Refusal to give evidence**

**45.**—(1) A person who appears before a committee of inquiry shall not, without lawful excuse, refuse to be sworn or to make an affirmation, or to produce any document or material, or to answer any question, which he is lawfully required to produce or answer.

[8/2000]

(2) Any person who contravenes subsection (1) shall be guilty of an offence and shall be liable on conviction to a fine not exceeding \$2,000 or to imprisonment for a term not exceeding 6 months or to both.

[8/2000]

### **Giving of false evidence**

**46.** Every person who wilfully gives false evidence when examined on oath or on affirmation before a committee of inquiry shall be guilty of an offence and shall be liable on conviction to a fine not exceeding \$10,000 or to imprisonment for a term not exceeding 7 years or to both.

[8/2000]

### **Evidence and procedure**

**47.** Except as otherwise provided in this Act, a committee of inquiry shall not be bound by the rules of evidence and may act in such manner as the committee of inquiry thinks most expedient.

[8/2000]

### **Admissibility of evidence**

**48.** No statement made in the course of any inquiry and no report of a committee of inquiry shall be admissible as evidence in proceedings other than proceedings, whether criminal or disciplinary, for an offence of giving or fabricating false evidence under any written law.

[8/2000]

### **Proceedings not open to public**

**49.—(1)** A committee of inquiry shall not sit in public.

(2) No person shall be allowed to attend the proceedings of a committee of inquiry, or address the committee of inquiry, except with the permission of the chairman or if the Minister so directs.

[8/2000]

### **Persons who may be affected by findings**

**50.—(1)** Where it appears to a committee of inquiry that any witness or person involved in the supervision or administration of an approved institution may be adversely affected by its findings, the committee shall notify him and give him an opportunity to be present at the proceedings of the committee of inquiry or at such part thereof as the chairman may specify.

[8/2000]

(2) The person notified under subsection (1) shall be allowed to give evidence and examine any witness.

[8/2000]

### **Record of proceedings**

**51.—(1)** The chairman shall record or cause to be recorded in writing the proceedings of the committee of inquiry.

[8/2000]

(2) The evidence of each witness before a committee of inquiry shall be read over to him and shall be signed by him.

[8/2000]

(3) A record of the proceedings of a committee of inquiry shall be signed by the chairman and the members of the committee, if any, and forwarded to the Minister.

[8/2000]

(4) The record of proceedings of a committee of inquiry or any part thereof or any information relating thereto shall be kept confidential and shall not be released to any person, other than a member of the committee, without the written permission of the Minister.

[8/2000]

### **Offence to influence or attempt to influence committee of inquiry**

**52.** Every person who, otherwise than in the course of duty, directly or indirectly by himself or by any other person in any manner whatsoever influences or attempts to influence any decision of a committee of inquiry or any member of a committee of inquiry shall be guilty of an offence and shall be liable on conviction to a fine not exceeding \$2,000 or to imprisonment for a term not exceeding 6 months or to both.

[8/2000]

## PART VII

### GENERAL

#### **Jurisdiction of court**

**53.** A District Court or a Magistrate's Court shall have jurisdiction to hear and determine all proceedings under this Act and, notwithstanding anything to the contrary in the Criminal Procedure Code (Cap. 68), a District Court shall have power to impose the full penalty or punishment in respect of any offence provided by this Act except the punishment of death.

[49/75]

**Indemnity**

**54.**—(1) The Government shall not be liable to make good any damage caused to any goods or property as a result of an entry, search or detention under the provisions of this Act unless the damage is caused by the wilful neglect or default of an officer employed by the Government.

(2) In the event of any dispute as to the amount of any damage so caused, the same shall be summarily ascertained and determined by a District Court or a Magistrate's Court.

**Protection of persons acting under authority of Act**

**55.** Any person who does any act in pursuance or intended pursuance of any of the provisions of this Act shall not be subject to any civil or criminal liability in respect thereof, whether on the ground of want of jurisdiction, mistake of law or fact, or any other ground, unless he has acted in bad faith or without reasonable care.

**Use of weapons**

**56.**—(1) Subject to this section, a prison officer may use any weapon against —

- (a) any inmate of any approved institution escaping or attempting to escape;
- (b) any person who does any act or attempts to do any act to facilitate the escape of an inmate of any approved institution; or
- (c) any person engaged in any attempt to damage or force or break open —
  - (i) the outside door or gate or enclosure wall of any approved institution or any other part of an approved institution; or
  - (ii) any part of any vehicle in which an inmate is conveyed.

[8/2000]

- (2) A prison officer may use any weapon against —
- (a) any inmate of any approved institution engaged in any combined outbreak; and
  - (b) any person engaged in any attempt to damage or force or break open —
    - (i) the outside door or gate or enclosure wall of any approved institution or any other part of an approved institution; or
    - (ii) any part of any vehicle in which an inmate is conveyed,

and may continue to use the weapon so long as the combined outbreak or attempt is actually being prosecuted.

*[8/2000]*

(3) Every prison officer may use weapons against an inmate of any approved institution using violence against any prison officer or other person, if the prison officer has reasonable ground to believe that the prison officer or other person is in danger of life or limb, or that other grievous hurt is likely to be caused to either of them.

*[8/2000]*

(4) A prison officer shall not resort to the use of any weapon under subsection (1) unless the officer has reasonable ground to believe that he cannot otherwise prevent the escape of any inmate.

*[8/2000]*

(5) Before using any firearm against an inmate or other person referred to in subsection (1), the prison officer shall give a warning to the inmate or that other person, as the case may be, that he is about to fire on him.

*[8/2000]*

(6) No prison officer shall, in the presence of his superior officer, use any firearm against an inmate or other person in the circumstances described in subsection (1) or (2) except under the orders of his superior officer.

*[8/2000]*

(7) The use of weapons under this section shall be, as far as possible, to disable and not to kill.

*[8/2000]*



(8) Every police officer who is for the time being serving in the capacity of an escort, or of a guard in or around any approved institution, for the purpose of ensuring the safe custody of any inmate, shall be deemed to have all the powers and privileges granted to a prison officer under this section.

[8/2000]

### **Employment of auxiliary police officers as escorts and guards**

**57.**—(1) For the purpose of assisting him in the discharge of his duties under this Act, the Commissioner of Prisons may employ such number of auxiliary police officers as he considers fit as escorts or guards to ensure the safe custody of the inmates who are under his custody.

[Act 1 of 2014 wef 01/07/2014]

(2) An inmate who is delivered into the custody of an auxiliary police officer under this section shall be deemed to be in legal custody within the meaning of section 40.

[8/2000]

(3) Every auxiliary police officer who is employed as an escort or a guard under subsection (1) shall, in the course of carrying out his duties as an escort or a guard, have the same powers as a prison officer under section 56.

[8/2000]

(4) Every auxiliary police officer employed under subsection (1) shall be deemed to be a public servant within the meaning of the Penal Code (Cap. 224).

[8/2000]

(5) For the purpose of this section, “auxiliary police officer” means a member of an auxiliary police force established under any other written law.

[8/2000; 3/2005]

### **Regulations**

**58.**—(1) The Minister may make regulations —

- (a) providing for the issue of licences for the import, export, sale, manufacture, production or distribution of controlled drugs;

- (b) prescribing the form, duration and terms and conditions of any licence and the fees payable therefor, and providing for the cancellation and suspension thereof;
- (c) authorising the sale or possession or other dealing in controlled drugs and prescribing the circumstances and conditions under which the persons by whom controlled drugs may be sold, had in possession or otherwise dealt in;
- (ca) authorising the possession of any drug paraphernalia (as defined in section 11B(5)) and prescribing the circumstances and conditions under which a person may possess it;  
*[Act 1 of 2019 wef 01/08/2019]*
- (cb) authorising the teaching, instructing or provision of information, of any activity mentioned in section 11D(1) and prescribing the circumstances and conditions under which the teaching, instructing or provision of information may take place;  
*[Act 1 of 2019 wef 01/08/2019]*
- (cc) authorising the dissemination or publication of information on the carrying out of any activity mentioned in section 11D(1) and prescribing the circumstances and conditions under which the information may be disseminated or published;  
*[Act 1 of 2019 wef 01/08/2019]*
- (d) requiring medical practitioners, dentists, pharmacists, veterinary surgeons and other persons who deal in controlled drugs as may be authorised by the regulations to keep records and make returns;
- (e) requiring any medical practitioner who attends to a person whom the medical practitioner considers or has reasonable grounds to suspect is addicted to any controlled drug to furnish to the prescribed authority such particulars with respect to that person as may be prescribed;
- (f) prohibiting any medical practitioner from administering, supplying and authorising the administration and supply to

persons addicted to controlled drugs, and from prescribing for those persons, those drugs;

- (g) as to the packaging and labelling of controlled drugs;
- (h) regulating the transport of controlled drugs and the methods to be used for destroying or otherwise disposing of those drugs when no longer required;
- (i) requiring precautions to be taken for the safe custody of controlled drugs;
- (j) providing for the inspection of any precautions taken or records kept in pursuance of any regulations made under this section;
- (k) providing for the treatment and rehabilitation of persons affected by the misuse of controlled drugs;
- (l) prescribing the punishment by a fine not exceeding \$10,000 or imprisonment for a term not exceeding 4 years or both to be imposed on the conviction for a breach of the regulations;
- (m) providing for the management, maintenance and inspection of approved institutions or community rehabilitation centres;  
*[Act 30 of 2012 wef 28/04/2014]*
- (n) prescribing the functions and procedure of Review Committees;
- (o) providing for the control, discipline (including the imposition of corporal punishment) and occupation of inmates and for the granting of leave to inmates for the purpose of their employment outside an approved institution or a community rehabilitation centre and to return to their residences or other designated places;  
*[Act 30 of 2012 wef 28/04/2014]*
- (p) prescribing the appointment and duties of officers of approved institutions or community rehabilitation centres;  
*[Act 30 of 2012 wef 28/04/2014]*

(pa) providing for any matter in respect of a person who is committed under section 34(1), including the medical examination or observation of that person;

*[Act 1 of 2019 wef 01/08/2019]*

(q) providing for the supervision and aftercare of persons referred to in section 34(2)(a), or who have undergone treatment and rehabilitation at approved or other institutions or who have been convicted of an offence under section 8(b), 31(2) or (2A) or 31A(2) or (2A), or an offence under section 34 of the Singapore Armed Forces Act;

*[Act 1 of 2019 wef 01/04/2019]*

(qa) prescribing the circumstances under which the Director may extend the period for which a person is subject to supervision under this Act;

(r) prescribing anything that may be prescribed;

(s) prescribing the functions and procedure of advisory committees;

(t) requiring the fingerprinting of inmates and the dissemination of this information to the police;

(u) prescribing the type of offences in the regulations which may be seizable offences for the purposes of the Criminal Procedure Code (Cap. 68); and

(v) generally for carrying out the purposes and provisions of this Act.

*[12/77; 28/79; 38/89; 20/98; 2/2006]*

(2) Regulations made by the Minister under this section may —

(a) make different provisions in relation to different controlled drugs, different classes of persons or different cases or circumstances;

(b) make the opinion, consent or approval of any prescribed authority or authorised person material for the purposes of any provision; and

(c) provide for the constitution and procedure of a tribunal to advise the Minister in any case of contravention of this Act

or the regulations by any medical practitioner, dentist, pharmacist, veterinary surgeon or other authorised person.

### **Specifying drugs as temporarily listed drugs in Fifth Schedule**

**58A.**—(1) The Minister may, by order published in the *Gazette*, amend the Fifth Schedule by specifying any drug as a temporarily listed drug in that Schedule if that drug is not specified in Part I, II or III of the First Schedule.

(2) Any drug specified in the Fifth Schedule on the date of commencement of section 23 of the Misuse of Drugs (Amendment) Act 2012, or any additional drug specified under subsection (1) as a temporarily listed drug, shall be deleted from the Fifth Schedule —

- (a) at the expiry of a period of 12 months commencing from the date the drug is so specified (referred to in this section as the initial period); or
- (b) at the expiry of a period of 24 months commencing from the date the drug is so specified, if before the expiry of the initial period, the Minister states, by notification published in the *Gazette*, that the drug shall remain a temporarily listed drug for a further period.

(3) Before the expiry of the period referred to in subsection (2)(a) or (b), the Minister may amend the Fifth Schedule by deleting any drug specified in that Schedule.

*[Act 30 of 2012 wef 01/05/2013]*

### **Power of Minister to amend First, Third and Fourth Schedules**

**59.** The Minister may, by order published in the *Gazette*, amend the First, Third and Fourth Schedules.

*[49/75; 20/98]*

## **FIRST SCHEDULE**

Sections 2 and 58A

*[Act 30 of 2012 wef 01/05/2013]*

FIRST SCHEDULE — *continued*

## CONTROLLED DRUGS

## PART I

## CLASS A DRUGS

## 1. The following substances and products:

- (1) Acetorphine
- (2) Acetylmethadol (also known as methadyl acetate)  
*[S 284/2021 wef 01/05/2021]*
- (3) Allylprodine
- (4) Alphacetylmethadol
- (5) Alphameprodine
- (6) Alphamethadol
- (7) Alphaprodine
- (8) *[Deleted by S 194/2017 wef 01/05/2017]*
- (9) Amphetamine
- (10) Anileridine
- (11) Benzethidine
- (12) Benzylmorphine (3-benzylmorphine)
- (13) 1-Benzylpiperazine (also known as BZP)
- (14) Betacetylmethadol
- (15) Betameprodine
- (16) Betamethadol
- (17) Betaprodine
- (18) Bezitramide
- (19) 1-(4-Bromo-2,5-dimethoxyphenyl)propan-2-amine (also known as 4-Bromo-2,5-dimethoxy- $\alpha$ -methylphenethylamine, 4-Bromo-2,5-dimethoxyamphetamine, Brolamfetamine or DOB) and its bromo and dimethoxy positional isomers in the phenyl ring  
*[S 349/2020 wef 01/05/2020]*
- (20) 2-(4-Bromo-2,5-dimethoxyphenyl)ethanamine (also known as 4-bromo-2,5-dimethoxyphenethylamine or 2C-B) and its bromo and dimethoxy positional isomers in the phenyl ring  
*[S 194/2017 wef 01/05/2017]*

FIRST SCHEDULE — *continued*

- (21) [*Deleted by S 200/2016 wef 01/05/2016*]
- (22) Buprenorphine
- (23) Cannabinol
- (24) Cannabinol derivatives
- (25) Cannabis and cannabis resin
- (26) Cathinone
- (27) Clonitazene
- (28) Coca leaf
- (29) Cocaine
- (30) Codoxime
- (31) 4-Cyano-2-dimethylamino-4,4-diphenylbutane
- (32) 4-Cyano-1-methyl-4-phenyl-piperidine
- (33) Desomorphine
- (34) Dextromoramide
- (34A) (2S)-2,6-Diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide (also known as Lisdexamphetamine or Lisdexamphetamine) and its stereoisomers  
*[S 354/2019 wef 01/05/2019]*
- (35) Diamorphine
- (36) Diampromide
- (36A) N,N-Diethyl-3-hydroxy-7-methyl-2-oxo-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide (also known as 2-Oxo-3-hydroxy-LSD) and its acyclic secondary and tertiary amide structural isomers  
*[S 792/2019 wef 01/12/2019]*
- (37) Diethylthiambutene
- (38) [*Deleted by S 200/2016 wef 01/05/2016*]
- (39) Difenoxin
- (40) Dihydroetorphine
- (41) Dihydromorphine
- (42) Dimenoxadole
- (43) Dimepheptanol

FIRST SCHEDULE — *continued*

- (44) 1-(2,5-Dimethoxy-4-methylphenyl)propan-2-amine (also known as 2,5-Dimethoxy-4, $\alpha$ -dimethylphenethylamine, 2-Amino-1-(2,5-dimethoxy-4-methyl)phenylpropane or DOM) and its methyl and dimethoxy positional isomers in the phenyl ring  
*[S 349/2020 wef 01/05/2020]*
- (45) 2,5-Dimethoxy- $\alpha$ -methylphenethylamine (also known as 2,5-Dimethoxyamphetamine or DMA) and its dimethoxy positional isomers in the phenyl ring  
*[S 792/2019 wef 01/12/2019]*
- (46) N, $\alpha$ -Dimethyl-3,4-(methylenedioxy)phenethylamine (also known as 3,4-Methylenedioxyamphetamine or MDMA) and its acyloxy or sulphonyl derivatives at the nitrogen atom, and the following example of such a derivative:
- (a) *tert*-Butyl N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]-N-methylcarbamate (also known as N-*tert*-Butoxycarbonyl-MDMA or t-Boc-MDMA)  
*[S 751/2020 wef 04/09/2020]*
- (47) 3-(1,2-Dimethylheptyl)-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran (also known as DMHP)  
*[S 792/2019 wef 01/12/2019]*
- (48) Dimethylthiambutene
- (49) *[Deleted by S 200/2016 wef 01/05/2016]*
- (50) Dioxaphetyl butyrate
- (51) Diphenoxylate
- (52) Dipipanone
- (53) Drotebanol
- (54) Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine
- (55) 4-Ethyl-2,5-dimethoxy- $\alpha$ -methylphenethylamine (also known as DOET)  
*[S 792/2019 wef 01/12/2019]*
- (56) N-Ethyl- $\alpha$ -methyl-3,4-(methylenedioxy)phenethylamine (also known as MDEA)
- (57) Ethylmethylthiambutene
- (58) Eticyclidine
- (59) Etonitazene



FIRST SCHEDULE — *continued*

- (60) Etorphine
- (61) Etoxeridine
- (62) [*Deleted by S 200/2016 wef 01/05/2016*]
- (63) Furethidine
- (64) Gamma hydroxybutyric acid
- (65) Hydrocodone
- (66) Hydromorphenol
- (67) Hydromorphone
- (68) 1-Hydroxy-3-pentyl-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6-H-dibenzo[b,d]pyran
- (69) Hydroxypethidine
- (70) Isomethadone
- (71) Ketamine and its acyloxy or sulphonyl derivatives at the nitrogen atom, and the following example of such a derivative:
  - (a) tert-Butyl N-methyl-N-((2-chlorophenyl)-1-oxocyclohexan-2-yl)carbamate (also known as N-tert-Butoxycarbonyl-ketamine or t-Boc-ketamine)  
*[S 751/2020 wef 04/09/2020]*
- (72) Ketobemidone
- (73) Levomethorphan
- (74) Levomoramide
- (75) Levophenacymorphan
- (76) Levorphanol
- (77) Lysergamide
- (78) Lysergide and other compounds structurally derived from lysergamide by substitution of any of the hydrogen atoms, and the following examples of such a compound:
  - (a) 1-Acetyl-N,N-diethyllysergamide (also known as N-acetyl-LSD or ALD-52)
  - (b) 6-Allyl-6-nor-lysergic acid diethylamide (also known as N-allyl-nor-LSD or AL-LAD)
  - (c) 6-Ethyl-6-nor-lysergic acid diethylamide (also known as ETH-LAD)

FIRST SCHEDULE — *continued*

- (d) 6-Propyl-6-nor-lysergic acid diethylamide (also known as PRO-LAD)
- (e) Lysergic acid 2,4-dimethylazetidide (also known as LSZ)
- (f) 1-Propionyl-N,N-diethyllysergamide (also known as 1-Propionyl-LSD or 1P-LSD)
- (g) 1-Butanoyl-N,N-diethyllysergamide (also known as 1-Butanoyl-LSD or 1B-LSD)  
*[S 751/2020 wef 04/09/2020]*
- (h) 1-Cyclopropionyl-N,N-diethyllysergamide (also known as 1-Cyclopropionyl-LSD or 1cP-LSD)  
*[S 284/2021 wef 01/05/2021]*
- (79) Mescaline
- (80) Metazocine
- (81) Methadone
- (82) *[Deleted by S 284/2021 wef 01/05/2021]*
- (83) Methamphetamine (also known as Methylamphetamine) and its acyloxy or sulphonyl derivatives at the nitrogen atom, and the following examples of such a derivative:
- (a) tert-Butyl N-methyl-N-(1-phenylpropan-2-yl)carbamate (also known as N-tert-Butoxycarbonyl-methamphetamine or t-Boc-methamphetamine)
- (b) N,4-Dimethyl-N-(3-phenyl-propan-2-yl)benzenesulfonamide (also known as N-Tosyl-methamphetamine)  
*[S 751/2020 wef 04/09/2020]*
- (84) *[Deleted by S 200/2016 wef 01/05/2016]*
- (85) 3-Methoxy- $\alpha$ -methyl-4,5-(methylenedioxy)phenethylamine (also known as 5-methoxy-MDA or MMDA)  
*[S 792/2019 wef 01/12/2019]*
- (86) p-Methoxy- $\alpha$ -methylphenethylamine (also known as 4-methoxyamphetamine or para-methoxyamphetamine) and its methoxy positional isomers in the phenyl ring  
*[S 194/2017 wef 01/05/2017]*
- (87) N-Methyl- $\alpha$ -ethyl-3,4-(methylenedioxy)phenethylamine (also known as MBDB)

FIRST SCHEDULE — *continued*

- (88) N-[ $\alpha$ -Methyl-3,4-(methylenedioxy)phenethyl]hydroxylamine (also known as N-Hydroxy MDA)  
*[S 792/2019 wef 01/12/2019]*
- (89)  $\alpha$ -Methyl-3,4-(methylenedioxy)phenethylamine (also known as Tenamfetamine or MDA)
- (90) 2-Methyl-3-morpholino-1,1-diphenylpropanecarboxylic acid
- (91) 1-Methyl-4-phenylpiperidine-4-carboxylic acid
- (92) 4-Methylaminorex
- (93) Methyldesorphine
- (94) Methyldihydromorphine (6-Methyldihydromorphine)
- (95) 4-Methylthioamphetamine
- (96) [*Deleted by S 233/2018 wef 01/05/2018*]
- (97) Metopon
- (98) Monoacetylmorphine
- (99) Morpheridine
- (100) Morphine
- (101) Morphine methobromide, morphine *N*-oxide and other pentavalent nitrogen morphine derivatives
- (102) Myrophine
- (103) Nicomorphine (3,6-dinicotinoyl-morphine)
- (104) Noracymethadol
- (105) Norbuprenorphine
- (106) Norketamine and its dehydro derivatives
- (107) Norlevorphanol
- (108) Normethadone
- (109) Normorphine
- (110) Norpipanone
- (111) Opium
- (112) Oxycodone
- (113) Oxymorphone

FIRST SCHEDULE — *continued*

- (114) Parahexyl (3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran)
- (115) Pethidine
- (116) Phenadoxone
- (117) Phenampromide
- (118) Phenazocine
- (119) Phenomorphan
- (120) Phenoperidine
- (120A) 4-Phenyl-N-(2-phenylethyl)piperidin-4-yl acetate (also known as 1-Phenethyl-4-phenyl-4-piperidinol acetate or PEPAP)  
*[S 354/2019 wef 01/05/2019]*
- (121) 4-Phenylpiperidine-4-carboxylic acid ethyl ester
- (122) Piminodine
- (123) Piritramide
- (124) Poppy-straw and concentrate of poppy-straw
- (125) Proheptazine
- (126) Properidine (1-Methyl-4-phenyl-piperidine-4-carboxylic acid isopropyl ester)
- (127) *[Deleted by S 200/2016 wef 01/05/2016]*
- (128) Psilocybine
- (129) Racemethorphan
- (130) Racemoramide
- (131) Racemorphan
- (132) *[Deleted by S 233/2018 wef 01/05/2018]*
- (133) Rolicyclidine
- (133A) Tapentadol  
*[S 572/2014 wef 01/09/2014]*
- (134) Tenocyclidine
- (134A) 6,7,8,14-Tetrahydro-4,5- $\alpha$ -epoxy-6-methoxy-17-methylmorphinan-3-ol (also known as 3-O-demethylthebaine or Oripavine)  
*[S 233/2018 wef 01/05/2018]*
- (135) Thebacon

FIRST SCHEDULE — *continued*

- (136) Thebaine
- (137) Tilidine
- (138) 1-(3-Trifluoromethylphenyl)piperazine (also known as TFMPP)
- (139) Trimeperidine
- (140) [*Deleted by S 284/2021 wef 01/05/2021*]

2. Any stereoisomeric form of a substance for the time being specified in paragraph 1, not being dextromethorphan or dextrorphan.

3. Any ester or ether of a substance for the time being specified in paragraph 1 or 2, not being a substance for the time being specified in Part II.

4. Any salt of a substance for the time being specified in any of paragraphs 1, 2 and 3.

5. Any preparation or other products containing a substance or product for the time being specified in any of paragraphs 1 to 4.

6. Any preparation designed for administration by injection which includes a substance or product for the time being specified in any of paragraphs 1, 2 and 3 of Part II.

7. Fentanyl and any compounds structurally derived from N-(1-Methyl-4-piperidyl)-N-phenyl formamide by substitution of any of the hydrogen atoms, including the following; and any salt of any substance falling within this item:

- (1) Acetylfentanyl (also known as desmethyl fentanyl)

[*S 200/2016 wef 01/05/2016*]

- (1AA) Acryloylfentanyl (also known as Acrylfentanyl)

[*S 233/2018 wef 01/05/2018*]

- (1A) Alfentanil

[*S 200/2016 wef 01/05/2016*]

- (2) Alpha-methyl fentanyl
- (3) Alpha-methyl fentanyl acetanilide
- (4) Alpha-methylthiofentanyl
- (5) Benzyl fentanyl
- (6) Beta-hydroxy fentanyl
- (7) Beta-hydroxy-3-methyl fentanyl

- (7A) Butyryl fentanyl (also known as butyrfentanyl)

[*S 194/2017 wef 01/05/2017*]

- (8) Carfentanil

FIRST SCHEDULE — *continued*

- (8AAA) Crotonylfentanyl  
*[S 349/2020 wef 01/05/2020]*
- (8AA) Cyclopropylfentanyl  
*[S 354/2019 wef 01/05/2019]*
- (8AB) 4-Fluorobutyrfentanyl (also known as para-Fluoro-butyrfentanyl or p-Fluoro-butyrfentanyl)  
*[S 354/2019 wef 01/05/2019]*
- (8AC) 2-Fluorofentanyl (also known as ortho-Fluorofentanyl)  
*[S 354/2019 wef 01/05/2019]*
- (8AD) 3-Fluorofentanyl (also known as meta-Fluorofentanyl)  
*[S 354/2019 wef 01/05/2019]*
- (8AE) 4-Fluorofentanyl (also known as para-Fluorofentanyl)  
*[S 354/2019 wef 01/05/2019]*
- (8A) 4-Fluoroisobutyrfentanyl (also known as 4-FIBF or pFIBF)  
*[S 233/2018 wef 01/05/2018]*
- (8B) Furanyl fentanyl  
*[S 233/2018 wef 01/05/2018]*
- (9) Lofentanil
- (9A) Methoxyacetylfentanyl  
*[S 354/2019 wef 01/05/2019]*
- (9B) 4-Methoxybutyrfentanyl (also known as para-Methoxy-butyrfentanyl or p-Methoxy-butyrylfentanyl)  
*[S 354/2019 wef 01/05/2019]*
- (10) 3-Methyl fentanyl
- (10A) 3-Methylthiofentanyl  
*[S 233/2018 wef 01/05/2018]*
- (10B) Ocfentanil  
*[S 233/2018 wef 01/05/2018]*
- (11) *[Deleted by S 354/2019 wef 01/05/2019]*
- (11A) Remifentanil  
*[S 233/2018 wef 01/05/2018]*
- (12) Sufentanil
- (12AA) Tetrahydrofuranyl fentanyl (also known as THF-F)  
*[S 233/2018 wef 01/05/2018]*
- (12A) Thiafentanil  
*[S 200/2016 wef 01/05/2016]*
- (13) Thiofentanyl

FIRST SCHEDULE — *continued*

## (14) Valeryl-fentanyl

*[S 349/2020 wef 01/05/2020]*8. *[Deleted by S 751/2020 wef 04/09/2020 wef 04/09/2020]*

9. Any compound containing a 3-(1-naphthylmethyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

- (1) 3-[4-Methylnaphthalen-1-yl)methyl]-1-pentyl-1H-indole (also known as JWH-184)
- (2) 3-(Naphthalen-1-ylmethyl)-1-pentyl-1H-indole (also known as JWH-175)

10. Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

- (1) [5-(2-Chlorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl) methanone (also known as JWH-369)
- (2) [5-(2-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl) methanone (also known as JWH-307)
- (3) [5-(3-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl) methanone (also known as JWH-368)
- (4) (1-Hexyl-5-phenyl-1H-pyrrol-3-yl)(naphthalen-1-yl)methanone (also known as JWH-147)
- (5) (1-Hexyl-1H-pyrrol-3-yl)(naphthalen-1-yl)methanone (also known as JWH-031)
- (6) [5-(2-Methylphenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl) methanone (also known as JWH-370)

FIRST SCHEDULE — *continued*

- (7) Naphthalen-1-yl[5-(naphthalen-1-yl)-1-pentyl-1H-pyrrol-3-yl]methanone (also known as JWH-309)
- (8) Naphthalen-1-yl(1-pentyl-5-phenyl-1H-pyrrol-3-yl)methanone (also known as JWH-145)
- (9) Naphthalen-1-yl(1-pentyl-1H-pyrrol-3-yl)methanone (also known as JWH-030)

11. Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

- (1) E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane (also known as JWH-176)

12. [*Deleted by S 751/2020 wef 04/09/2020 wef 04/09/2020*]

13. Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not substituted in the cyclohexyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

- (1) 2-[5-Hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol (also known as CP55,940)
- (2) 2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol (also known as CP47,497)

14. [*Deleted by S 751/2020 wef 04/09/2020 wef 04/09/2020*]

15. [*Deleted by S 751/2020 wef 04/09/2020 wef 04/09/2020*]

16. Any compound, other than bupropion, that is structurally derived from 2-amino-1-phenylpropan-1-one by modification in any of the following ways:

- (a) substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylendioxy, haloalkyl, or halide substituents, whether or not further



FIRST SCHEDULE — *continued*

substituted in the phenyl ring by one or more other univalent substituents;

- (b) substitution at the 3-position with an alkyl substituent;
- (c) substitution at the nitrogen atom with alkyl or dialkyl, benzyl or methoxybenzyl groups, or by inclusion of the nitrogen atom in a cyclic structure,

including any salt or stereoisomeric form of the above compounds, and any preparation or product containing the above compounds, for example:

- (1) 1-(1,3-Benzodioxol-5-yl)-2-(benzylamino)propan-1-one (also known as 3,4-Methylenedioxy-N-benzylcathinone or BMDP)  
[S 194/2017 wef 01/05/2017]
- (1AA) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)-1-butanone (also known as Dibutylone or bk-DMBDB)  
[S 233/2018 wef 01/05/2018]
- (1A) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)-1-propanone (also known as bk-MDDMA)  
[S 194/2017 wef 01/05/2017]
- (1B) 1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)-1-butanone (also known as Eutylone)  
[S 233/2018 wef 01/05/2018]
- (1C) 1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)pentan-1-one (also known as 1-(2H-1,3-Benzodioxol-5-yl)-2-(ethylamino)pentan-1-one) or N-Ethylpentylone or N-Ethylnorpentylone or Ephylone)  
[S 233/2018 wef 01/05/2018]  
[S 354/2019 wef 01/05/2019]
- (2) 1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)propan-1-one (also known as ethylone or 3,4-Methylenedioxy-N-ethylcathinone or bk-MDEA or MDEC)  
[S 194/2017 wef 01/05/2017]
- (3) 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (also known as butylone)
- (4) 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (also known as pentylone)
- (5) 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)propan-1-one (also known as methylone or 3,4-methylenedioxy-N-methylcathinone)
- (6) 1-(1,3-Benzodioxol-5-yl)-2-(pyrrolidin-1-yl)butan-1-one (also known as MDPBP)

FIRST SCHEDULE — *continued*

- (7) 1-(1,3-Benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (also known as 3,4-methylenedioxypropylvalerone or MDPV)
- (8) 1-(1,3-Benzodioxol-5-yl)-2-(pyrrolidin-1-yl)propan-1-one (also known as MDPPP)
- (8A) 2-(Benzylamino)-1-(4-methylphenyl)propan-1-one (also known as Benzedrone)  
*[S 194/2017 wef 01/05/2017]*
- (8AAA) 1-(4-Bromophenyl)-2-(ethylamino)propan-1-one (also known as 4-Bromoethcathinone or 4-BEC)  
*[S 233/2018 wef 01/05/2018]*
- (8AA) 1-(4-Bromophenyl)-2-(methylamino)propan-1-one (also known as 4-Bromomethcathinone or Brepheдрone or 4-BMC)  
*[S 194/2017 wef 01/05/2017]*
- (8AAB) 1-(4-Chlorophenyl)-2-(dimethylamino)propan-1-one (also known as 4-Chloro-N,N-dimethylcathinone)  
*[S 792/2019 wef 01/12/2019]*
- (8AB) 1-(4-Chlorophenyl)-2-(ethylamino)propan-1-one (also known as 4-Chloroethcathinone or 4-CEC)  
*[S 233/2018 wef 01/05/2018]*
- (8B) 1-(4-Chlorophenyl)-2-(methylamino)propan-1-one (also known as 4-Chloromethcathinone or Clephedrone or 4-CMC)  
*[S 254/2015 wef 01/05/2015]*
- (8C) 2-(Diethylamino)-1-phenyl-1-propanone (also known as amfepramone or diethylpropion or diethylcathinone)  
*[S 194/2017 wef 01/05/2017]*
- (9) 2-(Dimethylamino)-1-phenylpropan-1-one (also known as metamfepramone or dimethylcathinone)
- (10) 1-(3,4-Dimethylphenyl)-2-(methylamino)propan-1-one (also known as 3,4-Dimethylmethcathinone or 3,4-DMMC)  
*[S 254/2015 wef 01/05/2015]*
- (10A) 2-(Ethylamino)-1-(4-ethylphenyl)propan-1-one (also known as 4-Ethylethcathinone)  
*[S 194/2017 wef 01/05/2017]*
- (10B) 2-(Ethylamino)-1-(4-fluorophenyl)propan-1-one (also known as 4-Fluoroethcathinone or 4-FEC)  
*[S 194/2017 wef 01/05/2017]*
- (10C) 2-(Ethylamino)-1-(4-methylphenyl)pentan-1-one (also known as 4-Methyl- $\alpha$ -ethylaminopentiofenone or 4-MEAPP)  
*[S 233/2018 wef 01/05/2018]*

FIRST SCHEDULE — *continued*

- (11) 2-(Ethylamino)-1-(4-methylphenyl)propan-1-one (also known as 4-Methylethcathinone or 4-MEC)  
*[S 254/2015 wef 01/05/2015]*
- (12) 2-(Ethylamino)-1-phenylbutan-1-one (also known as N-ethylbuphedrone)
- (12A) 2-(Ethylamino)-1-phenylhexan-1-one (also known as N-Ethylhexedrone or Ethyl-hexedrone)  
*[S 349/2020 wef 01/05/2020]*
- (13) 2-(Ethylamino)-1-phenylpentan-1-one (also known as  $\alpha$ -Ethylaminopentiophenone or N-Ethylpentedrone)  
*[S 792/2019 wef 01/12/2019]*
- (14) 2-(Ethylamino)-1-phenylpropan-1-one (also known as ethcathinone)
- (14A) 1-(4-Ethylphenyl)-2-(methylamino)propan-1-one (also known as 4-Ethylmethcathinone or 4-EMC)  
*[S 254/2015 wef 01/05/2015]*
- (14B) 1-(4-Fluoro-3-methylphenyl)-2-(pyrrolidin-1-yl)pentan-1-one (also known as 4-Fluoro-3-methyl- $\alpha$ -pyrrolidinopentiophenone or 4-Fluoro-3-methyl- $\alpha$ -PVP)  
*[S 284/2021 wef 01/05/2021]*
- (15) 1-(4-Fluorophenyl)-2-(methylamino)propan-1-one (also known as 4-Fluoromethcathinone or Flephedrone or 4-FMC)  
*[S 254/2015 wef 01/05/2015]*
- (15AA) 1-(4-Fluorophenyl)-2-(pyrrolidin-1-yl)hexan-1-one (also known as 4-Fluoro-PHP)  
*[S 233/2018 wef 01/05/2018]*
- (15A) 1-(4-Fluorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one (also known as 4-Fluoro- $\alpha$ -PVP)  
*[S 254/2015 wef 01/05/2015]*
- (16) 1-(4-Methoxyphenyl)-2-(methylamino)propan-1-one (also known as 4-Methoxymethcathinone or Methedrone or bk-PMMA or PMMC)  
*[S 254/2015 wef 01/05/2015]*
- (17) 1-(4-Methoxyphenyl)-2-(pyrrolidin-1-yl)propan-1-one (also known as MOPPP)
- (17A) 2-(Methylamino)-1-(4-methylphenyl)butan-1-one (also known as 4-Methylbuphedrone or 4-Me-MABP)  
*[S 194/2017 wef 01/05/2017]*
- (18) 2-(Methylamino)-1-phenylbutan-1-one (also known as buphedrone)

FIRST SCHEDULE — *continued*

- (19) 2-(Methylamino)-1-phenylpentan-1-one (also known as pentedrone or  $\alpha$ -Methylaminovalerophenone)  
*[S 194/2017 wef 01/05/2017]*
- (20) 2-(Methylamino)-1-phenylpropan-1-one (also known as methcathinone)
- (21) 1-(4-Methylphenyl)-2-(methylamino)propan-1-one (also known as 4-Methylmethcathinone or Mephedrone or 4-MMC)  
*[S 254/2015 wef 01/05/2015]*
- (22) 1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)butan-1-one (also known as MPBP)
- (22A) 1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one (also known as 4-Methyl- $\alpha$ -pyrrolidinohexanophenone or MPHP)  
*[S 194/2017 wef 01/05/2017]*
- (23) 1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)pentan-1-one (also known as pyrovalerone)
- (23A) 1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)propan-1-one (also known as 4-Methyl- $\alpha$ -pyrrolidinopropiophenone or 4-MePPP)  
*[S 194/2017 wef 01/05/2017]*
- (24) 1-Phenyl-2-(pyrrolidin-1-yl)butan-1-one (also known as  $\alpha$ -PBP)
- (24A) 1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one (also known as Alpha-Pyrrolidinohexiophenone or Alpha-PHP or  $\alpha$ -PHP)  
*[S 349/2020 wef 01/05/2020]*
- (25) 1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-one (also known as  $\alpha$ -PVP)
- (26) 1-Phenyl-2-(pyrrolidin-1-yl)propan-1-one (also known as  $\alpha$ -PPP)

17. Any compound that is structurally derived from 2-aminopropan-1-one by substitution at the 1-position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylendioxyphenyl ring system), whether or not the compound is further modified in any of the following ways:

- (a) substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
- (b) substitution at the 3-position with an alkyl substituent; or
- (c) substitution at the 2-amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure,

including any salt or stereoisomeric form of the above compounds, and any preparation or product containing the above compounds, for example:

FIRST SCHEDULE — *continued*

- (1) 1-(Naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (also known as naphyrone or naphthylpyrovalerone)
- (2) 2-(Pyrrolidin-1-yl)-1-(thiophen-2-yl)pentan-1-one (also known as  $\alpha$ -Pyrrolidinopentiothiophenone or  $\alpha$ -PVT)

18. The following compounds, including any salt or stereoisomeric form of such compounds, and any preparation or product containing such compounds:

- (1) [*Deleted by S 751/2020 wef 04/09/2020*]
- (1AAA) [*Deleted by S 792/2019 wef 01/12/2019*]
- (1A) [*Deleted by S 751/2020 wef 04/09/2020*]
- (1AA) [*Deleted by S 751/2020 wef 04/09/2020*]
- (1AB) [*Deleted by S 751/2020 wef 04/09/2020*]
- (1AC) [*Deleted by S 751/2020 wef 04/09/2020*]
- (1AD) [*Deleted by S 751/2020 wef 04/09/2020*]
- (1AE) [*Deleted by S 751/2020 wef 04/09/2020*]
- (1AF) [*Deleted by S 751/2020 wef 04/09/2020*]
- (1AG) [*Deleted by S 751/2020 wef 04/09/2020*]
- (1B) [*Deleted by S 751/2020 wef 04/09/2020*]
- (2) [*Deleted by S 751/2020 wef 04/09/2020*]
- (2AAA) [*Deleted by S 751/2020 wef 04/09/2020*]
- (2A) 2-Amino-1-(4-bromo-2,5-dimethoxyphenyl)ethan-1-one (also known as bk-2C-B) and its bromo and dimethoxy positional isomers in the phenyl ring  
*[S 200/2016 wef 01/05/2016]*
- (2AAB) [*Deleted by S 751/2020 wef 04/09/2020*]
- (2AA) [*Deleted by S 751/2020 wef 04/09/2020*]
- (2AB) [*Deleted by S 751/2020 wef 04/09/2020*]
- (2B) [*Deleted by S 751/2020 wef 04/09/2020*]
- (2BA) [*Deleted by S 751/2020 wef 04/09/2020*]
- (2C) [*Deleted by S 751/2020 wef 04/09/2020*]
- (2CA) [*Deleted by S 751/2020 wef 04/09/2020*]
- (2CB) [*Deleted by S 751/2020 wef 04/09/2020*]

FIRST SCHEDULE — *continued*

- (2D) [Deleted by S 751/2020 wef 04/09/2020]
- (2DA) [Deleted by S 751/2020 wef 04/09/2020]
- (2DB) [Deleted by S 751/2020 wef 04/09/2020]
- (2E) [Deleted by S 751/2020 wef 04/09/2020]
- (2F) [Deleted by S 751/2020 wef 04/09/2020]
- (2G) [Deleted by S 751/2020 wef 04/09/2020]
- (2GA) [Deleted by S 751/2020 wef 04/09/2020]
- (2H) [Deleted by S 751/2020 wef 04/09/2020]
- (2I) [Deleted by S 751/2020 wef 04/09/2020]
- (2IA) [Deleted by S 751/2020 wef 04/09/2020]
- (2J) [Deleted by S 751/2020 wef 04/09/2020]
- (2K) [Deleted by S 751/2020 wef 04/09/2020]
- (2L) 4-(2-Aminopropyl)benzofuran (also known as 4-APB)  
[S 200/2016 wef 01/05/2016]
- (3) 5-(2-Aminopropyl)benzofuran (also known as 5-APB)
- (4) 6-(2-Aminopropyl)benzofuran (also known as 6-APB or BenzoFury)
- (4A) 7-(2-Aminopropyl)benzofuran (also known as 7-APB)  
[S 254/2015 wef 01/05/2015]
- (4B) 4-(2-Aminopropyl)-2,3-dihydrobenzofuran (also known as 4-APDB)  
[S 254/2015 wef 01/05/2015]
- (5) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (also known as 5-APDB)
- (6) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (also known as 6-APDB)
- (6A) 7-(2-Aminopropyl)-2,3-dihydrobenzofuran (also known as 7-APDB)  
[S 254/2015 wef 01/05/2015]
- (6AA) 1-(1-Benzofuran-5-yl)-N-ethylpropan-2-amine (also known as 5-EAPB) and its 4-yl, 6-yl and 7-yl isomers  
[S 200/2016 wef 01/05/2016]
- (6B) 1-Benzyl-4-methylpiperazine (also known as Methylbenzylpiperazine or MBZP)  
[S 233/2018 wef 01/05/2018]
- (6C) 2-Bis(4-fluorophenyl)methylsulfinyl-N-methylacetamide (also known as N-Methyl-4,4-difluoromodafinil or modafiendz) and its fluoro positional isomers in the phenyl rings  
[S 233/2018 wef 01/05/2018]

FIRST SCHEDULE — *continued*

- (6D) 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25B-NBOMe) and its bromo, dimethoxy and methoxy positional isomers in the respective phenyl rings  
*[S 233/2018 wef 01/05/2018]*
- (6E) 2-N-[2-(4-Bromo-2,5-dimethoxyphenylethyl)aminomethyl]phenol (also known as 25B-NBOH) and its bromo, dimethoxy and hydroxy positional isomers in the respective phenyl rings  
*[S 233/2018 wef 01/05/2018]*
- (6F) 4-Bromo-N-[2-(dimethylamino)cyclohexyl]-benzamide (also known as Bromadoline or U-47931E) and its bromo positional isomers in the phenyl ring and diamino positional isomers in the cyclohexyl ring  
*[S 284/2021 wef 01/05/2021]*
- (6G) 4-Bromo-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide (also known as N-Methyl U-47931E or N-Methyl Bromadoline) and its bromo positional isomers in the phenyl ring and diamino positional isomers in the cyclohexyl ring  
*[S 284/2021 wef 01/05/2021]*
- (6H) *[Deleted by S 751/2020 wef 04/09/2020]*
- (6I) *[Deleted by S 751/2020 wef 04/09/2020]*
- (7) 17-Carboxy-16,17-dihydromitragynine
- (8) 16-Carboxymitragynine
- (8AAA) 1-(4-Chloro-2,5-dimethoxyphenyl)propan-2-amine (also known as 4-Chloro-2,5-dimethoxy- $\alpha$ -methylphenethylamine, 4-Chloro-2,5-dimethoxyamphetamine, DOC, 3C-C, 4-Cl-2,5-DMA or 4-Chloro-2,5-DMA) and its chloro and dimethoxy positional isomers in the phenyl ring  
*[S 349/2020 wef 01/05/2020]*
- (8A) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine also known as 2C-C) and its chloro and dimethoxy positional isomers in the phenyl ring  
*[S 233/2018 wef 01/05/2018]*
- (8AA) 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25C-NBOMe) and its chloro, dimethoxy and methoxy positional isomers in the respective phenyl rings  
*[S 233/2018 wef 01/05/2018]*
- (8AB) 2-N-[2-(4-Chloro-2,5-dimethoxyphenylethyl)aminomethyl]phenol (also known as 25C-NBOH) and its chloro, dimethoxy and hydroxy positional isomers in the respective phenyl rings  
*[S 233/2018 wef 01/05/2018]*
- (8AC) *[Deleted by S 751/2020 wef 04/09/2020]*

FIRST SCHEDULE — *continued*

(8AD) [*Deleted by S 751/2020 wef 04/09/2020*]

(8B) 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (also known as MT-45)  
*[S 200/2016 wef 01/05/2016]*

(9) 17-O-Desmethyl-16,17-dihydropyridazinone

(10) 9-O-Desmethylpyridazinone

(10AAA) 3,4-Dibromo-N-methyl-N-(1-methyl-1-azaspiro[4.5]decan-6-yl)benzamide (also known as U-77891) and its dibromo positional isomers in the phenyl ring and their respective azaspiro[4.5]decanyl isomers  
*[S 284/2021 wef 01/05/2021]*

(10AA) 3,4-Dichloromethylphenidate and its dichloro positional isomers in the phenyl ring (also known as 3,4-DCMP)  
*[S 354/2019 wef 01/05/2019]*

(10A) 3,4-Dichloro-N-{{1-(dimethylamino)cyclohexyl}methyl}benzamide (also known as AH-7921) and its dichloro positional isomers in the phenyl ring  
*[S 254/2015 wef 01/05/2015]*

(10B) 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-47700) and its dichloro positional isomers in the phenyl ring and diamino positional isomers in the cyclohexyl ring  
*[S 194/2017 wef 01/05/2017]*

(10C) N,N-Diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzo[d]imidazol-1-yl)ethan-1-amine (also known as Isotonitazene) and its diethylamino structural isomers and their respective isopropoxy positional isomers in the phenyl ring and nitro positional isomers in the 6-membered ring of the benzimidazole structure  
*[S 284/2021 wef 01/05/2021]*

(11) 2,3-Dihydro-1H-inden-2-amine (also known as 2-Aminoindane)

(12) 6,7-Dihydro-5H-indeno[5,6-d][1,3]dioxol-6-amine (also known as 5,6-(methylenedioxy)-2-aminoindane or MDAI)

(13) 2,3-Dihydro-5-iodo-1H-inden-2-amine (also known as 5-Iodo-2-aminoindane or 5-IAI)

(14) [2,3-Dihydro-5-methyl-3-(morpholin-4-ylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl](naphthalen-1-yl)methanone

(14A) [*Deleted by S 751/2020 wef 04/09/2020*]

(15) {4-[2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl}methanol



FIRST SCHEDULE — *continued*

- (15A) 2-(2,5-Dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25H-NBOMe) and its dimethoxy and methoxy positional isomers in the respective phenyl rings  
*[S 233/2018 wef 01/05/2018]*
- (15B) 2-(2,5-Dimethoxyphenyl)ethanamine (also known as 2C-H) and its dimethoxy positional isomers in the phenyl ring  
*[S 200/2016 wef 01/05/2016]*
- (15C) 2-N-[2-(2,5-Dimethoxyphenylethyl)aminomethyl]phenol (also known as 25H-NBOH) and its dimethoxy and hydroxy positional isomers in the respective phenyl rings  
*[S 233/2018 wef 01/05/2018]*
- (16) 6,6-Dimethyl-3-(2-methyloctan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-1,9-diol
- (17) N,N-Dimethyl-1-phenylpropan-2-amine (also known as N,N-dimethylamphetamine)
- (18) Diphenyl(pyrrolidin-2-yl)methanol (also known as diphenylprolinol)
- (18A) 1-(1,2-Diphenylethyl)piperidine (also known as Diphenidine)  
*[S 284/2021 wef 01/05/2021]*
- (19) 2-Diphenylmethylpiperidine (also known as desoxypipradrol)
- (19AA) 2-(Ethylamino)-2-phenyl-cyclohexan-1-one (also known as Deschloro-N-ethyl-ketamine)  
*[S 284/2021 wef 01/05/2021]*
- (19AAA) *[Deleted by S 751/2020 wef 04/09/2020]*
- (19AAB) *[Deleted by S 751/2020 wef 04/09/2020]*
- (19AAC) *[Deleted by S 751/2020 wef 04/09/2020]*
- (19A) Ethylphenidate  
*[S 200/2016 wef 01/05/2016]*
- (19ABA) *[Deleted by S 751/2020 wef 04/09/2020]*
- (19ABB) *[Deleted by S 751/2020 wef 04/09/2020]*
- (19ABC) *[Deleted by S 751/2020 wef 04/09/2020]*
- (19ABD) *[Deleted by S 751/2020 wef 04/09/2020]*
- (19ABE) *[Deleted by S 751/2020 wef 04/09/2020]*
- (19ABF) 2-Fluorodeschloroketamine (also known as 2-Fluoroketamine or 2-FDCK) and its fluoro positional isomers in the phenyl ring  
*[S 349/2020 wef 01/05/2020]*

FIRST SCHEDULE — *continued*

- (19AB) 4-Fluoromethylphenidate and its fluoro positional isomers in the phenyl ring  
*[S 233/2018 wef 01/05/2018]*
- (19B) *[Deleted by S 751/2020 wef 04/09/2020]*
- (19C) *[Deleted by S 751/2020 wef 04/09/2020]*
- (20) *[Deleted by S 751/2020 wef 04/09/2020]*
- (20A) *[Deleted by S 751/2020 wef 04/09/2020]*
- (20AA) *[Deleted by S 751/2020 wef 04/09/2020]*
- (20AB) 5-(5-Fluoropentyl)-2-(2-phenylpropan-2-yl)-pyrido[4,3-b]indol-1-one (also known as 2-Cumyl-5-(5-fluoropentyl)-gamma-carbolin-1-one or 5-Fluoro-cumyl-PEGACLONE) and its phenylpropyl isomers and their respective fluoro positional isomers in the pentyl group  
*[S 349/2020 wef 01/05/2020]*
- (20B) 2-(3-Fluorophenyl)-3-methylmorpholine (also known as 3-Fluorophenmetrazine or 3F-phenmetrazine) and its fluoro positional isomers in the phenyl ring  
*[S 284/2021 wef 01/05/2021]*
- (20C) *[Deleted by S 751/2020 wef 04/09/2020]*
- (20D) *[Deleted by S 751/2020 wef 04/09/2020]*
- (21) 1-(4-Fluorophenyl)piperazine (also known as 4-Fluorophenylpiperazine or 4-FPP) and its fluoro positional isomers in the phenyl ring  
*[S 254/2015 wef 01/05/2015]*
- (22) 1-(4-Fluorophenyl)propan-2-amine (also known as 4-Fluoroamphetamine or 4-FA) and its fluoro positional isomers in the phenyl ring  
*[S 254/2015 wef 01/05/2015]*
- (23) 1-Hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromen-9-one
- (24) [9-Hydroxy-6-methyl-3-(5-phenylpentan-2-yl)oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate
- (25) 3-Hydroxy-2-[3-methyl-6-(2-propenyl)-cyclohex-2-en-1-yl]-5-pentyl-1,4-benzoquinone
- (26) 9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol (for example HU-210, HU-211)  
*[S 194/2017 wef 01/05/2017]*

FIRST SCHEDULE — *continued*

- (27) 7-Hydroxymitragynine
- (27AA) 5-(5-Hydroxypentyl)-2-(2-phenylpropan-2-yl)-pyrido[4,3-b]indol-1-one and its phenylpropyl isomers and their respective hydroxy positional isomers in the pentyl group  
*[S 284/2021 wef 01/05/2021]*
- (27AB) *[Deleted by S 751/2020 wef 04/09/2020]*
- (27A) 1-(1H-Indol-5-yl)propan-2-amine (also known as 5-IT) and its 4-yl, 6-yl and 7-yl isomers  
*[S 200/2016 wef 01/05/2016]*
- (27B) 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25I-NBOMe) and its dimethoxy, iodo and methoxy positional isomers in the respective phenyl rings  
*[S 233/2018 wef 01/05/2018]*
- (27C) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (also known as 2C-I) and its dimethoxy and iodo positional isomers in the phenyl ring  
*[S 200/2016 wef 01/05/2016]*
- (27D) 2-N-[2-(4-Iodo-2,5-dimethoxyphenylethyl)aminomethyl]phenol (also known as 25I-NBOH) and its dimethoxy, hydroxy and iodo positional isomers in the respective phenyl rings  
*[S 233/2018 wef 01/05/2018]*
- (27DA) *[Deleted by S 751/2020 wef 04/09/2020]*
- (27DB) *[Deleted by S 751/2020 wef 04/09/2020]*
- (27E) 3-Methoxy-2-(methylamino)-1-(4-methylphenyl)propan-1-one (also known as Mexedrone) and its methyl positional isomers in the phenyl ring  
*[S 233/2018 wef 01/05/2018]*
- (27F) N-[1-(3-Methoxyphenyl)cyclohexyl]-piperidine (also known as 3-Methoxyphencyclidine or 3-Methoxy-PCP or 3-MeO-PCP) and its methoxy positional isomers in the phenyl ring  
*[S 792/2019 wef 01/12/2019]*
- (28) 2-(3-Methoxyphenyl)-2-(N-ethylamino)cyclohexanone (also known as methoxetamine)
- (28A) 1-[1-(2-Methoxyphenyl)-2-phenylethyl]piperidine (also known as 2-MeO-Diphenidine or 2-MXP or methoxphenidine) and its methoxy positional isomers in the phenyl ring  
*[S 284/2021 wef 01/05/2021]*

FIRST SCHEDULE — *continued*

- (28B) N-Methyl-5-(2-aminopropyl)benzofuran (also known as 5-MAPB) and its 4-yl, 6-yl and 7-yl isomers  
*[S 284/2021 wef 01/05/2021]*
- (28C) *[Deleted by S 751/2020 wef 04/09/2020]*
- (28D) *[Deleted by S 751/2020 wef 04/09/2020]*
- (28DA) *[Deleted by S 751/2020 wef 04/09/2020]*
- (28E) *[Deleted by S 751/2020 wef 04/09/2020]*
- (28F) *[Deleted by S 751/2020 wef 04/09/2020]*
- (28G) *[Deleted by S 751/2020 wef 04/09/2020]*
- (28GA) *[Deleted by S 751/2020 wef 04/09/2020]*
- (28H) *[Deleted by S 751/2020 wef 04/09/2020]*
- (28I) *[Deleted by S 751/2020 wef 04/09/2020]*
- (28J) *[Deleted by S 751/2020 wef 04/09/2020]*
- (28K) *[Deleted by S 751/2020 wef 04/09/2020]*
- (29) N-Methyl-1-(4-fluorophenyl)propan-2-amine (also known as 4-Fluoromethamphetamine or 4-FMA) and its fluoro positional isomers in the phenyl ring  
*[S 254/2015 wef 01/05/2015]*
- (29AA) *[Deleted by S 751/2020 wef 04/09/2020]*
- (29A) *[Deleted by S 751/2020 wef 04/09/2020]*
- (30) N-Methyl-1-(4-methoxyphenyl)propan-2-amine (also known as 4-Methoxymethamphetamine or para-Methoxymethamphetamine or PMMA) and its methoxy positional isomers in the phenyl ring  
*[S 254/2015 wef 01/05/2015]*
- (30A) 4-Methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine (also known as 4,4'-Dimethylaminorex, 4,4'-DMAR or para-methyl-4-methylaminorex) and its methyl positional isomers in the phenyl ring  
*[S 200/2016 wef 01/05/2016]*
- (31) N-Methyl-1-(4-methylphenyl)propan-2-amine (also known as 4-Methylmethamphetamine or 4-MMA) and its methyl positional isomers in the phenyl ring  
*[S 254/2015 wef 01/05/2015]*
- (31A) *[Deleted by S 751/2020 wef 04/09/2020]*

FIRST SCHEDULE — *continued*

- (32) (N-Methyl-4-phenylpiperidin-4-yl)propanoate (also known as 1-Methyl-4-phenyl-4-piperidinol propionate, desmethylprodine or MPPP)  
*[S 587/2018 wef 01/10/2018]*
- (33) N-Methyl-1-(thiophen-2-yl)propan-2-amine (also known as methiopropamine) and its thiophen-3-yl isomer  
*[S 200/2016 wef 01/05/2016]*
- (34) 1-(4-Methylbenzo-1,3-dioxol-6-yl)propan-2-amine (also known as 5-methyl-MDA or 5-methyl-3,4-methylenedioxyamphetamine)
- (35) Mitragynine
- (35A) *[Deleted by S 751/2020 wef 04/09/2020]*
- (36) *[Deleted by S 751/2020 wef 04/09/2020]*
- (36A) Naphthalen-1-yl(4-pentyloxynaphthalen-1-yl)methanone (also known as CB-13)  
*[S 194/2017 wef 01/05/2017]*
- (37) 2-Phenyl-2-(methylamino)cyclohexanone (also known as Deschloroketamine)  
*[S 284/2021 wef 01/05/2021]*
- (36AA) *[Deleted by S 751/2020 wef 04/09/2020]*
- (36B) *[Deleted by S 751/2020 wef 04/09/2020]*
- (36C) *[Deleted by S 751/2020 wef 04/09/2020]*
- (37A) *[Deleted by S 751/2020 wef 04/09/2020]*
- (38) *[Deleted by S 751/2020 wef 04/09/2020]*
- (38AAA) *[Deleted by S 751/2020 wef 04/09/2020]*
- (38AA) *[Deleted by S 751/2020 wef 04/09/2020]*
- (38AB) *[Deleted by S 751/2020 wef 04/09/2020]*
- (38AC) 2-(2-Phenylpropan-2-yl)-5-pentyl-pyrido[4,3-b]indol-1-one (also known as 2-Cumyl-5-pentylgamma-carbolin-1-one or cumyl-PEGACLONE or SGT-151) and its phenylpropyl isomers  
*[S 349/2020 wef 01/05/2020]*
- (38B) 5-[(2-Phenylpropan-2-yl)-pyrido[4,3-b]indol-1-one-yl]pentanoic acid and its phenylpropyl isomers  
*[S 284/2021 wef 01/05/2021]*
- (38AD) *[Deleted by S 751/2020 wef 04/09/2020]*
- (38AE) *[Deleted by S 751/2020 wef 04/09/2020]*

FIRST SCHEDULE — *continued*

(38A) [*Deleted by S 751/2020 wef 04/09/2020*]

(38C) [*Deleted by S 751/2020 wef 04/09/2020*]

(39) Salvinorin A

[*S 323/2014 wef 01/05/2014*]

(40) 2,4,5-Trimethoxy- $\alpha$ -methylphenethylamine (also known as 2,4,5-Trimethoxyamphetamine or TMA-2) and its trimethoxy positional isomers in the phenyl ring

[*S 284/2021 wef 01/05/2021*]

19. Any compound (other than serotonin) structurally derived from 2-(1H-indol-3-yl)ethanamine (also known as tryptamine) by modification in any of the following ways:

- (a) substitution at the nitrogen atom of the side chain to any extent with alkyl or alkenyl substituents, or by inclusion of only the nitrogen atom of the side chain in a cyclic structure;
- (b) substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents;
- (c) substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, hydroxy, thioalkyl, alkylendioxy, halide or acetoxy substituents;
- (d) substitution at the 2-position of the tryptamine ring system with an alkyl substituent,

including any ether, salt or stereoisomeric form of any such compound, any preparation or product containing any such compound, and the following examples of such a compound:

- (1) 4-Acetoxy-N,N-diisopropyltryptamine (also known as 4-Acetoxy-DiPT or 4-AcO-DiPT)
- (2) 4-Acetoxy-N,N-dimethyltryptamine (also known as 4-Acetoxy-DMT or 4-AcO-DMT)
- (3) 5-Benzyloxytryptamine
- (4) 5-Bromo-N,N-dimethyltryptamine (also known as 5-Bromo-DMT)
- (5) 5-Bromotryptamine
- (6) 5-Chloro- $\alpha$ -methyltryptamine (also known as 5-Chloro-AMT)
- (7) 5-Chlorotryptamine
- (8) N,N-Diallyltryptamine
- (9) N,N-Diethyltryptamine

FIRST SCHEDULE — *continued*

- (10) N,N-Diisopropyltryptamine
- (11) N,N-Dimethyltryptamine
- (12) N,N-Dipropyltryptamine
- (13) Etryptamine
- (14) 5-Fluoro-N,N-dimethyltryptamine (also known as 5-Fluoro-DMT)
- (15) 5-Fluoro- $\alpha$ -methyltryptamine (also known as 5-Fluoro-AMT)
- (16) 5-Fluorotryptamine
- (17) 4-Hydroxy-N,N-diethyltryptamine (also known as 4-Hydroxy-DET or 4-HO-DET)
- (18) 4-Hydroxy-N,N-diisopropyltryptamine (also known as 4-Hydroxy-DiPT or 4-HO-DiPT)
- (19) 4-Hydroxy-N,N-dimethyltryptamine (also known as Psilocin)
- (20) 4-Hydroxy-N-methyl-N-ethyltryptamine (also known as 4-Hydroxy-MET or 4-HO-MET)
- (21) 4-Hydroxy-N-methyl-N-isopropyltryptamine (also known as 4-Hydroxy-MiPT or 4-HO-MiPT)
- (22) 4-Hydroxy- $\alpha$ -methyltryptamine (also known as 4-Hydroxy-AMT or 4-HO-AMT)
- (23) 5-Hydroxy-N-methyltryptamine (also known as 5-Hydroxy-NMT or 5-HO-NMT)
- (24) 5-Hydroxy-N,N-dimethyltryptamine (also known as Bufotenine)
- (25) 5-Methoxy-N,N-diallyltryptamine (also known as 5-Methoxy-DALT or 5-MeO-DALT)
- (26) 5-Methoxy-N,N-diethyltryptamine (also known as 5-Methoxy-DET or 5-MeO-DET)
- (27) 5-Methoxy-N,N-diisopropyltryptamine (also known as 5-Methoxy-DiPT or 5-MeO-DiPT)
- (28) 5-Methoxy-N,N-dimethyltryptamine (also known as 5-Methoxy-DMT or 5-MeO-DMT)
- (29) 5-Methoxy-N,N-dipropyltryptamine (also known as 5-Methoxy-DPT or 5-MeO-DPT)
- (30) 5-Methoxy-N-ethyl-N-isopropyltryptamine (also known as 5-Methoxy-EiPT or 5-MeO-EiPT)

FIRST SCHEDULE — *continued*

- (31) 5-Methoxy-N-ethyl-N-propyltryptamine (also known as 5-Methoxy-EPT or 5-MeO-EPT)
- (32) 5-Methoxy- $\alpha$ -ethyltryptamine (also known as 5-Methoxy-AET or 5-MeO-AET)
- (33) 5-Methoxy-N-methyl-N-isopropyltryptamine (also known as 5-Methoxy-MiPT or 5-MeO-MiPT)
- (34) 5-Methoxy- $\alpha$ -methyltryptamine (also known as 5-Methoxy-AMT or 5-MeO-AMT)
- (35) 5-Methoxy-N-methyltryptamine (also known as 5-Methoxy-NMT or 5-MeO-NMT)
- (36) 4-Methyl- $\alpha$ -ethyltryptamine (also known as 4-Methyl-AET)
- (37) 5-Methyltryptamine
- (38)  $\alpha$ -Methyltryptamine
- (39) N-Methyltryptamine

[S 200/2016 wef 01/05/2016]

20. Any compound structurally derived from indole-3-carboxaldehyde or indole-2-carboxaldehyde by substitution —

- (a) at the nitrogen atom of the indole ring with a type A substituent; and
  - (b) at the hydrogen atom of the carboxaldehyde with a type B substituent,
- whether or not the compound is further modified in any of the following ways:
- (c) substitution of the indole ring with a nitrogen heterocyclic analog;
  - (d) substitution to the indole ring or its nitrogen heterocyclic analog to any extent;
  - (e) substitution to the type B substituent to any extent,

including any salt or stereoisomeric form of the compound or derivative of the compound, any preparation or product containing the compound or derivative of the compound, and the following examples of such a compound or derivative:

- (1) [1-(5-Bromopent-1-yl)-1H-indazol-3-yl](naphthalene-1-yl)methanone (also known as 5-Bromo-THJ-018)
- (2) [1-(5-Bromopent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (also known as 5-Bromo-UR-144)
- (3) [1-(5-Chloropent-1-yl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (also known as 5-Chloro-THJ-018)



FIRST SCHEDULE — *continued*

- (4) [1-(5-Chloropent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (also known as 5-Chloro-UR-144)
- (5) [1-(4-Fluorobenzyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (also known as FUB-144 or FUB-UR-144)
- (6) [1-(5-Fluoropent-1-yl)-1H-benzimidazol-2-yl](naphthalen-1-yl)methanone (also known as FUBIMINA)
- (7) [1-(5-Fluoropent-1-yl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (also known as THJ-2201)
- (8) [1-(5-Fluoropent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (also known as XLR-11 or 5-Fluoro-UR-144)
- (9) [1-(5-Hydroxypent-1-yl)-1H-indazol-3-yl](naphthalen-1-yl)methanone
- (10) [1-(5-Hydroxypent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone
- (11) [1-(5-Iodopent-1-yl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (also known as 5-Iodo-THJ-018)
- (12) Naphthalen-1-yl[1-(pent-1-yl)-1H-indazol-3-yl]methanone (also known as THJ-018)
- (13) 5-[3-(1-Naphthoyl)-1H-indazol-1-yl]pentanoic acid
- (14) 5-[3-(1-Naphthoyl)-1H-indol-1-yl]pentanenitrile (also known as AM-2232)
- (15) (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (also known as UR-144)
- (16) 5-[3-(2,2,3,3-Tetramethylcyclopropanecarbonyl)-1H-indol-1-yl]pentanoic acid
- (17) (1-Butyl-1H-indol-3-yl)(naphthalen-1-yl)methanone (also known as JWH-073)
- (18) (4-Chloronaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone (also known as JWH-398)
- (19) [1-(4-Chloropent-1-yl)-1H-indol-3-yl](naphthalen-1-yl)methanone (also known as 4-Chloro-AM-2201)
- (20) (4-Ethyl-naphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone (also known as JWH-210)

FIRST SCHEDULE — *continued*

- (21) [1-(5-Fluoropent-1-yl)-1H-indol-3-yl](4-methylnaphthalen-1-yl) methanone (also known as MAM-2201)
- (22) [1-(5-Fluoropent-1-yl)-1H-indol-3-yl](naphthalen-1-yl)methanone (also known as AM-2201)
- (23) [1-(4-Fluoropent-1-yl)-1H-indol-3-yl](naphthalen-1-yl)methanone (also known as 4-Fluoro-AM-2201)
- (24) [1-(5-Fluoropent-1-yl)-6-nitro-1H-indol-3-yl](naphthalen-1-yl) methanone (also known as AM-1235)
- (25) [1-(Heptan-2-yl)-2-methyl-1H-indol-3-yl](naphthalen-1-yl) methanone (also known as JWH-011)
- (26) (1-Heptyl-1H-indol-3-yl)(naphthalen-1-yl)methanone (also known as JWH-020)
- (27) (1-Hexyl-1H-indol-3-yl)(naphthalen-1-yl)methanone (also known as JWH-019)
- (28) (4-Methoxynaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone (also known as JWH-081)
- (29) (2-Methyl-1-propyl-1H-indol-3-yl)(naphthalen-1-yl)methanone (also known as JWH-015)
- (30) (4-Methylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone (also known as JWH-122)
- (31) {1-[(1-Methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(naphthalen-1-yl)methanone (also known as AM-1220)
- (32) {1-[2-(Morpholin-4-yl)ethyl]-1H-indol-3-yl}(naphthalen-1-yl) methanone (also known as JWH-200)
- (33) Naphthalen-1-yl[1-(pent-4-en-1-yl)-1H-indol-3-yl]methanone (also known as JWH-022)
- (34) Naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone (also known as JWH-018)
- (35) Naphthalen-1-yl(1-propyl-1H-indol-3-yl)methanone (also known as JWH-072)
- (36) 2-(2-Chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (also known as JWH-203)
- (37) 1-[1-(2-Cyclohexylethyl)-1H-indol-3-yl]-2-(2-methoxyphenyl) ethanone (also known as RCS-8)

FIRST SCHEDULE — *continued*

- (38) 2-(2-Methoxyphenyl)-1-{1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}ethanone (also known as cannabipiperidiethanone)
- (39) 2-(2-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (also known as JWH-250)
- (40) 2-(3-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (also known as JWH-302)
- (41) 2-(4-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (also known as JWH-201)
- (42) 2-(2-Methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (also known as JWH-251)
- (43) [1-(5-Fluoropentyl)-1H-indol-3-yl](2-iodophenyl)methanone (also known as AM-694)
- (44) (2-Iodo-5-nitrophenyl){1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}methanone (also known as AM-1241)
- (45) (2-Iodophenyl){1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}methanone (also known as AM-2233)
- (46) (2-Iodophenyl)(1-pentyl-1H-indol-3-yl)methanone (also known as AM-679)
- (47) (4-Methoxyphenyl){2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl}methanone (also known as pravadoline)
- (48) (4-Methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone (also known as RCS-4)
- (49) 1-Adamantyl{1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}methanone (also known as AM-1248)
- (50) 1-Adamantyl(1-pentyl-1H-indol-3-yl)methanone (also known as AB-001)

[S 751/2020 wef 04/09/2020]

21. Any compound structurally derived from indole-3-carboxamide or indole-2-carboxamide by substitution —

- (a) at the nitrogen atom of the indole ring with a type A substituent; and
- (b) at any hydrogen atom of the carboxamide with a type B substituent,
- whether or not the compound is further modified in any of the following ways:
- (c) substitution of the indole ring with a nitrogen heterocyclic analog;

FIRST SCHEDULE — *continued*

- (d) substitution to the indole ring or its nitrogen heterocyclic analog to any extent;
- (e) substitution to the type B substituent to any extent,

including any salt or stereoisomeric form of the compound or derivative of the compound, any preparation or product containing the compound or derivative of the compound, and the following examples of such a compound or derivative:

- (1) N-(1-Adamantyl)-1-(5-bromopentyl)-1H-indazole-3-carboxamide (also known as 5-Bromo-APINACA or 5-Bromo-AKB48)
- (2) N-(1-Adamantyl)-1-(5-chloropentyl)-1H-indazole-3-carboxamide (also known as 5-Chloro-APINACA or 5-Chloro-AKB48)
- (3) N-(1-Adamantyl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as Adamantyl CHMINACA or SGT-37)
- (4) N-(1-Adamantyl)-1-(5-hydroxypentyl)-1H-indazole-3-carboxamide
- (5) N-(1-Adamantyl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as FUB-APINACA or FUB-AKB48)
- (5A) N-(1-Adamantyl)-1-(4-fluorobutyl)-1H-indazole-3-carboxamide (also known as 4-Fluoro-ABUTINACA or 4F-ABUTINACA or 4-Fluoro ABINACA)  
*[S 284/2021 wef 01/05/2021]*
- (6) N-(1-Adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also known as 5-Fluoro-APINACA or 5F-AKB48)
- (7) N-(1-Adamantyl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (also known as 5-Fluoro-APICA or STS-135)
- (7A) N-(1-Adamantyl)-4-hydroxybutyl-1H-indazole-3-carboxamide  
*[S 284/2021 wef 01/05/2021]*
- (8) N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (also known as APINACA)
- (9) N-(1-Adamantyl)-1-pentyl-1H-indole-3-carboxamide (also known as APICA)
- (10) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as MAB-CHMINACA or ADB-CHMINACA)
- (11) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide or ADB-FUBINACA)

FIRST SCHEDULE — *continued*

- (12) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also known as 5-Fluoro-ADB-PINACA)
- (13) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (also known as 5-Fluoro-ADBICA)
- (14) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (also known as ADB-PINACA)
- (15) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (also known as ADBICA)
- (15A) 4-{3-[(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)carbamoyl]-1H-indazole-1-yl}butanoic acid  
*[S 284/2021 wef 01/05/2021]*
- (16) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-chloropentyl)-1H-indazole-3-carboxamide (also known as 5-Chloro-AB-PINACA)
- (17) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as AB-CHMINACA)
- (18) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as N-[1-amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide or AB-FUBINACA)
- (19) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indole-3-carboxamide (also known as AB-FUBICA)
- (20) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also known as 5-Fluoro-AB-PINACA)
- (21) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (also known as AB-PINACA)
- (22) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as PX-3 or APP-CHMINACA)
- (23) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also known as PX-2 or 5-Fluoro-APP-PINACA)
- (24) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (also known as PX-1 or 5-Fluoro-APP-PICA)
- (25) Ethyl 2-[1-(4-fluorobenzyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as EMB-FUBINACA or AEB-FUBINACA or FUB-AEB)

FIRST SCHEDULE — *continued*

- (26) Ethyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as 5-Fluoro-EDMB-PINACA)
- (27) Ethyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as 5-Fluoro-AEB or 5-Fluoro-EMB-PINACA)
- (28) 2-[1-(4-Fluorobenzyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid
- (29) 2-[1-(4-Fluorobenzyl)-1H-indazole-3-carboxamido]-3-methylbutanoic acid
- (30) 2-[1-(4-Fluorobenzyl)-1H-indole-3-carboxamido]-3-methylbutanoic acid
- (31) 2-[1-(4-Fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid
- (31A) 2-[1-(4-Fluorobutyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoic acid  
*[S 284/2021 wef 01/05/2021]*
- (32) 5-Fluoropent-1-yl-N-naphthalen-1-yl-1H-indole-3-carboxamide (also known as CBM-2201, 5-Fluoro-NNEI, 5F-NNEI or MN-24F)
- (33) 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide (also known as 5-Fluoro-cumyl-PICA)
- (34) 2-[1-(5-Fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid
- (35) 2-[1-(5-Fluoropentyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoic acid
- (36) 2-[1-(5-Fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoic acid
- (36A) 2-[1-(5-Fluoropentyl)-1H-indole-3-carboxamido]-3-phenylpropanoic acid  
*[S 284/2021 wef 01/05/2021]*
- (36B) 1-(5-Hydroxypentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide  
*[S 284/2021 wef 01/05/2021]*
- (37) Methyl 2-[1-(cyclohexylmethyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as MDMB-CHMINACA)
- (38) Methyl 2-[1-(cyclohexylmethyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as MA-CHMINACA)

FIRST SCHEDULE — *continued*

- (39) Methyl 2-[1-(cyclohexylmethyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoate (also known as Methyl N-{{1-(cyclohexylmethyl)-1H-indol-3-yl}carbonyl}-3-methyl-L-valinate or MDMB-CHMICA)
- (40) Methyl 2-[1-(cyclohexylmethyl)-1H-indole-3-carboxamido]-3-methylbutanoate (also known as MMB-CHMICA)
- (41) Methyl 3,3-dimethyl-2-[1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido]butanoate (also known as MDMB-4en-PINACA or MDMB-PINACA N1-pentyl-4-en isomer or MDMB(N)-022)
- (42) Methyl 2-[1-(4-fluorobenzyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as MDMB-FUBINACA)
- (43) Methyl 2-[1-(4-fluorobenzyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate or MMB-FUBINACA or AMB-FUBINACA or FUB-AMB)
- (44) Methyl 2-[1-(4-fluorobenzyl)-1H-indole-3-carboxamido]-3-methylbutanoate (also known as MMB-FUBICA or AMB-FUBICA)
- (45) Methyl 2-[1-(4-fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as Methyl 2-{{1-(4-fluorobutyl)-1H-indazole-3-carbonyl}amino}-3,3-dimethylbutanoate, 4F-MDMB-BINACA, 4F-MDMB-BUTINACA or 4-Fluoro-MDMB-BINACA)
- (46) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as 5-Fluoro-MDMB-PINACA or 5-Fluoro-ADB)
- (47) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as Methyl 2-{{1-(5-fluoropentyl)-1H-indazole-3-carbonyl}amino}-3-methylbutanoate, 5F-AMP, 5-Fluoro-AMP, 5F-MMB-PINACA, 5F-AMB-PINACA, 5-Fluoro-AMB or 5-Fluoro-MMB-PINACA)
- (48) Methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoate (also known as Methyl 2-{{1-(5-fluoropentyl)-1H-indole-3-carbonyl}amino}-3,3-dimethylbutanoate, 5F-MDMB-PICA, 5F-MDMB-2201, 5-Fluoro-MDMB-2201 or 5-Fluoro-MDMB-PICA)
- (49) Methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3-phenylpropanoate (also known as 5-Fluoro-MPP-PICA or 5-Fluoro-MPhP-PICA or MPHP-2201)

FIRST SCHEDULE — *continued*

- (50) Methyl 2-[1-(4-hydroxybutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate
- (51) Methyl 2-[1-(5-hydroxypentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate
- (51A) Methyl 2-[1-(5-hydroxypentyl)-1H-indole-3-carboxamido]-3-phenylpropanoate
- [S 284/2021 wef 01/05/2021]*
- (52) N-(1-Methyl-1-phenylethyl)-1-(4-cyanobutyl)-1H-indazole-3-carboxamide (also known as 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide or Cumyl-4CN-BINACA or 4-Cyano cumyl-butinaca or SGT-78)
- (53) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide (also known as 2-[(1-Butyl-1H-indazol-3-yl)formamido]-3,3-dimethylbutanamide or ADB-BUTINACA)
- (54) 1-Pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide (also known as Cumyl-PICA)
- (55) 5-{3-[(1-Adamantyl)carbamoyle]-1H-indazole-1-yl}pentanoic acid
- (56) 5-{3-[(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)carbamoyle]-1H-indazole-1-yl}pentanoic acid
- (57) 5-{3-[(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)carbamoyle]-1H-indole-1-yl}pentanoic acid
- (58) 5-{3-[(1-Amino-3-methyl-1-oxobutan-2-yl)carbamoyle]-1H-indazole-1-yl}pentanoic acid
- (59) 4-{3-[(2-Phenylpropan-2-yl)carbamoyle]-1H-indazole-1-yl}butanoic acid
- [S 284/2021 wef 01/05/2021]*
- (60) 2-[1-(Pent-4-en-1-yl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid
- (61) 2-[1-(4,5-Dihydroxypentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid
- (62) 2-(1-Butyl-1H-indazole-3-carboxamido)-3,3-dimethylbutanoic acid
- (63) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-hydroxybutyl)-1H-indazole-3-carboxamide
- (64) 5-{3-[(2-Phenylpropan-2-yl)carbamoyle]-1H-indol-1-yl}pentanoic acid



FIRST SCHEDULE — *continued*

- (65) 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (also known as 5-Fluoro-cumyl-PINACA)
- (66) Ethyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3-methylbutanoate (also known as 5-Fluoro-EMB-PICA or EMB-2201)
- (67) Methyl 2-[1-(4-fluorobutyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoate (also known as Methyl 2-[[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate, 4F-MDMB-BICA, 4F-MDMB-BUTICA or 4-Fluoro-MDMB-BUTICA)

[S 751/2020 wef 04/09/2020]

22. Any compound structurally derived from indole-3-carboxylic acid or indole-2-carboxylic acid by substitution —

- (a) at the nitrogen atom of the indole ring with a type A substituent; and
- (b) at the hydrogen atom of the carboxylic acid with a type B substituent,
- whether or not the compound is further modified in any of the following ways:

- (c) substitution of the indole ring with a nitrogen heterocyclic analog;
- (d) substitution to the indole ring or its nitrogen heterocyclic analog to any extent;
- (e) substitution to the type B substituent to any extent,

including any salt or stereoisomeric form of the compound or derivative of the compound, any preparation or product containing the compound or derivative of the compound, and the following examples of such a compound or derivative:

- (1) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate (also known as 5-Fluoro-SDB-005)
- (2) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (also known as NM-2201 or CBL-2201)
- (3) Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate (also known as SDB-005)
- (4) Quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate (also known as BB-22 or QUCHIC)
- (5) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (also known as 5-Fluoro-PB-22 or 5-Fluoro-QUPIC)
- (6) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (also known as PB-22 or QUPIC)

[S 751/2020 wef 04/09/2020]

FIRST SCHEDULE — *continued*

## PART II

## CLASS B DRUGS

1. The following substances and products:

Acetyldihydrocodeine.	Nicodicodine.
Codeine.	Norcodeine.
Dextropropoxyphene.	Phencyclidine.
Dihydrocodeine.	Phenmetrazine.
Ethylmorphine (3-ethylmorphine).	Pholcodine.
Fenetylline.	Propiram.
Methylphenidate.	Zipeprol.
Nicocodine.	

2. Any stereoisomeric form of a substance for the time being specified in paragraph 1.

3. Any salt of a substance for the time being specified in paragraph 1 or 2.

4. Any preparation or other product containing a substance or product for the time being specified in any of paragraphs 1 to 3, not being a preparation falling within paragraph 6 of Part I.

## PART III

## CLASS C DRUGS

1. The following substances:

Benzphetamine.	Methaqualone.
Chlorphentermine.	Nimetazepam.
Flunitrazepam.	Phendimetrazine.
Mecloqualone.	Pipradrol.
Mephentermine.	Secobarbital.
	Triazolam.

2. Any stereoisomeric form of a substance for the time being specified in paragraph 1.

3. Any salt of a substance for the time being specified in paragraph 1 or 2.

FIRST SCHEDULE — *continued*

4. Any preparation or other product containing a substance for the time being specified in any of paragraphs 1 to 3.

## PART IV

## MEANING OF CERTAIN TERMS USED IN THIS SCHEDULE

For the purposes of this Schedule —

“cannabinol derivatives” means the following substances, namely tetrahydro derivatives of cannabinol and their carboxylic acid derivatives, and 3-alkyl homologues of cannabinol or its tetrahydro derivatives;

“coca leaf” means the leaf of any plant of the genus *Erythroxylon* from whose leaves cocaine can be extracted either directly or by chemical transformation;

“concentrate of poppy-straw” means the material produced when poppy-straw has entered into a process for the concentration of its alkaloids;

“opium poppy” means any plant from which morphine may be produced;

“preparation” means a mixture, solid or liquid, containing a controlled drug;

“poppy-straw” means all parts, except the seeds, of the opium poppy, after mowing;

[40/93; 2/2006; S 88/79; S 238/83; S 229/84; S 272/84;  
S 31/86; S 50/90; S 564/91; S 66/92; S 262/95; S 223/96;  
S 469/97; S 391/99; S 232/2000; S 493/2001; S 30/2004;  
S 507/2005; S 491/2006]

FIRST SCHEDULE — *continued**[S 751/2020 wef 04/09/2020]*

“type A substituent” means —

- (a) an alkyl group;
- (b) a cyanoalkyl group;
- (c) an alkenyl group;
- (d) a cycloalkylmethyl group;
- (e) a cycloalkylethyl group;
- (f) a 1-(N-methyl-2-piperidinyl)methyl group;
- (g) a 2-(4-morpholinyl)ethyl group;
- (h) a 1-(N-methyl-2-pyrrolidinyl)methyl group;
- (i) a 1-(N-methyl-3-morpholinyl)methyl group;
- (j) a tetrahydropyranylmethyl group;
- (k) an alkyl phenyl group; or
- (l) a halogen, hydroxy and/or carboxylic acid derivative of any group mentioned in paragraphs (a) to (k);

*[S 751/2020 wef 04/09/2020]*

“type B substituent” means —

- (a) an alkyl group;
- (b) an alkenyl group;
- (c) an alkylamido group;
- (d) an alkylcarboxylic acid group;
- (e) a phenyl group;
- (f) an alkyl phenyl group;
- (g) a cycloalkyl group;
- (h) a cycloalkylmethyl group;
- (i) a cycloalkylethyl group;
- (j) an adamantyl group;
- (k) a naphthyl group;
- (l) a norbornyl group;
- (m) a 1,2,3,4-tetrahydronaphthyl group; or

FIRST SCHEDULE — *continued*

- (n) a heterocyclic analog of any group mentioned in paragraphs (e) to (m).

FIRST SCHEDULE — *continued**[S 751/2020 wef 04/09/2020]*

## SECOND SCHEDULE

Sections 2, 33 and 33B

*[Act 30 of 2012 wef 01/01/2013]*

## OFFENCES PUNISHABLE ON CONVICTION

SECOND SCHEDULE — *continued*

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
5	<p>(1) Unauthorised traffic in controlled drug except as otherwise provided in this Schedule</p> <p>(2) Unauthorised traffic in opium where the quantity is —</p> <p>(a) not less than 800 grammes and not more than 1,200 grammes and containing not less</p>	<p>Maximum 20 years and 15 strokes</p> <p>Minimum 5 years and 5 strokes</p>	<p>Maximum 20 years and 10 strokes</p> <p>Minimum 3 years and 3 strokes</p>	<p>Maximum 10 years and 5 strokes</p> <p>Minimum 2 years and 2 strokes</p>	<p>—</p> <p>—</p> <p>Maximum 30 years or imprisonment for life and 15 strokes</p>	<p>—</p> <p>—</p> <p>—</p>

## SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
	<p>than 20 grammes of morphine</p> <p>(b) more than 1,200 grammes and containing more than 30 grammes of morphine</p> <p>(3) Unauthorised traffic in controlled drug (except opium) containing such quantity of morphine being —</p>	—	—	—	<p>Minimum 20 years and 15 strokes</p> <p>Death</p>	—



SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
	(a) not less than 20 grammes and not more than 30 grammes	—	—	—	Maximum 30 years or imprisonment for life and 15 strokes	—
	(b) more than 30 grammes	—	—	—	Minimum 20 years and 15 strokes Death	—
	(4) Unauthorised traffic in controlled drug containing such quantity of diamorphine being —	—	—	—	Maximum 30 years or imprisonment for life and 15 strokes	—
	(a) not less than 10 grammes and not more than 15 grammes	—	—	—	Maximum 30 years or imprisonment for life and 15 strokes	—

## SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
	<p>(b) more than 15 grammes</p> <p>(5) Unauthorised traffic in controlled drug containing such quantity of cocaine being —</p> <p>(a) not less than 20 grammes and not more than 30 grammes</p>	—	—	—	<p>Minimum 20 years and 15 strokes</p> <p>Death</p> <p>Maximum 30 years or imprisonment for life and 15 strokes</p> <p>Minimum 20 years and 15 strokes</p>	—

SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment			
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved
	(b) more than 30 grammes	—	—	—	—
	(6) Unauthorised traffic in cannabis where the quantity is —				Death
	(a) not less than 330 grammes and not more than 500 grammes	—	—	—	Maximum 30 years or imprisonment for life and 15 strokes
	(b) more than 500 grammes	—	—	—	Minimum 20 years and 15 strokes Death
		—	—	—	—

## SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
	(7) Unauthorised traffic in cannabis mixture where the quantity is — (a) not less than 660 grammes and not more than 1,000 grammes  (b) more than 1,000 grammes	—	—	—	Maximum 30 years or imprisonment for life and 15 strokes  Minimum 20 years and 15 strokes  Death	—  —  —
	(8) Unauthorised traffic in cannabis resin where the quantity is —	—	—	—	—	—

## SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment			
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved
	(a) not less than 130 grammes and not more than 200 grammes	—	—	—	—
	(b) more than 200 grammes	—	—	—	—
	(9) Unauthorised traffic in controlled drug containing such quantity of methamphetamine being —	—	—	—	—
	(a) not less than 167 grammes and not	—	—	—	Maximum 30 years or imprisonment for life and 15 strokes
		—	—	—	Minimum 20 years and 15 strokes
		—	—	—	Death
		—	—	—	Maximum 30 years or imprisonment for life and 15 strokes

SECOND SCHEDULE — *continued*

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
6	more than 250 grammes	—	—	—	Minimum 20 years and 15 strokes	—
	(b) more than 250 grammes	—	—	—	Death	—
6	(1) Unauthorised manufacture of controlled drug except as otherwise provided in this Schedule	Maximum 30 years or imprisonment for life and 15 strokes	Maximum 30 years or imprisonment for life and 15 strokes	Maximum 20 years and 15 strokes	—	—
		Minimum 10 years and 5 strokes	Minimum 10 years and 5 strokes	Minimum 5 years and 5 strokes	—	—

SECOND SCHEDULE — *continued*

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
	(2) Unauthorised manufacture of morphine, or any salt of morphine, ester of morphine or salt of ester of morphine	—	—	—	Death	—
	(3) Unauthorised manufacture of diamorphine or any salt of diamorphine	—	—	—	Death	—
	(4) Unauthorised manufacture of cocaine or any salt of cocaine	—	—	—	Death	—
	(5) Unauthorised manufacture of methamphetamine or any salt of methamphetamine	—	—	—	Death	—

SECOND SCHEDULE — *continued*

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
7	(1) Unauthorised import or export of controlled drug except as otherwise provided in this Schedule  (2) Unauthorised import or export of opium where the quantity is — (a) not less than 800 grammes and not more than 1,200 grammes and containing not less	Maximum 30 years or imprisonment for life and 15 strokes  Minimum 5 years and 5 strokes	Maximum 30 years or imprisonment for life and 15 strokes  Minimum 5 years and 5 strokes	Maximum 20 years and 15 strokes  Minimum 3 years and 5 strokes	—  —  Maximum 30 years or imprisonment for life and 15 strokes	—  —  —



SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
	<p>than 20 grammes of morphine</p> <p>(b) more than 1,200 grammes and containing more than 30 grammes of morphine</p> <p>(3) Unauthorised import or export of controlled drug (except opium) containing such quantity of morphine being —</p>	—	—	—	<p>Minimum 20 years and 15 strokes</p> <p>Death</p>	—

## SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
	(a) not less than 20 grammes and not more than 30 grammes	—	—	—	Maximum 30 years or imprisonment for life and 15 strokes	—
	(b) more than 30 grammes	—	—	—	Minimum 20 years and 15 strokes Death	—
	(4) Unauthorised import or export of controlled drug containing such quantity of diamorphine being —	—	—	—	Maximum 30 years or imprisonment for life and 15 strokes	—
	(a) not less than 10 grammes and not more than 15 grammes	—	—	—	Maximum 30 years or imprisonment for life and 15 strokes	—

SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
	<p>(b) more than 15 grammes</p> <p>(5) Unauthorised import or export of controlled drug containing such quantity of cocaine being —</p> <p>(a) not less than 20 grammes and not more than 30 grammes</p>	—	—	—	<p>Minimum 20 years and 15 strokes</p> <p>Death</p> <p>Maximum 30 years or imprisonment for life and 15 strokes</p> <p>Minimum 20 years and 15 strokes</p>	—

## SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
	(b) more than 30 grammes	—	—	—	Death	—
	(6) Unauthorised import or export of cannabis where the quantity is —					
	(a) not less than 330 grammes and not more than 500 grammes	—	—	—	Maximum 30 years or imprisonment for life and 15 strokes	—
	(b) more than 500 grammes	—	—	—	Minimum 20 years and 15 strokes Death	—

SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment			
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved
					General
	(7) Unauthorised import or export of cannabis mixture where the quantity is — (a) not less than 660 grammes and not more than 1,000 grammes  (b) more than 1,000 grammes	—	—	—	Maximum 30 years or imprisonment for life and 15 strokes
	(8) Unauthorised import or export of cannabis resin where the quantity is —	—	—	—	Minimum 20 years and 15 strokes  Death

## SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
	(a) not less than 130 grammes and not more than 200 grammes	—	—	—	Maximum 30 years or imprisonment for life and 15 strokes	—
	(b) more than 200 grammes	—	—	—	Minimum 20 years and 15 strokes Death	—
	(9) Unauthorised import or export of controlled drug containing such quantity of methamphetamine being —	—	—	—	—	—
	(a) not less than 167 grammes and not	—	—	—	Maximum 30 years or imprisonment for life and 15 strokes	—

SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
	more than 250 grammes				Minimum 20 years and 15 strokes	—
	(b) more than 250 grammes				Death	—
8 (a)	Unauthorised possession of a controlled drug					Maximum 10 years or \$20,000 or both Minimum for second or subsequent offence 2 years

## SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
8 (b)	<i>[Deleted by Act 1 of 2019 wef 01/04/2019]</i>	—	—	—	—	Maximum 3 years or \$10,000 or both
9	Possession of pipes, utensils, etc., for smoking, administration or consumption of a controlled drug	—	—	—	—	Maximum 20 years or \$40,000 or both
10	Cultivation of cannabis, opium, coca plant	—	—	—	—	Minimum 3 years or \$5,000 or both
10A	Manufacture, supply, possession, import or export of	—	—	—	—	Maximum 20 years or



SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
11	equipment, materials or substances useful for manufacture of controlled drugs Being the owner, tenant, occupier or person concerned in the management of premises and permitting or suffering certain activities to take place there	Maximum 10 years or \$40,000 or both	Maximum 10 years or \$40,000 or both	Maximum 5 years or \$10,000 or both	—	\$200,000 or both
11E	Causing or procuring young person or vulnerable person to commit certain offences	Minimum 2 years or \$4,000 or both Maximum 30 years and 15 strokes	Minimum 2 years or \$4,000 or both Maximum 30 years and 15 strokes	Minimum 12 months or \$2,000 or both Maximum 20 years and 15 strokes	—	—

SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment			
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved
13	[Deleted by Act 1 of 2019 wef 01/04/2019]	Minimum 10 years and 10 strokes	Minimum 6 years and 6 strokes	Minimum 4 years and 4 strokes	
30(1)(a)	Obstructing exercise of powers	—	—	—	Maximum 3 years or \$5,000 or both Minimum 6 months or \$1,000 or both Maximum 3 years or
30(1)(b)	Failure to comply with lawful requirements	—	—	—	—

SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
						\$5,000 or both Minimum 6 months or \$1,000 or both
30(1)(c)	Failure to furnish information	—	—	—	—	Maximum 3 years or \$5,000 or both Minimum 6 months or \$1,000 or both
30(1)(d)	Furnishing false information	—	—	—	—	Maximum 12 months or

SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
31(2)	[Deleted by Act 1 of 2019 wef 01/04/2019]	—	—	—	—	\$5,000 or both
31(2A)	Failure to comply with order of Director for urine test	—	—	—	—	Maximum 4 years or \$10,000 or both
31A(2)	[Deleted by Act 1 of 2019 wef 01/04/2019]	—	—	—	—	Maximum 4 years or \$10,000 or both
31A(2A)	Failure to comply with order of Director for hair test	—	—	—	—	Maximum 4 years or \$10,000 or both

SECOND SCHEDULE — continued

Section creating offence	General nature of offence	Punishment				
		Class A drug involved	Class B drug involved	Class C drug involved	Specified drug or quantity thereof or drug with specified content involved	General
31B(2)	Failure to provide oral fluid	—	—	—	—	Maximum 2 years or \$5,000 or both

SECOND SCHEDULE — *continued**[Act 1 of 2019 wef 01/08/2019]**[Act 1 of 2019 wef 01/04/2019]**[Act 30 of 2012 wef 01/05/2013]**[20/98; 2/2006]*

## THIRD SCHEDULE

Section 2

CONTROLLED EQUIPMENT, MATERIALS OR SUBSTANCES USEFUL  
FOR MANUFACTURING CONTROLLED DRUGS

## PART I

## 1. The following substances:

Acetic anhydride also known as Acetic oxide

Alpha-phenylacetoacetamide also known as APAA

Alpha-phenylacetoacetonitrile, also known as APAAN, and its optical isomers

N-acetylanthranilic acid also known as N-Acetyl-*o*-aminobenzoic acid

4-Anilino-N-phenethylpiperidine also known as ANPP

3-(1,3-Benzodioxol-5-yl)-2-methyl-2-oxiranecarboxylic acid also known as 3,4-MDP-2-P methyl glycidic acid or PMK glycidic acid

Ephedrine also known as  $\beta$ -Hydroxy-N-methylamphetamine

Ergometrine also known as Ergonovine or Ergobasine or [8 $\beta$ (S)]-9,10-Didehydro-N-(2-hydroxy-1-methylethyl)-6-methyl-6-methylergoline-8-carboxamide

Ergotamine also known as 12'-Hydroxy-2'-methyl-5' $\alpha$ -(phenylmethyl) ergotaman-3',6',18'-trione

Isosafrole also known as 1,2-(Methylenedioxy)-4-propenylbenzene

Lysergic acid also known as 9,10-Didehydro-6-methylergoline-8 $\beta$ -carboxylic acid

Methyl alpha-phenylacetoacetate (also known as MAPA)

Methyl 3-(1,3-benzodioxol-5-yl)-2-methyl-2-oxiranecarboxylate also known as 3,4-MDP-2-P methyl glycidate or PMK glycidate

3,4-methylenedioxyphenyl-2-propanone

Norephedrine

Norpseudoephedrine

N-Phenethyl-4-piperidone also known as NPP

1-Phenyl-2-propanone also known as Phenylacetone

Phenylacetic acid also known as Benzeneacetic acid or  $\alpha$ -Toluic acid

THIRD SCHEDULE — *continued*

Piperonal also known as 3,4-(Methylenedioxy)benzaldehyde or Piperonylaldehyde

Potassium permanganate

Pseudoephedrine also known as  $\beta$ -Hydroxy-N-methylamphetamine

Safrole also known as 4-Allyl-1,2-methylenedioxybenzene.

[S 349/2020 wef 01/05/2020]

[S 354/2019 wef 01/05/2019]

[S 625/2017 wef 01/11/2017]

[S 572/2014 wef 01/09/2014]

2. The salts of the substances listed in paragraph 1 whenever the existence of such salts is possible.

[S 272/2013 wef 01/05/2013]

[20/98; S 404/2000]

3. Any substance which is a preparation or product containing ephedrine (also known as  $\beta$ -Hydroxy-N-methylamphetamine) or pseudoephedrine (also known as  $\beta$ -Hydroxy-N-methylamphetamine).

[S 440/2014 wef 01/07/2014]

## PART II

1. The following substances:

Acetone also known as 2-Propanone or Dimethyl ketone

Anthranilic acid also known as *o*-Aminobenzoic acid

Ethyl ether also known as Ether or Diethyl ether or Ethyl oxide or Diethyl oxide or Ethoxyethane or 1,1'-Oxybisethane

Hydrochloric acid

Methyl ethyl ketone also known as 2-Butanone

Piperidine also known as Hexahydropyridine

Sulphuric acid

Toluene also known as Methylbenzene or Phenylmethane.

2. The salts of the substances listed in paragraph 1 whenever the existence of such salts is possible.

[S 272/2013 wef 01/05/2013]

[20/98]



## FOURTH SCHEDULE

Sections 2 and 33A

## SPECIFIED DRUGS

1. Amphetamine
2. N, $\alpha$ -Dimethyl-3,4-(methylenedioxy)phenethylamine (also known as 3,4-Methylenedioxymethamphetamine or MDMA)  
*[S 323/2014 wef 01/05/2014]*  
*[S 792/2019 wef 01/12/2019]*
- 2A. Buprenorphine
- 2B. Cannabinol
- 2C. Cannabinol derivatives as defined in Part IV of the First Schedule
- 2D. Cannabis
- 2E. Cocaine
3. Diamorphine
- 3A. Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine
4. N-Ethyl- $\alpha$ -methyl-3,4-(methylenedioxy)phenethylamine (also known as MDEA)  
*[S 323/2014 wef 01/05/2014]*
5. Ketamine
6. Methamphetamine (also known as Methylamphetamine)
7.  $\alpha$ -Methyl-3,4-(methylenedioxy)phenethylamine (also known as Tenamfetamine or MDA)  
*[S 323/2014 wef 01/05/2014]*
8. Monoacetylmorphine
9. Morphine
10. Nimetazepam
- 10A. Norbuprenorphine
11. Norketamine and its dehydro derivatives
12. Opium.  
*[2/2006; S 560/2006; S 402/2007]*

## FIFTH SCHEDULE

Sections 24, 26, 27, 32 and 58A

## TEMPORARILY LISTED DRUGS

1. The following compounds, including any salt or stereoisomeric form of such compounds, and any preparation or product containing such compounds:

- (1) [*Deleted by S 284/2021 wef 01/05/2021*]
- (2) [*Deleted by S 284/2021 wef 01/05/2021*]
- (3) [*Deleted by S 284/2021 wef 01/05/2021*]
- (4) [*Deleted by S 349/2020 wef 01/05/2020*]
- (5) [*Deleted by S 349/2020 wef 01/05/2020*]
- (6) [*Deleted by S 349/2020 wef 01/05/2020*]
- (7) [*Deleted by S 349/2020 wef 01/05/2020*]
- (8) [*Deleted by S 349/2020 wef 01/05/2020*]

LEGISLATIVE HISTORY  
MISUSE OF DRUGS ACT  
(CHAPTER 185)

This Legislative History is provided for the convenience of users of the Misuse of Drugs Act. It is not part of the Act.

**1. Act 5 of 1973 — Misuse of Drugs Act 1973**

Date of First Reading : 22 November 1972  
(Bill No. 46/72 published on  
25 November 1972)

Date of Second and Third Readings : 16 February 1973

Date of commencement : 7 July 1973

**2. G. N. No. S 46/1974 — Misuse of Drugs (Amendment to First Schedule) Order 1974**

Date of commencement : 15 February 1974

**3. G. N. No. S 59/1975 — Misuse of Drugs (Amendment to First Schedule) Order 1975**

Date of commencement : 27 March 1975

**4. Act 49 of 1975 — Misuse of Drugs (Amendment) Act 1975**

Date of First Reading : 11 November 1975  
(Bill No. 55/75 published on  
11 November 1975)

Date of Second and Third Readings : 20 November 1975

Date of commencement : 12 December 1975

**5. Act 12 of 1977 — Misuse of Drugs (Amendment) Act 1977**

Date of First Reading : 2 September 1977  
(Bill No. 14/77 published on  
7 September 1977)

Date of Second and Third Readings : 9 November 1977

Date of commencement : 1 January 1978

**6. G. N. No. S 14/1978 — Misuse of Drugs (Amendment to First Schedule) Order 1978**

Date of commencement : 27 January 1978

- 7. Reprint 2 of 1978 — Misuse of Drugs Act 1973**  
Date of operation : 15 December 1978
- 8. G. N. No. S 88/1979 — Misuse of Drugs (Amendment of First Schedule) Order 1979**  
Date of commencement : 20 April 1979
- 9. Act 28 of 1979 — Misuse of Drugs (Amendment) Act 1979**  
Date of First Reading : 7 September 1979  
(Bill No. 27/79 published on  
11 September 1979)  
Date of Second and Third Readings : 21 September 1979  
Date of commencement : 1 October 1979
- 10. G. N. No. S 238/1983 — Misuse of Drugs (Amendment of First Schedule) Order 1983**  
Date of commencement : 4 October 1983
- 11. G. N. No. S 229/1984 — Misuse of Drugs (Amendment of First Schedule) Order 1984**  
Date of commencement : 31 August 1984
- 12. G. N. No. S 272/1984 — Misuse of Drugs (Amendment of First Schedule) (No. 2) Order 1984**  
Date of commencement : 2 November 1984
- 13. G. N. No. S 31/1986 — Misuse of Drugs (Amendment of First Schedule) Order 1986**  
Date of commencement : 7 February 1986
- 14. 1985 Revised Edition — Misuse of Drugs Act (Chapter 185)**  
Date of operation : 30 March 1987
- 15. G. N. No. S 50/1990 — Misuse of Drugs Act (Amendment of First Schedule) Order 1990**  
Date of commencement : 15 February 1990
- 16. Act 38 of 1989 — Misuse of Drugs (Amendment) Act 1989**  
Date of First Reading : 6 October 1989  
(Bill No. 39/89 published on  
7 October 1989)  
Date of Second and Third Readings : 30 November 1989

- Date of commencement : 15 February 1990
- 17. G. N. No. S 564/1991 — Misuse of Drugs (Amendment of First Schedule) Order 1991**
- Date of commencement : 2 January 1992
- 18. G. N. No. S 66/1992 — Misuse of Drugs Act (Amendment of First Schedule) Order 1992**
- Date of commencement : 1 March 1992
- 19. Act 40 of 1993 — Misuse of Drugs (Amendment) Act 1993**
- Date of First Reading : 12 October 1993  
(Bill No. 33/93 published on  
13 October 1993)
- Date of Second and Third Readings : 10 November 1993
- Date of commencement : 10 December 1993
- 20. G. N. No. S 262/1995 — Misuse of Drugs Act (Amendment of First Schedule) Order 1995**
- Date of commencement : 16 June 1995
- 21. G. N. No. S 223/1996 — Misuse of Drugs Act (Amendment of First Schedule) Order 1996**
- Date of commencement : 17 May 1996
- 22. 1997 Revised Edition — Misuse of Drugs Act (Chapter 185)**
- Date of operation : 30 May 1997
- 23. G. N. No. S 469/1997 — Misuse of Drugs Act (Amendment of First Schedule) Order 1997**
- Date of commencement : 17 October 1997
- 24. Act 20 of 1998 — Misuse of Drugs (Amendment) Act 1998**
- Date of First Reading : 20 April 1998  
(Bill No. 17/98 published on  
21 April 1998)
- Date of Second and Third Readings : 1 June 1998
- Date of commencement : 20 July 1998
- 25. 1998 Revised Edition — Misuse of Drugs Act (Chapter 185)**
- Date of operation : 15 December 1998

**26. G. N. No. S 391/1999 — Misuse of Drugs Act (Amendment of First Schedule) Order 1999**

Date of commencement : 9 September 1999

**27. Act 8 of 2000 — Prisons (Amendment) Act 2000**

(Consequential amendments made to Act by)

Date of First Reading : 17 January 2000  
(Bill No. 5/2000 published on  
18 January 2000)

Date of Second and Third Readings : 21 February 2000

Date of commencement : 17 April 2000

**28. G. N. No. S 232/2000 — Misuse of Drugs Act (Amendment of First Schedule) Order 2000**

Date of commencement : 15 May 2000

**29. G. N. No. S 404/2000 — Misuse of Drugs Act (Amendment of Third Schedule) Order 2000**

Date of commencement : 11 September 2000

**30. Act 4 of 2001 — Health Sciences Authority Act 2001**

(Consequential amendments made to Act by)

Date of First Reading : 12 January 2001  
(Bill No. 3/2001 published on  
13 January 2001)

Date of Second and Third Readings : 22 February 2001

Date of commencement : 1 April 2001

**31. 2001 Revised Edition — Misuse of Drugs Act (Chapter 185)**

Date of operation : 31 July 2001

**32. G. N. No. S 493/2001 — Misuse of Drugs Act (Amendment of First Schedule) Order 2001**

Date of commencement : 8 October 2001

**33. G. N. No. S 30/2004 — Misuse of Drugs Act (Amendment of First and Fourth Schedules) Order 2004**

Date of commencement : 30 January 2004

**34. Act 3 of 2005 — CISCO (Dissolution) Act 2005**

(Consequential amendments made to Act by)

- Date of First Reading : 19 October 2004  
(Bill No. 52/2004 published on  
20 October 2004)
- Date of Second and Third Readings : 25 January 2005
- Date of commencement : 10 June 2005

**35. G. N. No. S 507/2005 — Misuse of Drugs Act (Amendment of First Schedule) Order 2005**

- Date of commencement : 1 August 2005

**36. Act 2 of 2006 — Misuse of Drugs (Amendment) Act 2006**

- Date of First Reading : 21 November 2005  
(Bill No. 40/2005 published on  
22 November 2005)
- Date of Second and Third Readings : 16 January 2006
- Date of commencement : 1 March 2006

**37. G. N. No. S 491/2006 — Misuse of Drugs Act (Amendment of First Schedule) Order 2006**

- Date of commencement : 14 August 2006

**38. G. N. No. S 560/2006 — Misuse of Drugs Act (Amendment of Fourth Schedule) Order 2006**

- Date of commencement : 1 October 2006

**39. G. N. No. S 402/2007 — Misuse of Drugs Act (Amendment of Fourth Schedule) Order 2007**

- Date of commencement : 1 August 2007

**40. Act 22 of 2007 — Dentists (Amendment) Act 2007**

(Consequential amendments made to Act by)

- Date of First Reading : 27 February 2007  
(Bill No. 9/2007 published on  
27 February 2007)
- Date of Second and Third Readings : 12 April 2007
- Date of commencement : 1 January 2008

**41. 2008 Revised Edition — Misuse of Drugs Act**

- Date of operation : 31 March 2008

**42. G. N. No. S 685/2010 — Misuse of Drugs Act (Amendment of First Schedule) Order 2010**

Date of commencement : 15 November 2010

**43. Act 15 of 2010 — Criminal Procedure Code 2010**

Date of First Reading : 26 April 2010  
(Bill No. 11/2010 published on  
26 April 2010)

Date of Second and Third Readings : 19 May 2010

Date of commencement : 2 January 2011

**44. Act 30 of 2012 — Misuse of Drugs (Amendment) Act 2012**

Date of First Reading : 15 October 2012  
(Bill No. 27/2012 published on  
15 October 2012)

Date of Second and Third Readings : 14 November 2012

Date of commencement : 1 January 2013

**45. Act 30 of 2012 — Misuse of Drugs (Amendment) Act 2012**

Date of First Reading : 15 October 2012  
(Bill No. 27/2012 published on  
15 October 2012)

Date of Second and Third Readings : 14 November 2012

Date of commencement : 1 May 2013

**46. G.N. No. S 272/2013 — Misuse of Drugs Act (Amendment of First and Third Schedules) Order 2013**

Date of commencement : 1 May 2013

**47. G.N. No. S 273/2013 — Misuse of Drugs Act (Amendment of Fifth Schedule) Order 2013**

Date of commencement : 2 May 2013

**48. Act 30 of 2012 — Misuse of Drugs (Amendment) Act 2012**

Date of First Reading : 15 October 2012  
(Bill No. 27/2012 published on  
15 October 2012)

Date of Second and Third Readings : 14 November 2012

Date of commencement : 28 April 2014



- 49. G.N. No. S 323/2014 — Misuse of Drugs Act (Amendment of First, Fourth and Fifth Schedules) Order 2014**  
Date of commencement : 1 May 2014
- 50. G.N. No. S 440/2014 — Misuse of Drugs Act (Amendment of Third Schedule) Order 2014**  
Date of commencement : 1 July 2014
- 51. Act 1 of 2014 — Prisons (Amendment) Act 2014**  
Date of First Reading : 11 November 2013 (Bill No. 22/2013 published on 11 November 2013)  
Date of Second and Third Readings : 21 January 2014  
Date of commencement : 1 July 2014
- 52. G.N. No. S 572/2014 — Misuse of Drugs Act (Amendment of First, Third and Fifth Schedules) Order 2014**  
Date of commencement : 1 September 2014
- 53. G.N. No. S 254/2015 — Misuse of Drugs Act (Amendment of First and Fifth Schedules) Order 2015**  
Date of commencement : 1 May 2015
- 54. G.N. No. S 614/2015 — Misuse of Drugs Act (Amendment of Fifth Schedule) Order 2015**  
Date of commencement : 1 November 2015
- 55. G.N. No. S 200/2016 — Misuse of Drugs Act (Amendment of First and Fifth Schedules) Order 2016**  
Date of commencement : 1 May 2016
- 56. G.N. No. S 194/2017 — Misuse of Drugs Act (Amendment of First and Fifth Schedules) Order 2017**  
Date of commencement : 1 May 2017
- 57. G.N. No. S 625/2017 — Misuse of Drugs Act (Amendment of Third and Fifth Schedules) Order 2017**  
Date of commencement : 1 November 2017
- 58. G.N. No. S 233/2018 — Misuse of Drugs Act (Amendment of First and Fifth Schedules) Order 2018**  
Date of commencement : 1 May 2018

**59. G.N. No. S 587/2018 — Misuse of Drugs Act (Amendment of First Schedule) Order 2018**

Date of commencement : 1 October 2018

**60. G.N. No. S 150/2019 — Misuse of Drugs Act (Amendment of First Schedule) Order 2019**

Date of commencement : 25 March 2019

**61. Act 1 of 2019 — Misuse of Drugs (Amendment) Act 2019**

Date of First Reading : 19 November 2018 (Bill No. 51/2018 published on 19 November 2018)

Date of Second and Third Readings : 15 January 2019

Date of commencement : 1 April 2019

**62. G.N. No. S 354/2019 — Misuse of Drugs Act (Amendment of First, Third and Fifth Schedules) Order 2019**

Date of commencement : 1 May 2019

**63. Act 1 of 2019 — Misuse of Drugs (Amendment) Act 2019**

Date of First Reading : 19 November 2018 (Bill No. 51/2018 published on 19 November 2018)

Date of Second and Third Readings : 15 January 2019

Date of commencement : 1 August 2019

**64. G.N. No. S 792/2019 — Misuse of Drugs Act (Amendment of First, Fourth and Fifth Schedules) Order 2019**

Date of commencement : 1 December 2019

**65. G.N. No. S 349/2020 — Misuse of Drugs Act (Amendment of First, Third and Fifth Schedules) Order 2020**

Date of commencement : 1 May 2020

**66. G.N. No. S 751/2020 — Misuse of Drugs Act (Amendment of First Schedule) Order 2020**

Date of commencement : 4 September 2020

**67. G.N. No. S 284/2021 — Misuse of Drugs Act (Amendment of First and Fifth Schedules) Order 2021**

Date of commencement : 1 May 2021

**ABBREVIATIONS**

C.P.	Council Paper
G.N. No. S (N.S.)	Government Notification Number Singapore (New Series)
G.N. No.	Government Notification Number
G.N. No. S	Government Notification Number Singapore
G.N. Sp. No. S	Government Notification Special Number Singapore
L.A.	Legislative Assembly
L.N.	Legal Notification (Federal/Malaysian Subsidiary Legislation)
M. Act	Malayan Act/Malaysia Act
M. Ordinance	Malayan Ordinance
Parl.	Parliament
S.S.G.G. (E) No.	Straits Settlements Government Gazette (Extraordinary) Number
S.S.G.G. No.	Straits Settlements Government Gazette Number

COMPARATIVE TABLE  
MISUSE OF DRUGS ACT  
(CHAPTER 185)

The following provisions in the 2001 Revised Edition of the Misuse of Drugs Act have been renumbered by the Law Revision Commissioners in this 2008 Revised Edition.

This Comparative Table is provided for the convenience of users. It is not part of the Misuse of Drugs Act.

<b>2008 Ed.</b>	<b>2001 Ed.</b>
—	<b>31—(5)</b> ( <i>Deleted by Act 2/2006</i> )
PART V	PART IVA
PART VI	PART V
PART VII	PART VI

**COMPARATIVE TABLE  
MISUSE OF DRUGS ACT  
(CHAPTER 185)**

The following provisions in the 1998 Revised Edition of the Misuse of Drugs Act have been renumbered by the Law Revision Commissioners in this 2001 Revised Edition.

This Comparative Table is provided for the convenience of users. It is not part of the Misuse of Drugs Act.

<b>2001 Ed.</b>	<b>1998 Ed.</b>
<b>33—(2) and (3)</b>	<b>33—(2)</b>
<b>(4)</b>	<b>(3)</b>
<b>(5)</b>	<b>(4)</b>
<b>PART IV</b>	<b>PART IV</b>
<b>34</b>	<b>37</b>
<b>35</b>	<b>38—(1) and (2)</b>
<b>36</b>	<b>39</b>
<b>37</b>	<b>40</b>
<b>38</b>	<b>41</b>
<b>39</b>	<b>42</b>
<b>40</b>	<b>43</b>
<b>PART V</b>	<b>PART IV</b>
<b>41</b>	<b>43C</b>
<b>42</b>	<b>43D</b>
<b>43</b>	<b>43E</b>
<b>44</b>	<b>43F</b>
<b>45</b>	<b>43G</b>
<b>46</b>	<b>43H</b>
<b>47</b>	<b>43I</b>
<b>48</b>	<b>43J</b>
<b>49</b>	<b>43K</b>

<b>2001 Ed.</b>	<b>1998 Ed.</b>
<b>50</b>	<b>43L</b>
<b>51</b>	<b>43M</b>
<b>52</b>	<b>43N</b>
<b>PART VI</b>	<b>PART IV</b>
<b>53</b>	<b>34</b>
<b>54</b>	<b>35</b>
<b>55</b>	<b>36</b>
<b>56</b>	<b>43A</b>
<b>57</b>	<b>43B</b>
<b>58</b>	<b>44</b>
<b>59</b>	<b>45</b>